Cover page
Cover page | 12 Months Ended |
Dec. 31, 2020shares | |
Document Information [Line Items] | |
Document Type | 40-F/A |
Amendment Flag | true |
Document Period End Date | Dec. 31, 2020 |
Document Fiscal Year Focus | 2020 |
Document Fiscal Period Focus | FY |
Entity Registrant Name | Cresco Labs Inc. |
Entity Central Index Key | 0001832928 |
Current Fiscal Year End Date | --12-31 |
Entity Current Reporting Status | Yes |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Interactive Data Current | Yes |
Document Annual Report | true |
ICFR Auditor Attestation Flag | false |
Entity Address, Country | CA |
Amendment Description | This Amendment No. 1 to Form 40-F (the “Form 40-F/A”) for the year ended December 31, 2020 is being filed to furnish the financial statements of Cresco Labs Inc. (the “Company”) for the fiscal year ended December 31, 2020 formatted in eXtensible Business Reporting Language (“XBRL”). In accordance with the policy of the Securities and Exchange Commission (the “Commission”) stated in Release No. 33-9002, we are filing this Form 40-F/A within the 30-day period available to first-time XBRL filers following the filing of our Form 40-F, as filed with the Commission on March 30, 2021. |
Special Subordinate Voting Shares [Member] | |
Document Information [Line Items] | |
Entity Common Stock, Shares Outstanding | 63,868,296 |
Subordinate Voting Shares [Member] | |
Document Information [Line Items] | |
Entity Common Stock, Shares Outstanding | 194,163,398 |
Proportionate Voting Shares [Member] | |
Document Information [Line Items] | |
Entity Common Stock, Shares Outstanding | 170,556.45 |
Super Voting Shares [Member] | |
Document Information [Line Items] | |
Entity Common Stock, Shares Outstanding | 500,000 |
Consolidated Statements of Fina
Consolidated Statements of Financial Position - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 136,339 | $ 49,102 |
Restricted cash | 4,435 | 5,050 |
Accounts receivable, net | 29,266 | 16,455 |
Biological assets | 46,049 | 31,791 |
Inventory, net | 136,605 | 49,555 |
Loans receivable, short-term | 2,438 | 644 |
Other current assets | 6,622 | 6,741 |
Total current assets | 361,754 | 159,338 |
Non-current assets: | ||
Property and equipment, net | 195,231 | 155,839 |
Right-of-use assets | 92,169 | 46,696 |
Intangible assets, net | 195,518 | 94,206 |
Loans receivable, long-term | 21,224 | 18,633 |
Investments | 4,360 | 1,278 |
Goodwill | 451,861 | 137,719 |
Deferred tax asset | 7,299 | 1,761 |
Other non-current assets | 3,708 | 1,084 |
Total non-current assets | 971,370 | 457,216 |
TOTAL ASSETS | 1,333,124 | 616,554 |
Current liabilities: | ||
Accounts payable and other accrued expenses | 86,326 | 62,834 |
Short-term borrowings | 15,046 | |
Income tax payable | 49,411 | 15,198 |
Current portion of lease liabilities | 24,742 | 12,019 |
Deferred consideration, contingent consideration and other payables | 19,115 | 59,940 |
Derivative liabilities, short-term | 178 | |
Total current liabilities | 194,640 | 150,169 |
Long-term liabilities: | ||
Long-term notes payable and loans payable | 169,475 | 550 |
Derivative liabilities, long-term | 30,129 | 15,243 |
Lease liabilities | 145,320 | 82,856 |
Deferred tax liability | 52,998 | 23,212 |
Deferred consideration and contingent consideration | 7,247 | 21,901 |
Other long-term liabilities | 8,557 | |
Total long-term liabilities | 413,726 | 143,762 |
TOTAL LIABILITIES | 608,366 | 293,931 |
SHAREHOLDERS' EQUITY: | ||
Share capital | 826,341 | 275,851 |
Contributed surplus | 34,923 | 25,863 |
Accumulated other comprehensive loss | (621) | |
Accumulated deficit | (286,197) | (114,632) |
Equity of Cresco Labs Inc. | 574,446 | 187,082 |
Non-controlling interests | 150,312 | 135,541 |
TOTAL SHAREHOLDERS' EQUITY | 724,758 | 322,623 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 1,333,124 | $ 616,554 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Profit or loss [abstract] | ||
Revenue, net | $ 476,251 | $ 128,534 |
Costs of sales - production costs | (270,529) | (82,904) |
Gross profit before fair value adjustments | 205,722 | 45,630 |
Realized changes in fair value of inventory sold | (214,901) | (91,080) |
Unrealized gain on changes in fair value of biological assets | 293,119 | 109,531 |
Gross profit | 283,940 | 64,081 |
Expenses: | ||
Selling, general and administrative | 206,738 | 94,118 |
Depreciation and amortization | 21,361 | 4,219 |
Total expenses | 228,099 | 98,337 |
Income (loss) before other (expense) income and income taxes | 55,841 | (34,256) |
Other (expense) income: | ||
Interest expense, net | (39,493) | (7,875) |
Other (expense) income, net | (8,009) | (8,647) |
Loss from investment in associates | (1,181) | (63) |
Total other (expense) income, net | (48,683) | (16,585) |
Income (loss) before income taxes | 7,158 | (50,841) |
Income tax expense | (43,720) | (14,461) |
Net loss | (36,562) | (65,302) |
Net income (loss) attributable to non-controlling interests, net of tax | 45,363 | (22,101) |
Net loss attributable to Cresco Labs Inc. | $ (81,925) | $ (43,201) |
Net loss per share - attributable to Cresco Labs Inc. shareholders | ||
Loss per share - basic | $ (0.39) | $ (0.37) |
Loss per share - diluted | $ (0.39) | $ (0.37) |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Statement of comprehensive income [abstract] | ||
Net loss | $ (36,562) | $ (65,302) |
Other comprehensive loss for the period Items that may be reclassified subsequently to profit or loss: | ||
Foreign currency translation differences, net of tax | (621) | |
Total comprehensive loss for the period | (37,183) | (65,302) |
Comprehensive income (loss) attributable to non-controlling interests, net of tax | 45,684 | (22,101) |
Total comprehensive loss attributable to Cresco Labs Inc. | $ (82,547) | $ (43,201) |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands | Total | Share capital [member] | Shares to be issued or canceled [member] | Contributed surplus [member] | Accumulated deficit [member] | Accumulated other comprehensive loss [member] | Non- controlling interests [member] |
Beginning Balance at Dec. 31, 2018 | $ 282,981 | $ 142,118 | $ 20,064 | $ 11,594 | $ (52,745) | $ 161,950 | |
Cumulative effect of adoption of new accounting pronouncement IFRS 16 Leases | (2,992) | (1,466) | (1,526) | ||||
Exercise of options | 1,181 | 1,775 | (594) | ||||
Exercise of warrants | 1,245 | 1,674 | (429) | ||||
Equity-based compensation expense | 15,393 | 15,393 | |||||
Change in ownership interest | (834) | (438) | (396) | ||||
Income tax reserve | 292 | (101) | 393 | ||||
Issuance of shares related to MedMar | 19,497 | (19,497) | |||||
Distributions to limited liability company unit holders | (3,630) | (2,942) | (688) | ||||
Equity issued related to Valley Ag acquisition | 48,881 | 48,881 | |||||
Shares issued through equity raise, net of costs | 45,975 | 45,975 | |||||
Cresco LLC shares redeemed | 15,931 | (14,233) | (1,698) | ||||
Cancellation of shares | (567) | (567) | |||||
Net loss | (65,302) | (43,201) | (22,101) | ||||
Ending Balance at Dec. 31, 2019 | 322,623 | 275,851 | 25,863 | (114,632) | 135,541 | ||
Exercise of options and warrants | 3,416 | 7,657 | 21 | (4,262) | |||
Equity-based compensation expense | 8,851 | 11,407 | 275 | (2,831) | |||
Income tax reserve | 633 | 761 | (128) | ||||
Employee taxes on certain share-based payment arrangements | 2,825 | 10,043 | (7,218) | ||||
Distributions to limited liability company unit holders | (18,773) | (1,818) | (162) | (16,793) | |||
Equity issued related to Valley Ag acquisition | 436,168 | 412,663 | (923) | 24,428 | |||
Shares issued through equity raise, net of costs | 6,054 | 3,554 | 2,500 | ||||
Cresco LLC shares redeemed | 103,149 | (89,350) | (13,799) | ||||
Net impact pursuant to tax receivable agreement | 144 | 144 | |||||
Foreign currency translation | (621) | $ (621) | |||||
Net loss | (36,562) | (81,925) | 45,363 | ||||
Ending Balance at Dec. 31, 2020 | $ 724,758 | $ 824,468 | $ 1,873 | $ 34,923 | $ (286,197) | $ (621) | $ 150,312 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (36,562) | $ (65,302) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 40,019 | 11,910 |
Bad debt expense and provision expense for expected credit loss | 1,747 | 436 |
Share-based compensation expense | 18,494 | 14,867 |
Loss on investments | 2,430 | 878 |
(Gain) loss on changes in fair value of deferred and contingent consideration | (2,029) | 3,720 |
Loss on derivative instruments and warrants | 13,155 | 3,190 |
(Gain) loss on loans receivable | (921) | 279 |
Accrued interest expense, net of income | 4,261 | 0 |
Realized changes in fair value of inventory sold | 214,901 | 82,659 |
Loss on inventory write-offs and provision | 9,900 | 8,421 |
Unrealized (gain), net of losses, on changes in fair value of biological assets | (293,119) | (109,531) |
Change in deferred taxes | (4,447) | 1,176 |
Accretion of discount and deferred financing costs on debt arrangements | 6,142 | 0 |
Foreign currency loss (gain) | 2,394 | (444) |
Acquisition termination charges settled in equity | 1,279 | 0 |
Gain on debt modification | (5,409) | 0 |
Loss, net of (gains), on other adjustments to net loss | 366 | 670 |
Provision expense to be settled in equity | 13,600 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (5,250) | (12,782) |
Inventory | (297,197) | (109,601) |
Biological assets | 280,864 | 96,849 |
Other current assets | (843) | (4,645) |
Deposits and other assets | (1,267) | (102) |
Accounts payable and other accrued expenses | (6,529) | 36,516 |
Other current liabilities | (1,119) | 3,033 |
Income tax payable | 34,309 | 12,614 |
NET CASH USED IN OPERATING ACTIVITIES | (10,831) | (25,189) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchases of property and equipment | (78,272) | (91,673) |
Purchases of intangibles | (2,105) | (4,453) |
Proceeds from sale and leaseback transactions and lease tenant incentives | 57,699 | 38,532 |
Payment of acquisition consideration, net of cash acquired | (14,768) | (28,608) |
Distribution to associates | 0 | (1,500) |
Loans receivable for entities to be acquired | (6,667) | (19,894) |
NET CASH USED IN INVESTING ACTIVITIES | (44,113) | (107,596) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from September 2019 financing | 0 | 55,476 |
Proceeds from exercise of stock options, warrants and share issuances | 6,200 | 3,177 |
Proceeds from at-the-market offering | 3,521 | 0 |
Proceeds from the issuance of long-term debt | 186,000 | 0 |
Payment of debt, financing issuance costs and non-extending lender fees | (7,605) | (3,196) |
Repayment of debt | (10,340) | 0 |
Payment of acquisition-related contingent consideration | (1,719) | 0 |
Acquisition of non-controlling interests | (203) | (834) |
Distributions to non-controlling interest redeemable unit holders | (16,793) | (688) |
Distributions to other members | (162) | (2,942) |
Payments for taxes related to net share settlements of restricted stock units | (8,672) | 0 |
Principal payments of leases | (7,553) | (2,084) |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 142,674 | 48,909 |
Effect of foreign currency exchange rate changes on cash | (1,108) | 0 |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 86,622 | (83,876) |
Cash and cash equivalents and restricted cash, beginning of period | 54,152 | 138,028 |
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | 140,774 | 54,152 |
CASH PAID DURING THE PERIOD FOR: | ||
Income tax, net | 13,491 | 247 |
Interest | 29,183 | 5,350 |
NON-CASH TRANSACTIONS: | ||
Equity issued for acquisitions and escrows | 435,705 | 48,881 |
Non-controlling interests redeemed for equity | 13,799 | 1,698 |
Increase to net lease liability | 53,444 | 92,484 |
Derivative liability incurred for business combinations | 0 | 5,437 |
Conversion of loan to investment in associate | 0 | 6,783 |
Liability incurred to purchase property and equipment | 8,262 | 15,798 |
Cashless exercise of stock options | $ 2,784 | $ 113 |
Nature of Operations
Nature of Operations | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Nature of Operations | NOTE 1. NATURE OF OPERATIONS Cresco Labs Inc. (“Cresco” or the “Company”), formerly known as Randsburg International Gold Corp. was incorporated in the Province of British Columbia under the Company Act (British Columbia) on July 6, 1990. The Company is one of the largest vertically-integrated multi-state cannabis operators in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products primarily through Sunnyside*, Cresco’s national dispensary brand, and third-party retail stores. Employing a consumer-packaged goods approach to cannabis, Cresco’s house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, High Supply, Mindy’s Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. The Company operates in and/or has ownership interests in Illinois, Pennsylvania, Ohio, California, Maryland, Nevada, Arizona, New York, Massachusetts, Michigan and Canada, pursuant to the Illinois Compassionate Use of Medical Cannabis Pilot Program Act and the Illinois Cannabis Regulation and Tax Act, the Pennsylvania Compassionate Use of Medical Cannabis Act, the Ohio Medical Marijuana Control Program, the California Medicinal and Adult-Use On December 30, 1997, the Company changed its name from Randsburg Gold Corporation to Randsburg International Gold Corp. (“Randsburg”) and consolidated its common shares on a five (5) old for one (1) new basis. On November 30, 2018, in connection with a reverse takeover (the “Transaction”), the Company (i) consolidated its outstanding Randsburg common shares on an 812.63 old for one (1) new basis, and (ii) filed an alteration to its Notice of Articles with the British Columbia Registrar of Companies to change its name from Randsburg to Cresco Labs Inc. and to amend the rights and restrictions of its existing classes of common shares, redesignate such classes as the class of Subordinate Voting Shares (“SVS”) and create the classes of Proportionate Voting Shares (“PVS”), and Super Voting Shares (“MVS”). Pursuant to the Transaction, among the Company (then Randsburg) and Cresco Labs, LLC (“Cresco Labs”), a series of transactions were completed on November 30, 2018 resulting in a reorganization of Cresco Labs and Randsburg in which Randsburg became the indirect parent and sole voting unitholder of Cresco. The transaction constituted a reverse takeover of Randsburg by Cresco Labs under applicable securities laws. Cresco Labs was formed as a limited liability company under the laws of the state of Illinois on October 8, 2013 and is governed by the Pre-Combination Pre-Combination On December 3, 2018, the Company began trading on the Canadian Securities Exchange under the ticker symbol “CL.” On March 6, 2019, Cresco shares were approved to be quoted on the Over-the-Counter The Company’s head office is located at Suite 110, 400 W Erie St, Chicago, IL 60654. The registered office is located at Suite 2200, 1055 West Hastings Street, Vancouver, BC V6E 2E9. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Significant Accounting Policies | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Preparation The accompanying consolidated financial statements of the Company have been prepared under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations of the IFRS Interpretations Committee (“IFRIC”) in effect for the years ended December 31, 2020 and 2019. The consolidated financial statements were approved and authorized for issue by the Board of Directors of the Company on March 26, 2021. (b) Basis of Measurement The accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for biological assets which are measured at fair value less cost to sell; certain investments in associates, which are accounted for under the equity method; loans receivable measured at fair value through profit or loss (“FVTPL”); and certain investments, derivative instruments, and contingent consideration, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets and the contractual obligation for liabilities. Management has applied judgment in concluding that there remain no material uncertainties related to events or conditions that may cast doubt upon the entity’s ability to continue as a going concern, which includes judgment of the effects of subsequent events (see Note 25); and the Company’s ability to realize its assets and settle its obligations in the normal course of operations for at least twelve months from the date of the financial statements. (c) Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries, as determined by management, is the United States (“U.S.”) dollar. The Company’s presentation currency is the U.S. dollar. As such, the accompanying consolidated financial statements are presented in U.S. dollars. All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured period-end Assets and liabilities of foreign operations having a functional currency other than the U.S. dollar are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in other comprehensive loss. (d) Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee, and has the ability to use its power to affect its returns. The following are Cresco’s wholly owned or effectively controlled subsidiaries and entities over which the Company has control as of December 31, 2020. Entity Location Purpose Percentage Held Cresco Labs Inc. British Columbia, Canada Parent Company Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100 % Cresco Labs, LLC Illinois Operating Entity 49.98 % Cresco Labs Notes Issuer, LLC Illinois Holding Company 100 % Gloucester Street Capital, LLC New York Holding Company 100 % Valley Agriceuticals, LLC New York Operating Entity 100 % MedMar Inc. Illinois Holding Company 100 % MedMar Lakeview, LLC (Sunnyside - Lakeview and Sunnyside - River North) Illinois Dispensary 87.6 % MedMar Rockford, LLC (Sunnyside - Rockford and Sunnyside - South Beloit) Illinois Dispensary 75 % CannaRoyalty Corp. (Origin House) Ontario, Canada Holding Company 100 % Cali-AntiFragile Corp. California Holding Company 100 % Alta Supply Inc. (Continuum) California Distribution 100 % Kaya Management Inc. California Production 100 % RPE Inc. (Continuum) California Distribution 100 % FloraCal California Cultivation 100 % Cub City, LLC California Distribution 100 % CRHC Holdings Corp. Ontario, Canada Holding Company 100 % 2360149 Ontario Inc. (180 Smoke) Ontario, Canada Nicotine Vape Company 100 % Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85 % (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company. Entity Location Purpose Percentage Held Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 98.77 % Wellbeings, LLC Delaware CBD Wellness Product Development 100 % Cresco Labs SLO, LLC California Holding Company 100 % SLO Cultivation Inc. California Cultivation and Production Facility 80 % Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs PA, LLC Pennsylvania; Registered: Illinois Holding Company 100 % Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100 % Cresco Labs Arizona, LLC Arizona Holding Company 100 % Arizona Facilities Supply, LLC Arizona/Maryland Cultivation, Production and Dispensary Facility 100 % Cresco Labs Tinad, LLC Illinois Holding Company 100 % PDI Medical III, LLC (Sunnyside - Buffalo Grove and Sunnyside - Naperville) Illinois Dispensary 100 % Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100 % Phoenix Farms of Illinois, LLC (Sunnyside - Champaign and Sunnyside - Danville) Illinois Dispensary 100 % JDC Elmwood, LLC Illinois Holding Company 100 % FloraMedex, LLC (Sunnyside - Elmwood Park and Sunnyside - Schaumburg) Illinois Dispensary 100 % Cresco Edibles, LLC Illinois Holding Company 100 % TSC Cresco, LLC Illinois Licensing 75 % Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling (e) Cash and Cash Equivalents Cash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. (f) Restricted Cash Restricted cash represents amounts held in escrow related to investments, acquisitions, facility requirements and building improvements. The Company held $4.4 million and $5.1 million of restricted cash as of December 31, 2020 and 2019, respectively. (g) Accounts Receivable Accounts receivables are classified as financial assets initially recognized at fair value and subsequently measured at amortized cost, less any provisions for impairment. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations. (h) Biological Assets The Company’s biological assets consist of cannabis plants and are valued at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of internally produced Work-in-process All production costs related to biological assets are expensed as incurred and are included as Cost of sales – production costs. They include the direct cost of seeds and growing materials as well as other indirect costs such as utilities and supplies used in the growing process. Indirect labor for individuals involved in the growing and quality control process is also included, as well as depreciation on production equipment and overhead costs such as rent to the extent it is associated with the growing space. Unrealized fair value gains/losses on growth of biological assets are recorded in a separate line in the Consolidated Statements of Operations. The Company capitalizes cost incurred after harvest to bring the products to their present location and condition in accordance with International Accounting Standards (“IAS”) 2 Inventories (i) Inventory Inventories of purchased finished goods and packing materials are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell at harvest which becomes the deemed cost. Any subsequent post-harvest costs are capitalized to inventory. Post-harvest costs include costs such as materials, labor and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Cost of sales - production costs also includes certain excise taxes and community benefit fees. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Products for resale and supplies and consumables are valued at lower of cost and net realizable value. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value. (j) Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the useful life of the asset. The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year-end Category Methodology Estimated Useful Life Leasehold Improvements Amortized over the lesser of the life of the lease or estimated useful life of the improvement 1 - 15 years Machinery and Equipment Over the estimated useful life of the asset 5 - 15 years Furniture and Fixtures Over the estimated useful life of the asset 3 - 8 years Vehicles Over the estimated useful life of the asset 5 years Website and Software Over the estimated useful life of the asset 3 - 7 years Computer Equipment Over the estimated useful life of the asset 3 - 7 years Buildings and Building Improvements Over the estimated useful life of the asset 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred. (k) Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any, over the following terms: Category Estimated Useful Life Market-Related Intangibles 12 - 18 months Customer Relationships 7 - 19 years Non-Compete 4 - 5 years Internally Developed Software 10 years Trade Names 10 years Permit Application Fees 1 - 2 years The estimated useful lives and residual values are reviewed at each year end, and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses, which, for valuation purposes, represent the future benefits associated with the Company’s cultivation, processing, and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment (refer to Note 9 for additional details on impairment testing). During the year ended December 31, 2020, the Company recorded an impairment charge of $1.2 million on a market-related intangible asset due to changing market conditions. The Company fully recovered the value of this intangible asset and recorded an impairment reversal of $1.2 million. For the years ended December 31, 2020 and 2019, the Company did not recognize any impairment losses. (l) Investments in Associates The Company determines how to account for investments based on the level of control it has over the investment. If it is determined that the Company has control, then the investment should be consolidated. Investments in which the Company has significant influence, but no control, are considered investments in associates. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but without control or joint control over those policies. Investments in associates are accounted for using the equity method of accounting. Interests in associates accounted for using the equity method are initially recognized at cost. The carrying value is then adjusted for the Company’s share of comprehensive loss, additional contributions to the investee and additional distributions from the investee. The carrying value of associates is assessed for impairment at each balance sheet date. The Company’s investments in equity-accounted investees are classified within Investments in the Consolidated Statements of Financial Position. Investments in which the Company does not have significant influence or control are first recognized at cost. At each reporting period, changes from the initial cost and fair value are recognized through profit and loss and balances are classified within Investments in the Consolidated Statements of Financial Position. Refer to Note 8 for additional information on the Company’s Investments in Associates. (m) Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net tangible and intangible assets acquired. Goodwill is allocated to the cash-generating unit (“CGU”) or CGUs which are expected to benefit from the synergies of the combination. Goodwill is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to CGUs or groups of CGUs representing the lowest level that the assets are monitored for internal reporting purposes. Goodwill and indefinite-lived intangible assets are tested for impairment by comparing the carrying value of each CGU containing the assets to its recoverable amount (the higher of the asset’s fair value less costs of disposal and value-in-use); (n) Income Taxes Tax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive income (loss) or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive income (loss) or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income (loss) or equity, respectively. (o) Financial Instruments The Company recognizes all financial instruments in accordance with IFRS 9 Financial Instruments Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are incremental and are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities measured at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expires, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. The classification of financial instruments dictates how these assets and liabilities are measured subsequently in the Company’s consolidated financial statements. (i) Financial Instruments Measured at Fair Value Through Profit or Loss Financial instruments are classified as FVTPL when they are held for trading. A financial instrument is held for trading if it was acquired for the purpose of sale in the near term. Derivative financial instruments that are not designated and effective as hedging instruments are also classified as FVTPL. Financial instruments classified as FVTPL are stated at fair value with any changes in fair value recognized in earnings for the period. Financial assets in this category include certain short-term investments, derivatives and contingent consideration. Loans receivable primarily consist of loans to entities in which the Company has a potential future investment. These loans are measured at either FVTPL if they have derivative qualities or at amortized cost, less expected credit losses. Refer to Note 20 for additional information on the inputs utilized in the determination of fair values, including fair value hierarchy considerations. (ii) Financial Assets Measured at Amortized Cost Financial assets measured at amortized cost are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial assets are measured at amortized cost using the effective interest method, less any impairment losses. Financial assets in this category include cash and cash equivalents, trade receivables, other receivables, and loans receivable. (iii) Impairment of Financial Assets The Company assesses at each statement of financial position date whether there is objective evidence that a financial asset or group of financial assets is impaired. The Company recognizes expected credit losses (“ECL”) for trade receivables based on the simplified approach under IFRS 9. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime ECLs at each reporting date from the date of the trade receivable. Evidence of impairment may include indications that a debtor or a group of debtors is experiencing significant financial difficulty such as defaulting or delinquency in interest or principal payments; likely to enter bankruptcy or other financial reorganization; or experiencing a measurable decrease in the estimated future cash flows according to observable data such as changes in arrears or economic conditions that correlate with defaults. Trade receivables are reviewed qualitatively on a case-by-case For financial assets carried at amortized cost, the Company recognizes loss allowances for ECLs on its financial assets measured at amortized cost. ECLs are a probability-weighted estimate of credit losses. The Company applies a three-stage approach to measure ECLs. The Company measures loss allowance at an amount equal to twelve months of expected losses for performing loans receivable if the credit risk at the reporting date has not increased significantly since initial recognition (Stage 1) and at an amount equal to lifetime expected losses on loans receivable that have experienced a significant increase in credit risk since origination (Stage 2) and at an amount equal to lifetime expected losses which are credit impaired (Stage 3). The Company considers a significant increase in credit risk to have occurred if contractual payments are more than 30 days past due and considers the loans receivable to be in default if they are 90 days past due. A significant increase in credit risk or default may have also occurred if there are other qualitative factors (including forward looking information) to consider; such as borrower specific information (i.e., change in credit assessment). Objective evidence of impairment of financial assets carried at amortized cost exists if the counterparty is experiencing significant financial difficulty, there is a breach of contract, concessions are granted to the counterparty that would not normally be granted, or it is probable the counterparty will enter into bankruptcy or a financial reorganization. Refer to Note 3 for additional information on the impact of allowance for doubtful accounts and refer to Note 20 for additional information on the impact of ECLs. (iv) Financial Liabilities Measured at Amortized Cost Financial liabilities measured at amortized cost are recognized initially at fair value net of any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. Other financial liabilities are de-recognized Summary of the Company’s Classification and Measurements of Financial Assets and Liabilities IFRS 9 Account Classification Measurement Cash and cash equivalents Amortized cost Amortized cost Restricted cash Amortized cost Amortized cost Accounts receivable Amortized cost Amortized cost Loans receivable Amortized cost or FVTPL Amortized cost or fair value Investments FVTPL Fair value Accounts payable and accrued expenses and Other long-term liabilities Amortized cost Amortized cost Deferred consideration, contingent consideration and other payables FVTPL Fair value Derivative liabilities FVTPL Fair value Short-term borrowings Amortized cost Amortized cost Lease liabilities Amortized cost Amortized cost Long-term notes payable and loans payable Amortized cost Amortized cost (p) Leases The Company adopted IFRS 16 Leases IFRS 16 permits entities to elect practical expedients to simplify the ongoing application of IFRS 16. On an ongoing basis, the Company elected to adopt the following practical expedient: (i) The Company has elected not to recognize right-of-use The Company has entered into leases primarily for its corporate office, cultivation and processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes an ROU asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options which are considered reasonably certain to be exercised are mainly those for which operational decisions have been made which make the leased assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid which are then discounted using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid less interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase, or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. The depreciation expense on ROU assets replaces rent expense. The value of the ROU asset is periodically reduced by impairment losses, if any, and adjusted for certain revaluations of the lease liability. Upon adoption on January 1, 2019, the Company recognized ROU assets of $32.5 million and lease liabilities of $37.7 million, accumulated deficit of $1.5 million, a reduction of deferred rent of $2.2 million and a reduction of non-controlling The following reconciliation to the opening balance for lease liabilities under IFRS 16 as of January 1, 2019 is based on leases at December 31, 2018: ($ in thousands) Lease obligations in accordance with IAS 17 at December 31, 2018 $ 60,451 Leases not commenced at January 1, 2019 (929 ) Exemption for short-term leases (133 ) Lease extension options 34,841 Other 1,149 Obligations from lease arrangements (undiscounted) $ 95,379 Effect of discounting (57,672 ) Lease liability recognized as of January 1, 2019 $ 37,707 Refer to Note 7 for additional information on leases. (q) Revenue Recognition The Company’s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. IFRS 15 Revenue from Contracts with Customers 1. Identify the contract with a customer; 2. Identify the performance obligations in the contract; 3. Determine the transaction price, which is the total consideration provided by the customer; 4. Allocate the transaction price among the performance obligations in the contract based on their relative fair values; and 5. Recognize revenue when the relevant criteria are met for each unit (at a point in time or over time). The Company recognizes revenue upon satisfaction of the performance obligation, when control of the promised goods is transferred to the Company’s customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods, upon delivery and acceptance by wholesale customers and upon sale to retail customers. Revenue is presented net of sales tax and other related taxes. The company satisfies the following criteria prior to deeming control to have transferred to customers in bill-and-hold 1. The reason for the bill-and-hold 2. Products is identified separately as belonging to the customer; 3. Products currently are ready for physical transfer to the customer; and 4. Products cannot be used or directed to another customer. Contract Costs In accordance with IFRS 15, incremental costs to obtain a contract are capitalized and amortized over the contract term if the cost are expected to be recoverable. The Company does not capitalize incremental costs to obtain a contract where the contract duration is expected to be one year or less. As of December 31, 2020 and 2019, the Company did not have any costs capitalized. (r) Classification of Expenses The expenses in the accompanying Consolidated Statements of Operations are presented by function. The Company recognizes excise tax as Cost of sales—production costs or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively. See Note 16 for details of expenses by nature. (s) Share-Based Compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, non-employees re-measured For awards where the holder has the election of settling their award in either cash or equity, the fair value of share-based compensation is remeasured at the end of each reporting period until the corresponding awards are settled. (t) Earnings (Loss) Per Share The Company presents basic and diluted earnings (loss) per share. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to shareholders by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding, for the effects of all dilutive potential shares, which are comprised of redeemable LLC shares, warrants, options and restricted stock units (“RSUs”) issued. Items with an anti-dilutive impact are excluded from the calculation. The number of shares included with respect to options, warrants, redeemable shares and RSUs is computed using the treasury stock method. (u) Significant Accounting Judgments, Estimates, and Assumptions The preparation of the Company’s consolidated financial statements under IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of certain assets and liabilities. Estimates and related assumptions are based on historical experience and other relevant factors. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis for reasonableness and relevancy. Where revisions are required, they are recognized in the period in which the estimate is revised for the current as well as future periods that are affected. Significant judgements, estimates, and assumptions that have the most significant effect on the amounts recognized in the accompanying consolidated financial statements are described below. (i) ECL on Loan Receivables and Trade Receivables The Company calculates ECLs for trade receivables based on the historical default rates over the expected life of the trade receivable and adjusts for forward-looking estimates, which are determined through the exercise of judgement. The Company calculates ECLs for loan receivables by considering cash shortfalls on a discounted basis it would incur in |
Accounts Receivable
Accounts Receivable | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Accounts Receivable | NOTE 3. ACCOUNTS RECEIVABLE As of December 31, 2020 and 2019, Accounts receivable, net consisted of the following: ($ in thousands) 2020 2019 Accounts receivable, gross $ 29,962 $ 16,726 Allowance for doubtful accounts (696 ) (271 ) Total Accounts receivable, net $ 29,266 $ 16,455 See Note 20 for the analysis of accounts receivable aging and disclosure of bad debt expense. |
Biological Assets
Biological Assets | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Biological Assets | NOTE 4. BIOLOGICAL ASSETS The Company’s biological assets consist of cannabis plants. The changes in the carrying value of Biological assets for the periods ended December 31, 2020 and 2019, consisted of the following: ($ in thousands) Biological assets at January 1, 2019 $ 17,673 Biological Assets Acquired (Note 13) 1,436 Transferred to inventory upon harvest (96,849 ) Changes in fair value of biological assets 109,531 Biological assets at December 31, 2019 $ 31,791 Biological assets acquired (Note 13) 2,002 Transferred to inventory upon harvest (280,863 ) Changes in fair value of biological assets 293,119 Biological assets at December 31, 2020 $ 46,049 Biological assets are measured at fair value less costs to sell until harvest. All production costs related to biological assets are expensed as incurred. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The fair value was determined using an expected cash flow model which assumes the biological assets at the balance sheet date will grow to maturity, be harvested and converted into finished goods inventory and sold in the adult-use This model utilizes the following significant assumptions: Inputs and assumptions Calculation method Effect changes of unobservable inputs has on fair value Selling price per gram, less cost to sell Based on observable market data or calculated wholesale prices with reasonable margins. An increase in selling price per gram would increase the fair value of biological assets. Attrition rate Based on weighted average number of plants lost during each stage of production. An increase in attrition rate would result in a decrease to the fair value of biological assets. Average yield per plant Based on the average number of grams of dried cannabis inventory expected to be harvested from each cannabis plant. An increase to the average yield per plant would result in an increase to the fair value of biological assets. Cumulative stage of completion in the production process Based on an average number of days in production over a total average grow cycle of between 12 and 16 weeks. An increase to the average stage of completion of the plants would result in an increase to the fair value of biological assets. The Company’s estimates are, by their nature, subject to change and differences from the above assumptions will be reflected in Unrealized gain or loss on changes in fair value of biological assets in future periods. The Company estimates the harvest yields for cannabis at various stages of growth. As of December 31, 2020 and 2019, it was expected that the Company’s biological assets would yield approximately 21.4 million and 13.1 million grams, respectively. The Company has quantified the sensitivity of the inputs in relation to biological assets as of December 31, 2020 and 2019 and expects the following effect on fair value as shown in the table below: ($ in thousands, except inputs) Effect on fair value Significant inputs & assumptions Range of inputs (as of December 31, 2020) Sensitivity 2020 2019 Selling price per gram, less cost to sell $1.25 to $6.23 Increase 5% $ 2,292 $ 6,360 Decrease 5% (2,292 ) (6,360 ) Attrition rate 7% to 15% Increase 5% (2,425 ) (1,602 ) Decrease 5% 1,729 1,298 Average yield per plant 43 grams to 136 grams Increase 5% 2,292 1,590 Decrease 5% (2,292 ) (1,590 ) Cumulative stage of completion 35% - 55% complete Increase 5% 5,330 3,177 Decrease 5% (5,326 ) (3,177 ) |
Inventory
Inventory | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Inventory | NOTE 5. INVENTORY As of December 31, 2020 and 2019, inventory was comprised primarily of cannabis and cannabis-related products. The Company wrote off $5.9 million of inventory, net of reversals during the year ended December 31, 2020 primarily related to work-in-process work-in-process work-in-process The Company recorded $4.0 million and $nil of inventory reserves in Costs of sales – production costs for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, the Company had inventory reserves of $4.2 million and $0.2 million, respectively. Inventory as of December 31, 2020 and 2019, consisted of the following: ($ in thousands) 2020 2019 Raw materials $ 67,176 $ 16,521 Raw materials—non-cannabis 15,496 5,820 Work-in-process 24,906 14,100 Finished goods 29,027 13,114 Total Inventory $ 136,605 $ 49,555 During the years ended December 31, 2020 and 2019, the Company recognized $485.4 million and $174.0 million, respectively, of inventory expensed in the Consolidated Statements of Operations, which includes $270.5 million and $82.9 million, respectively, of Cost of sales – production costs and $214.9 million and $91.1 million, respectively, of non-cash |
Property And Equipment
Property And Equipment | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Property And Equipment | NOTE6. PROPERTY AND EQUIPMENT As of December 31, 2020 and 2019, Property and equipment consisted of the following: ($ in thousands) Land and Machinery Furniture Lesaehold Website, Vehicles Contruction Total Cost Balance as of January 1, 2019 $ 11,125 $ 4,449 $ 2,088 $ 17,828 $ 1,096 $ 386 $ 4,378 $ 41,350 Additions 3,683 9,473 7,635 36,793 1,446 295 46,103 105,428 Transfers 5,397 694 — 4,837 — — (10,928 ) — Purchase related to sale-leaseback transactions 37,062 — — — — — — 37,062 Sales related to sale-leaseback transactions (37,062 ) — — — — — — (37,062 ) Business acquisitions 7,802 1,034 735 3,507 173 34 2,495 15,780 As of December 31, 2019 $ 28,007 $ 15,650 $ 10,458 $ 62,965 $ 2,715 $ 715 $ 42,048 $ 162,558 Additions 1,055 5,908 4,804 10,415 2,409 878 45,225 70,694 Transfers 1,728 1,290 2,191 56,401 125 21 (61,756 ) — Disposals — (110 ) (33 ) (214 ) (24 ) — — (381 ) Sales related to sale-leaseback transactions (22,083 ) — — — — — (11,403 ) (33,486 ) Additions from acquisition — 455 473 11,615 585 331 5,166 18,625 Effect of foreign exchange and other adjustments — 6 (273 ) 130 (43 ) — (50 ) (230 ) As of December 31, 2020 $ 8,707 $ 23,199 $ 17,620 $ 141,312 $ 5,767 $ 1,945 $ 19,230 $ 217,780 Accumulated depreciation Balance as of January 1, 2019 $ (50 ) $ (335 ) $ (234 ) $ (633 ) $ (327 ) $ (50 ) $ — $ (1,629 ) Depreciation (382 ) (913 ) (760 ) (2,509 ) (416 ) (110 ) — (5,090 ) As of December 31, 2019 $ (432 ) $ (1,248 ) $ (994 ) $ (3,142 ) $ (743 ) $ (160 ) $ — $ (6,719 ) Depreciation (315 ) (1,985 ) (2,203 ) (10,189 ) (1,262 ) (333 ) — (16,287 ) Sales related to sale-leaseback transactions — — — 457 — — — 457 As of December 31, 2020 $ (747 ) $ (3,233 ) $ (3,197 ) $ (12,874 ) $ (2,005 ) $ (493 ) $ — $ (22,549 ) Net book value As of December 31, 2019 $ 27,575 $ 14,402 $ 9,464 $ 59,823 $ 1,972 $ 555 $ 42,048 $ 155,839 As of December 31, 2020 $ 7,960 $ 19,966 $ 14,423 $ 128,438 $ 3,762 $ 1,452 $ 19,230 $ 195,231 As of December 31, 2020 and 2019, costs related to construction at the Company’s facilities and dispensaries were capitalized in construction in progress and not depreciated. Depreciation will commence when construction is completed and the facilities and dispensaries are available for their intended use. Depreciation of $16.3 million and $5.1 million was incurred during the years ended December 31, 2020 and 2019, respectively, of which $4.1 million and $1.2 million, respectively, is included in Selling, general and administrative expenses, with the remainder in Cost of sales – production costs and ending inventory. As of December 31, 2020 and 2019, ending inventory includes $0.7 million and $0.4 million of capitalized depreciation, respectively. For the years ended December 31, 2020 and 2019, $11.9 million and $3.7 million, respectively, of depreciation was recorded to Cost of sales – production costs, which includes $0.5 million and $0.1 million, respectively, related to depreciation capitalized to inventory in prior years. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Leases | NOTE 7. LEASES The Company is the lessee in the majority of its leasing arrangements and has entered into leases primarily for its corporate office, cultivation and processing facilities, and dispensaries. Depending upon the type of lease, the original lease terms generally range from less than one year to 20 years. Certain leases include renewal options ranging from less than one year to 35 years. The Company is reasonably certain to exercise renewal options ranging from less than one year to 10 years on certain leases. As of December 31, 2020 and 2019, the Company’s leases include the following ROU assets: ($ in thousands) 2020 2019 Real estate $ 92,159 $ 46,696 Vehicles 10 — Total ROU assets $ 92,169 $ 46,696 Included in the ROU assets balance is $18.0 million of additions resulting from the acquisition of CannaRoyalty Corp. (“Origin House”) and $36.6 million of additions related to new leases, partially offset by $0.1 million of terminations for the year ended December 31, 2020. Total lease-related interest expense of $20.4 million and $7.1 million was recorded for the years ended December 31, 2020 and 2019, respectively. Total leasing depreciation of $8.7 million and $4.1 million was recorded for the years ended December 31, 2020 and 2019, respectively. For the years ended December 31, 2020 and 2019, $4.7 million and $1.6 million, respectively, of leasing depreciation is included in Selling, general and administrative expense with the remainder in Cost of sales – production costs and ending inventory. As of December 31, 2020 and 2019, ending inventory includes $0.2 million and $0.1 million of capitalized depreciation, respectively. For the years ended December 31, 2020 and 2019, $3.9 million and $2.6 million, respectively, of depreciation was recorded to Cost of sales – production costs, which includes $0.1 million and $0.3 million, respectively, related to depreciation capitalized to inventory in prior years. For short-term leases with durations of twelve months or less, the Company recorded $1.1 million and $0.3 million in rent expense for the years ended December 31, 2020 and 2019, respectively, within Selling, general and administrative expenses. The Company recognizes this expense on a straight-line basis over the lease term. The Company is the lessor in three real estate operating leasing arrangements and one equipment finance leasing arrangement. For the year ended December 31, 2020, the Company recorded rental income in Other (expense) income, net, of $0.7 million in relation to the operating leases. The operating leases have a 10-year During the year ended December 31, 2020, the Company entered into and amended certain sale and leaseback agreements whereby the Company sold properties with a total net book value of $33.0 million. The Company recorded an immaterial loss on asset sale in Selling, general and administrative expense and $0.5 million of closing and other transaction settlement costs in Other (income) expense, net, in the Consolidated Statement of Operations. The new and amended 2020 sale and leaseback transactions resulted in net funding of $29.9 million, a net increase to ROU assets of $25.2 million, a net increase to lease liabilities of $24.5 million and expected additional tenant improvement allowance reimbursements of $52.9 million, with the remaining impact related to settlement of security deposits, prepaid expenses and the settlement of the $0.6 million Hope Heal Health Loan (“HHH Loan”). During the year ended December 31, 2019, the Company entered into certain sale and leaseback agreements whereby the Company sold properties with a total net book value of $37.1 million. The Company recorded a gain on lease termination of $6.4 million and loss on asset disposal of $7.1 million that resulted in a $0.7 million loss included in Other (expense) income, net in the Consolidated Statement of Operations. The sale and leaseback transactions resulted in net proceeds of $36.4 million, a net increase to ROU assets of $0.1 million and a net increase to lease liabilities of $36.6 million, with the remaining impact related to settlement of security deposits and prepaid expenses. The properties, in which CHP Fresco, a related party, previously had an indirect ownership interest, are used in Illinois cultivation operations. The Company has received tenant improvement allowance reimbursements of $27.3 million across all leasing arrangements for the year ended December 31, 2020 and expects to receive an additional $47.7 million for these arrangements. As of December 31, 2020, maturities of lease liabilities were as follows: ($ in thousands) 2021 $ 33,207 2022 33,560 2023 34,265 2024 35,528 2025 36,324 Thereafter 354,986 Total lease payments $ 527,870 Less: imputed interest (310,142 ) Less: tenant improvement allowance (47,666 ) Present value of lease liabilities 170,062 Less: current lease liabilities (24,742 ) Present value of long-term lease liabilities $ 145,320 As of December 31, 2020, contractual receipts due to the Company for lease contracts in which the Company is the lessor were as follows: ($ in thousands) 2021 $ 642 2022 591 2023 609 2024 642 2025 646 Thereafter 2,783 Total lease payments $ 5,913 The lessor arrangements will become intercompany transactions upon the Company’s acquisition of Verdant Creations, LLC. Refer to Note 25 for additional information regarding the acquisition of Verdant Creations, LLC. |
Investments
Investments | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Investments | NOTE 8. INVESTMENTS The following is a detailed discussion of the Company’s types of investments held: (a) Investments at Fair Value The Company has investments in three entities: 420 Capital Management, LLC (“420 Capital”), a cannabis investment company; Lighthouse Strategies, LLC (“Lighthouse”), a diversified cannabis investment company; and Fleurish Cannabis, Inc. (“Fleurish”), an entity that focuses on cannabis production licenses. The 420 Capital, Lighthouse and Fleurish investments are accounted for at fair value. On August 12, 2019, the Company settled its outstanding loan receivable with Lighthouse of $3.3 million through receipt of Lighthouse membership units approximating 1% ownership of the parent company, with a fair value of $1.9 million as of December 31, 2020. See Note 20 for additional details. Upon the acquisition of Origin House on January 8, 2020, the Company obtained a 1.3% ownership stake in Fleurish with a fair value of $0.1 million as of the acquisition date. See Note 13 for additional details. The following is a summary of the investments at fair value held as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 420 Capital $ 68 $ 68 Lighthouse 1,049 1,209 Fleurish 51 — MassRoots, Inc. — 1 Total Investments $ 1,168 $ 1,278 The Company recorded a mark-to-market (b) Investment in Associates As part of the Origin House acquisition on January 8, 2020, the Company acquired an investment in Trichome Financial Corp. (“Trichome”), a lending entity that focuses its investments on cannabis and cannabis-related companies. At the acquisition date, the Trichome investment was valued at $4.3 million. The Company’s ownership stake in Trichome upon acquisition and as of December 31, 2020 is approximately 23%. The following is a summary of the investment in associates accounted for as an equity method investment and held as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 Trichome $ 3,192 $ — Total Investment $ 3,192 $ — The Company recorded a loss on investment of $1.2 million and $0.6 million for the years ended December 31, 2020 and 2019, respectively, and distributions of $nil and $1.6 million for the years ended December 31, 2020 and 2019, respectively. In the prior year, the Company held an approximately 13% ownership interest in CHP Fresco, a real estate holding entity that owns indirect investments in entities that own properties used in the Company’s Illinois production facilities. Based on various qualitative factors surrounding the investment, such as representation in management of the entity and its relationship as lessee with the investee entities, the Company conferred significant influence. As of December 31, 2019, CHP Fresco became an inactive entity in which the Company expected no future activity. The Company received a distribution of $1.5 million related to the dissolution of the CHP Fresco entity and its assets, resulting in a $1.3 million realized gain recorded in Other (expense) income, net in the Consolidated Statements of Operations for the year ended December 31, 2019. |
Intangible Assets and Goodwill
Intangible Assets and Goodwill | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Disclosure of intangible assets and goodwill [text block] | NOTE 9. INTANGIBLE ASSETS AND GOODWILL As of December 31, 2020 and 2019, Intangible assets and Goodwill consisted of the following: ($ in thousands) Customer Trade Permit Licenses Other Goodwill Total Cost Balance at January 1, 2019 $ 5,429 $ — $ 2,389 $ 18,047 $ 1,833 $ 51,146 $ 78,844 Additions — — 4,453 — — 13 4,466 Additions from acquisitions 1,500 — — 65,400 300 86,560 153,760 Balance at December 31, 2019 $ 6,929 $ — $ 6,842 $ 83,447 $ 2,133 $ 137,719 $ 237,070 Additions — — 1,886 — 2,722 — 4,608 Additions from acquisitions 52,200 41,800 — 5,900 2,865 320,552 423,317 Foreign exchange — — — — — 4 4 Measurement period adjustments 11,400 (2,100 ) — — (111 ) (6,414 ) 2,775 Balance at December 31, 2020 $ 70,529 $ 39,700 $ 8,728 $ 89,347 $ 7,609 $ 451,861 $ 667,774 Accumulated amortization Balance at January 1, 2019 $ (130 ) $ — $ (1,866 ) $ — $ (238 ) $ — $ (2,234 ) Amortization (728 ) — (1,399 ) — (784 ) — (2,911 ) Balance at December 31, 2019 $ (858 ) $ — $ (3,265 ) $ — $ (1,022 ) $ — $ (5,145 ) Amortization (4,271 ) (3,970 ) (3,853 ) — (3,156 ) — (15,250 ) Balance at December 31, 2020 $ (5,129 ) $ (3,970 ) $ (7,118 ) $ — $ (4,178 ) $ — $ (20,395 ) Net book value December 31, 2019 $ 6,071 $ — $ 3,577 $ 83,447 $ 1,111 $ 137,719 $ 231,925 December 31, 2020 $ 65,400 $ 35,730 $ 1,610 $ 89,347 $ 3,431 $ 451,861 $ 647,379 (a) Other Intangibles includes market-related intangibles, non-compete During the year ended December 31, 2020, the Company recorded a measurement period adjustment related to the acquisition of Origin House, retrospectively applied to the acquisition date. See Note 13 for further details. Amortization of $15.3 million and $2.9 million was recorded for the years ended December 31, 2020 and 2019, respectively, of which $12.6 million and $1.4 million, respectively, is included in Selling, general and administrative expenses, with the remainder in Cost of sales – production costs and ending inventory. As of December 31, 2020 and 2019, ending inventory includes $0.3 million and $0.3 million of capitalized amortization, respectively. For the years ended December 31, 2020 and 2019, $2.8 million and $1.4 million, respectively, of amortization expense was recorded to Cost of sales – production costs, which includes $0.3 million and $0.1 million, respectively, related to amortization capitalized to inventory in prior years. License intangible assets of $5.9 million were acquired from business combinations and are classified as indefinite-lived intangible assets as the Company cannot continue as a going concern without such licenses. See Note 13 for additional details. The Company recognized as part of the net assets acquired from the Origin House acquisition $2.4 million of market-related intangible assets for an exclusive distribution agreement with King’s Garden, Inc. (“King’s Garden”), in California, amortized over the life of the agreement. During the year ended December 31, 2020, the Company recorded an impairment charge of $1.2 million on the market-related intangible due to changing market conditions. The Company fully recovered the value of this intangible asset and recorded an impairment reversal of $1.2 million. On November 18, 2020, King’s Garden exercised its supplier renewal option for an additional one-year one-year For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to CGUs representing the lowest level that the assets are monitored for internal reporting purposes. CGUs are determined based on the smallest identifiable group of assets that generate cash inflows that are largely independent of cash inflows from other assets or group of assets. Management has determined the Company’s CGUs that hold such goodwill and indefinite-lived intangible assets to be California, Illinois, Maryland, Arizona, New York and Massachusetts. Annual impairment testing involves determining the recoverable amount of the CGU groups to which goodwill is allocated and comparing this to the carrying value of the CGU groups. The measurement of the recoverable amount of the CGU groups was calculated based on the higher of the CGUs fair value less costs to sell or value in use, which are Level 3 measurements within the fair value hierarchy. The calculation of the recoverable amount based on discounting the future cash flows (value in use) was based on the following key assumptions: • Cash flows were projected based on the Company’s long-term business plan for the periods 2021 through 2025. • Cash flows beyond 2025 were projected to grow at a perpetual growth rate, which was estimated to be 3%. • The business plan contains forecasts based on past experience of actual operating results in conjunction with anticipated future growth opportunities. While the forecast does assume some organic growth, largely related to synergies gained through further incorporation of recent acquisitions into the Company’s infrastructure, the primary engine of growth is strategic in nature and is consistent with the projects and expectations as articulated in the Company’s strategic plan. • Discount rates applied in determining the recoverable amount of the CGU groups range between 13% and 14.5% based on the pre-tax The Company believes a reasonable increase or decrease in the discount rates or perpetual growth rates used in the analysis would not cause the recoverable amount to decrease below the carrying value. |
Accounts Payable And Other Accr
Accounts Payable And Other Accrued Expenses | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Accounts Payable And Other Accrued Expenses | NOTE 10. ACCOUNTS PAYABLE AND OTHER ACCRUED EXPENSES As of December 31, 2020 and 2019, Accounts payable and other accrued expenses were comprised of the following: ($ in thousands) 2020 2019 Accounts payable $ 26,170 $ 32,463 Accrued expenses 34,843 24,133 Payroll liabilities 14,858 5,195 Excise taxes payable 8,675 540 Contract liability 1,182 — Tax penalty 578 455 Property taxes payable 20 48 Total Accounts payable and other accrued expenses $ 86,326 $ 62,834 |
Share Capital
Share Capital | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Share Capital | NOTE 11. SHARE CAPITAL (a) Authorized The authorized share capital of the Company, which has no par value, is comprised of the following: i. Unlimited Number of Subordinate Voting Shares Holders of SVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SVS will be entitled to one vote in respect of each SVS held. As long as any SVS remain outstanding, the Company will not, without the consent of the holders of the SVS by separate special resolution, prejudice or interfere with any right attached to the SVS. Holders of SVS will be entitled to receive as and when declared by the directors of the Company, dividends in cash or property of the Company. ii. Unlimited Number of Proportionate Voting Shares Holders of PVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of PVS will be entitled to one vote in respect of each SVS into which such PVS could ultimately be converted to 200 votes per PVS. As long as any PVS remain outstanding, the Company will not, without the consent of the holders of the PVS and MVS by separate special resolution, prejudice or interfere with any right or special right attached to the PVS. The holder of PVS have the right to receive dividends, out of any cash or other assets legally available therefore, pari passu as to dividends and any declaration or payment of any dividend on the SVS. During the years ended December 31, 2020 and 2019, 0.1 million and 0.2 million PVS, respectively, were exchanged for 28.9 million and 37.1 million SVS, respectively, at a rate of 1 PVS for 200 SVS. iii. 500,000 Super Voting Shares Holders of MVS shall be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company shall have the right to vote. At each such meeting, holders of MVS shall be entitled to 2,000 votes in respect of each MVS held. iv. Unlimited Number of Special Subordinate Voting Shares (“SSVS”) Holders of SSVS will be entitled to notice of and to attend any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company will have the right to vote. At each such meeting, holders of SSVS will be entitled to a 0.00001 vote in respect of each SSVS held. As long as any SSVS remain outstanding, the Company will not, without the consent of the holders of the SSVS by separate special resolution, prejudice or interfere with any right attached to the SSVS. Holders of SSVS will be entitled to receive dividends in cash or property of the Company, if and when declared by the Board. v. Redeemable Units As part of the Transaction, unit holders of Cresco Labs, LLC exchanged their units for a new class of redeemable units in Cresco Labs, LLC. Each Redeemable unit is only exchangeable for the equivalent of one SVS in Cresco Labs Inc. (without any obligation to redeem in cash). These unit holders hold an interest only in Cresco Labs, LLC; they participate in the earnings of only Cresco Labs, LLC and not the earnings of the combined entity. (b) Issued and Outstanding As of December 31, 2020 and 2019, issued and outstanding shares and units consisted of the following: (in thousands) Notes Redeemable Units Subordinate Voting Shares (SVS) Super Proportionate Special Shares Beginning balance, January 1, 2019 143,844 26,711 500 82,803 — 3,020 Stock options exercised — 575 — 342 — — Warrants exercised Note 11(c) — 170 — — — — Issuance of MedMar shares Note 11(b)(vi) — — — 3,020 — (3,020 ) Issuance of Valley Ag shares Note 11(b)(vi) — — — 8,660 — — PVS converted to SVS and adjustments Note 11(a) — 37,122 — (36,888 ) — — Cresco LLC redemption Note 11(e) (1,672 ) 1,672 — — — — Share issuance from equity raise Note 11(b)(vi) — 7,350 — — — — Ending balance, December 31, 2019 142,172 73,600 500 57,937 — — Beginning balance, January 1, 2020 142,172 73,600 500 57,937 — — Options and warrants exercised Note 11(c), 12 — 1,688 — 12 — 23 RSUs issued Note 12 — 2,034 — — — 28 Issuance of shares related to acquisitions Note 11(b)(ii-v) — 70,084 — 233 — (155 ) Issuance of shares related to distribution agreements Note 11(b)(ii) — — — — — 249 Cresco LLC redemption Note 11(e) (15,834 ) 15,681 — — — — PVS converted to SVS Note 11(a) — 28,871 — (28,871 ) — — Issuances related to employee taxes on certain share-based payment arrangements Note 12 — 1,336 — — — — Share issuances Note 11(b)(i) — 792 — — 1 — Ending balance, December 31, 2020 126,338 194,086 500 29,311 1 145 * PVS presented on an “as-converted” (1-to-200) ** SSVS presented on an “as-converted” (1-to-0.00001) (i) Share Issuances In December 2019, the Company entered an agreement (“ATM Offering”) with Canaccord Genuity Corp to sell up to C$55 million SVS at an at-the-market During the year ended December 31, 2020, the Company issued 44 thousand SVS, valued at $0.2 million. The Company recognized gains on the sale and foreign currency exchange of $0.5 million in equity during the year ended December 31, 2020 related to share issuances for shares withheld for employee taxes on certain share-based payment arrangements as a result of the change in share price between employee exercise and sale of shares. The Company issued 1 thousand SSVS (as-converted), (ii) Issuance of Shares—Origin House In January 2020, in conjunction with the acquisition of Origin House, the Company issued 66.5 million SVS, valued at $396.6 million. During the year ended December 31, 2020, the Company issued 1.6 thousand SVS, valued at $7.2 million, to satisfy certain obligations related to deferred consideration related to legacy acquisitions by Origin House. In May 2020, the Company issued 0.3 million SVS, valued at $1.0 million, in accordance with the post combination remuneration agreement associated with Origin House’s previous acquisition of FloraCal. In May 2020, the Company also issued 0.8 million SVS, valued at $2.2 million, to settle the deferred consideration associated with Origin House’s previous acquisition of Cub City, LLC (“Cub City”). See Note 13 for additional details. In November 2020, the Company recognized 0.2 million Cresco shares to be issued to King’s Garden with a value of $2.5 million for renewal of the exclusive distribution agreement. These shares can be issued any time during the renewal term. See Note 9 for additional details. During the year ended December 31, 2020, the Company canceled 0.2 million shares, valued at -$0.9, in connection with the settlement of the previously disclosed provision related to the Origin House acquisition. See Note 19 for further details. (iii) Issuance of Shares – MedMar Lakeview In April 2020, the Company issued 0.1 million SVS, valued at $0.4 million, to satisfy certain obligations related to contingent consideration. In August 2020, the Company issued 19 thousand SVS, valued at $0.1 million, to satisfy certain obligations related to contingent consideration. In December 2020, the Company issued 0.1 million SVS, valued at $1.1 million, to satisfy certain obligations related to contingent consideration. See Note 13 for further details. (iv) Issuance of Shares – Gloucester Street Capital, LLC (Valley Agriceuticals LLC or “Valley Ag”) During the year ended December 31, 2020, the Company issued a total of 0.3 million PVS (as-converted), In May 2020, the Company issued 0.5 million SVS, valued at $1.5 million, to satisfy a portion of the Company’s make-whole liability. See Note 13 and Note 20 for further details. (v) Issuance of Shares – Tryke In April 2020, the Company issued 0.3 million SVS, valued at $1.3 million, in accordance with the termination agreement which canceled the previously announced purchase agreement to acquire certain assets of and an interest in Tryke Companies, LLC, and certain subsidiaries and affiliates. (vi) 2019 Issuances and Activity a. Issuance of Shares – Valley Ag In October 2019, the acquisition of Valley Ag was closed and 8.7 million PVS (as converted) of Cresco Labs Inc., valued at $48.9 million, were issued in conjunction with the consideration of the acquisition. b. September 2019 Financing In September 2019, the Company completed an underwritten unit offering to issue 7.4 million “Offered Units” at a price of $7.55 per unit. The Offered Units comprised of one share and one-half On October 24, 2019, the Company issued an additional 0.6 million share purchase warrants at a price of $1.64 per additional warrant for gross proceeds of $0.9 million, pursuant to the partial exercise of the Underwriter’s over-allotment option related to the September 2019 financing discussed above. See Note 20 for further details. c. Issuance of Shares – MedMar In April 2019, the acquisition of MedMar Inc. was approved by regulators and 3.0 million shares of Cresco Labs Inc. were issued in conjunction with the consideration of the acquisition. (c) Stock Purchase Warrants Each whole warrant entitles the holder to purchase one SVS or PVS of the Company. A summary of the status of the warrants outstanding is as follows: Number of Weighted- average Balance as of January 1, 2019 397,079 $ 5.35 Issued 6,226,250 7.78 Exercised (169,545 ) 6.16 Balance as of December 31, 2019 6,453,784 $ 7.73 Exercised (270,635 ) 6.05 Balance as of December 31, 2020 6,183,149 $ 7.80 * PVS presented on an “as-converted” (1-to-200) During the year ended December 31, 2020, the Company recorded $2.5 million of warrant exercises into share capital. The 6.2 million outstanding warrants are from issuances to underwriters associated with the September 2019 financing and sellers from the Valley Ag acquisition, classified as long-term derivative liabilities. See Note 20 for information about valuation of liability-classified warrants. During the year ended December 31, 2020, 0.2 million equity-classified warrants were exercised prior to their expiration for $1.4 million, resulting in a realized foreign currency exchange gain of $13 thousand and an increase to share capital of $2.0 million. During the year ended December 31, 2019, 35 thousand broker warrants were exercised for $0.2 million, resulting in a realized foreign currency exchange gain of $35 thousand and an increase to share capital of $0.4 million. No equity-classified warrants were issued during the years ended December 31, 2020 and 2019. No equity-classified warrants remain outstanding as of December 31, 2020 as all previously outstanding equity-classified warrants were exercised prior to expiration. (d) Distribution to Non-controlling During the year ended December 31, 2020, in accordance with the underlying operating agreements, the Company declared and paid required tax distribution amounts to 2019 unit holders of Cresco Labs, LLC and other minority holders of $9.5 million. During the year ended December 31, 2020, in accordance with the underlying operating agreements, the company declared required cash distributions to the minority interest holders of MedMar Rockford, LLC and MedMar Lakeview, LLC. The total declared distribution was $1.8 million, which will reduce non-controlling During the year ended December 31, 2020, the Company declared and made additional tax-related non-controlling During the year ended December 31, 2019, in accordance with the underlying operating agreements, the Company declared and paid a distribution of profits to 2018 unit holders of Cresco Labs, LLC and other minority holders of $3.6 million. (e) Changes in Ownership and Non-controlling During the year ended December 31, 2020, redemptions of 15.7 million redeemable units occurred which were converted into an equivalent number of SVS. This redemption resulted in a decrease of 6.1% in non-controlling In April 2020, the holders of the non-controlling In February 2019, the Company acquired an additional 1% of Phoenix Farms of Illinois, LLC decreasing non-controlling non-controlling In May 2019, the Company acquired the remaining 10% of non-controlling During the year ended December 31, 2019, redemptions of 1.7 million redeemable units occurred which were converted into an equivalent number of SVS. This redemption resulted in a decrease of 0.7% in non-controlling As of and for the year ended December 31, 2020, non-controlling ($ in thousands) TSC MedMar Inc. MedMar Inc. Cresco Labs Ohio, SLO Inc. Other 1 Eliminations Total Non-current $ 4,064 $ 32,680 $ 20,634 $ 11,392 $ 23,848 $ 878,752 $ — $ 971,370 Current assets 31,489 26,199 37,996 41,258 79,822 298,846 (153,856 ) 361,754 Non-current — (11,942 ) (2,279 ) (7,113 ) (10,643 ) (381,749 ) — (413,726 ) Current liabilities (24,209 ) (31,706 ) (26,686 ) (47,512 ) (120,195 ) (107,753 ) 163,421 (194,640 ) Net assets $ 11,344 $ 15,231 $ 29,665 $ (1,975 ) $ (27,168 ) $ 688,096 $ 9,565 $ 724,758 Net assets attributable to NCI $ 3,197 $ 3,264 $ 4,468 $ 70 $ (5,383 ) $ 144,695 3 $ — $ 150,311 Revenue $ 16,874 $ 31,320 $ 38,417 $ 14,646 $ 19,772 $ 386,257 $ (31,035 ) $ 476,251 Gross profit 9,882 16,404 20,136 3,332 (4,901 ) 243,674 (4,587 ) 283,940 Total comprehensive income (loss) $ 8,440 $ 3,559 $ 10,738 $ (7,996 ) $ (12,214 ) $ (39,089 ) $ — $ (36,562 ) Comprehensive income (loss) allocated to NCI $ 2,110 $ 441 $ 2,684 $ (80 ) $ (2,443 ) $ 42,651 $ — $ 45,363 NCI percentage at December 31, 2020 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 50.02 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 50.02% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments As of and for the year ended December 31, 2019, non-controlling ($ in thousands) TSC MedMar Inc. MedMar Inc. Cresco Labs Ohio, SLO Other 1 Eliminations Total Non-current $ 3,185 $ 16,667 $ 21,419 $ 12,575 $ 23,317 $ 380,053 $ — $ 457,216 Current assets 14,081 750 1,644 30,949 47,529 116,472 (52,087 ) 159,338 Non-current — (1,634 ) (1,993 ) (95 ) (13,940 ) (126,100 ) — (143,762 ) Current liabilities (13,442) (1,479) (2,172) (37,660) (68,822) (78,522) 51,928 (150,169) Net assets $ 3,824 $ 14,304 $ 18,898 $ 5,769 $ (11,916 ) $ 291,903 $ (159 ) $ 322,623 Net assets attributable to NCI $ 1,567 $ 2,907 $ 2,081 $ 150 $ (2,940 ) $ 131,776 $ — $ 135,541 Revenue $ 6,417 $ 4,088 $ 5,310 $ 7,759 $ 21,148 $ 99,290 $ (15,478 ) $ 128,534 Gross profit 5,037 1,999 2,565 2,210 (505 ) 61,935 (9,160 ) 64,081 Total comprehensive income (loss) $ 5,747 $ (980 ) $ (555 ) $ (6,259 ) $ (15,295 ) $ (47,960 ) $ — $ (65,302 ) Comprehensive income (loss) allocated to NCI $ 1,437 $ (121 ) $ (139 ) $ (63 ) $ (3,059 ) $ (20,156 ) $ — $ (22,101 ) NCI percentage at December 31, 2019 25.0 % 1 12.4 % Holders 25.0 % Holders 1.0 % Holders 20.0 % Holders 56.2 % Holders Holders 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 56.2% NCI related to NCI for Cresco Labs Inc. |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Share-Based Compensation | NOTE 12. SHARE-BASED COMPENSATION The Company has a share-based compensation plan (the “Plan”) for key employees and service providers. Under the Plan, options issued have no voting rights and vest proportionately over periods ranging from the grant date to four years from the issuance date. Stock options exercised are converted to SVS. A summary of the status of the options outstanding consisted of the following: Number of Weighted- Outstanding – January 1, 2019 19,500,000 $ 2.11 Granted 4,474,000 7.48 Exercised (934,682 ) 1.37 Forfeited (669,150 ) 2.88 Outstanding – December 31, 2019 22,370,168 $ 3.19 Granted 7,278,021 5.04 Exercised (1,945,401 ) 2.12 Origin House replacement awards 629,275 4.24 Forfeited (5,845,350 ) 2.77 Outstanding - December 31, 2020 22,486,713 $ 3.96 Exercisable - December 31, 2020 9,550,535 $ 3.25 The following table summarizes the stock options outstanding as of December 31, 2020: Expiration date Stock Exercise 1 Stock October 2022 17,578 $ 3.13 17,578 April 2025 1,758 4.49 879 May 2025 3,516 6.01 2,636 June 2025 205,273 0.50 - 5.80 203,954 July 2025 3,515 5.43 2,637 September 2025 250,000 1.00 — January - February 2026 75,000 1.00 75,000 May - June 2026 600,000 1.00 600,000 November - December 2026 17,500 1.00 17,500 January 2027 5,000 1.00 3,750 October 2027 200,000 1.00 200,000 November 2027 250,000 1.00 - 1.14 162,500 December 2027 328,120 1.14 - 4.17 265,620 March 2028 254,028 1.14 121,250 May - June 2028 610,000 2.25 235,000 July 2028 235,000 2.25 - 3.75 125,139 August 2028 403,120 3.75 - 6.31 240,620 September 2028 7,014,374 1.13 - 3.75 3,818,541 October - November 2028 1,788,750 3.75 868,750 December 2028 220,000 6.50 110,000 January 2029 149,876 6.67 149,876 February 2029 85,000 6.50 21,250 March 2029 272,000 11.25 68,000 June 2029 1,171,250 10.28 297,500 September 2029 1,186,250 5.90 293,750 December 2029 582,000 6.86 145,500 March 2030 597,000 2.99 — May 2030 3,812,023 4.56 1,312,023 June 2030 885,000 4.11 — July 2030 19,544 5.39 19,544 September 2030 555,000 6.00 — December 2030 689,238 9.86 - 10.19 171,738 22,486,713 9,550,535 1 Origin House replacement awards are denominated in Canadian dollars. Exercise prices have been translated to U.S. dollar equivalents as of December 31, 2020. Weighted average stock price of options on the dates on which options were exercised during the years ended December 31, 2020 and 2019 was $5.96 and $7.12 per option, respectively. The fair value of stock options granted under the Plan during the years ended December 31, 2020 and 2019, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2020 2019 Risk-free annual interest rate 0.54% - 1.79 % 1.97% to 2.49 % Expected annual dividend yield — — Expected stock price volatility 65% to 81 % 77% to 88 % Expected life of stock options 5 to 7 years 5.5 to 7 years Forfeiture rate 5% - 15 % 0% to 3% Fair value at grant date $1.84 to $6.48 $3.88 to $8.26 Stock price at grant date $2.99 to $10.19 $5.90 to $11.25 Exercise price range $2.99 to $10.19 $5.90 to $11.25 Volatility was estimated by using the average historical volatility of comparable companies from a representative peer group of publicly traded companies. An increase in volatility would result in an increase in fair value at grant date. The expected life in years represents the period of time that options issued are expected to be outstanding. The risk-free rate is based on U.S. treasury bills with a remaining term equal to the expected life of the options. The forfeiture rate is estimated based on historical forfeitures experienced by the Company. During the years ended December 31, 2020 and 2019, the weighted-average fair value of stock options granted was $3.05 and $5.52 per option, respectively. As of December 31, 2020, stock options outstanding have a weighted-average remaining contractual life of 8.1 years. During the year ended December 31, 2020, the Company issued 0.6 million replacement options with a weighted average exercise price of $4.24 per option in connection with the Origin House acquisition. The replacement options have expiration dates ranging between October 2022 and August 2028. As of December 31, 2020, 0.3 million options with a weighted average exercise price of $5.13 per option are exercisable. Restricted Stock Units During 2019, the Company established an RSU program to provide employees an additional avenue to participate in the successes of the Company. The fair value of RSUs granted was determined by the fair value of the Company’s share price on the date of grant. A number of RSUs granted had the ability to settle in cash. These awards were determined to be liability classified awards and are required to be marked-to-market A summary of outstanding RSUs is provided below: Number of Weighted Outstanding - January 1, 2019 — $ — Granted 404,215 8.58 Outstanding – December 31, 2019 404,215 $ 8.58 Granted 661,190 6.00 Origin House replacement awards 3,430,456 5.96 Vested and settled (3,435,527 ) 5.23 Forfeited (66,005 ) 8.91 Outstanding - December 31, 2020 994,329 $ 6.54 Liability classified as of December 31, 2020 2,210 $ 9.86 All liability classified awards above are vested and pending issuance into shares. During the year ended December 31, 2020, the Company issued 3.4 million replacement RSUs with a weighted average fair value of $5.96 per share in connection with the Origin House acquisition. As a result of the acquisition, the vesting of the replacement RSUs was accelerated, with Canadian participants having the option to defer settlement. As such, there is no post-acquisition compensation expense required for these awards. Deferred Share Awards During the year ended December 31, 2020, the Company issued 1.6 million replacement deferred share awards in connection with the Origin House acquisition. The awards have a fair value of $5.96 per share, which is based on the Company’s share price as of the acquisition date. Awards are considered to be fully vested as of the acquisition date and therefore require no post-acquisition compensation expense. During the year ended December 31, 2020, 1.5 million shares settled into share capital. The remaining 0.1 million shares are pending issuance into shares as of December 31, 2020. Expense Attribution The Company recorded compensation expense for option awards in the amount of $15.8 million and $14.5 million for the years ended December 31, 2020 and 2019, respectively. For the years ended December 31, 2020 and 2019, the Company expensed $15.3 million and $13.8 million, respectively, to Selling, general and administrative expenses, with the remainder in Cost of sales – production costs and ending inventory. Unrecognized compensation expense as of December 31, 2020 for option awards is $16.8 million and will be recorded over the course of the next four years. The Company recorded compensation expense for RSU awards in the amount of $1.5 million and $1.2 for the years ended December 31, 2020 and 2019, respectively, of which $1.0 million and $0.3 million, respectively, is included in Selling, general and administrative expenses, with the remainder in Cost of sales – production costs and ending inventory. Unrecognized compensation expense as of December 31, 2020 is $3.2 million and will be recognized over the course of the next three years. The Company recorded post-acquisition compensation expense for replacement options in the amount of $51 thousand for the year ended December 31, 2020 in Selling, general and administrative expenses. Unrecognized compensation for replacement options was $6 thousand as of December 31, 2020 and will be recognized through the third quarter of 2021. As of December 31, 2020 and 2019, ending inventory includes immaterial and $0.9 million capitalized compensation expense related to both options and RSUs, respectively. Ending inventory includes compensation expense reductions attributable to an increased estimated forfeiture rate recognized during the year ended December 31, 2020 based on the Company’s historically experienced forfeitures. For the years ended December 31, 2020 and 2019, $1.8 million and $0.8 million, respectively, of compensation expense was recorded to Cost of sales – production costs, which includes $0.9 million and $39 thousand, respectively, related to compensation expense capitalized to inventory in prior years. |
Acquisitions
Acquisitions | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Acquisitions | NOTE 13. ACQUISITIONS (a) Business Combinations The table below summarizes significant business combinations completed during the year ended December 31, 2020: Completed during the year ended December 31, 2020 Origin House (ii) ($ in thousands) Total consideration Common shares issued $ 396,575 Replacement awards 31,671 Total consideration $ 428,246 Net identifiable assets (liabilities) acquired Cash $ 32,984 Accounts receivable 7,565 Inventory 14,658 Biological assets 2,002 Other current assets 2,197 Property and equipment 18,625 Right-of-use 17,984 Loans receivable, long-term 331 Investment in associate 4,302 Investments 139 Customer relationships 63,600 Trade names 39,700 Licenses 5,900 Market related intangibles 2,374 Internally developed software 380 Total identifiable assets acquired $ 212,741 Short-term liabilities $ (24,349 ) Lease liabilities (18,002 ) Deferred and contingent consideration (3,807 ) Notes payable (22,045 ) Deferred tax liabilities (30,200 ) Net identifiable assets acquired $ 114,338 Purchase price allocation Net identifiable assets acquired $ 114,338 Goodwill 313,908 Total consideration $ 428,246 Under IFRS 3, the Company retrospectively adjusted the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of the acquisition date. During the year ended December 31, 2020, the Company updated its valuation of Origin House intangible assets acquired, which resulted in an increase of $9.2 million to the acquisition date value of intangible assets and an associated increase of $2.8 million to the acquisition date value of the deferred tax liability, resulting in an offsetting reduction in goodwill. The Company has completed the purchase accounting related to Origin House and is no longer within the measurement period as of the issuance of the Consolidated Financial Statements. (i) Wellbeings On October 5, 2020, the Company acquired all remaining equity interests and voting rights of Wellbeings LLC (“Wellbeings”). As a result of this acquisition, the Company has control over a business that distributes and sells high quality CBD wellness products. No consideration was transferred for this step acquisition, other than the Company recognized $0.2 million of goodwill and assumed $0.2 million of net liabilities. The Company recognized a $0.5 million loss on a previous investment in Wellbeings, offset by a gain of $0.3 million related to the reversal of an expected credit loss on a loan that was extended to Wellbeings by the Company prior to the acquisition. (ii) Origin House On January 8, 2020, the Company announced that it had closed its acquisition of 100% of the membership interests of Origin House. As a result of this acquisition, the Company now holds additional licenses to cultivate and process medical and adult-use adult-use Total consideration for the acquisition was $428.2 million. The consideration consisted of 66.5 million SVS issued as of the acquisition date, valued at $396.6 million, and 5.7 million replacement awards, valued at $31.7 million. The replacement awards are comprised of 3.4 million replacement RSUs, 1.6 million deferred share awards and 0.6 million replacement options. The Company recorded an increase of $51 thousand of post-acquisition share-based compensation expense related to the replacement options for the year ended December 31, 2020. See Note 12 for additional details. As part of the acquisition, the Company recorded reserves of $0.1 million for potential The Company calculated, on a pro forma basis, the combined results of the acquired entity as if the Origin House acquisition had occurred as of January 1, 2020. These unaudited pro forma results are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of January 1, 2020 or of the future consolidated operating results. Total unaudited pro forma Revenue and Net loss for the combined company for the year ended December 31, 2020 was $476.9 million and $37.0 million, respectively. Contributed revenue and Net loss from the Origin House acquisition for the year ended December 31, 2020 was $88.7 million and $30.7 million, respectively. Since the first quarter of 2019, the Company has recorded transaction costs of $5.5 million in connection with the Origin House acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations. The table below summarizes business combinations completed during the year ended December 31, 2019: Completed during the year ended December 31, 2019 Valley Ag (iii) HHH (iv) Total ($ in thousands) Total consideration Cash $ 18,774 $ — $ 18,774 Deferred cash consideration 25,990 26,606 52,596 Common shares issued 48,881 — 48,881 Derivative liability consideration 5,437 — 5,437 Contingent consideration 20,346 — 20,346 Loan settlement 10,146 4,807 14,953 $ 129,574 $ 31,413 $ 160,987 Net identifiable assets (liabilities) acquired Cash $ 1,199 $ 313 $ 1,512 Accounts receivable 145 306 451 Inventory 800 4,703 5,503 Biological assets — 1,436 1,436 Other current assets 558 18 576 Property & equipment 7,256 8,524 15,780 Right-of-use 6,836 — 6,836 Other non-current 81 1 82 Customer relationships 1,200 300 1,500 Non-compete — 300 300 License 53,400 12,000 65,400 Total identifiable assets acquired $ 71,475 $ 27,901 $ 99,376 Short-term liabilities $ (690 ) $ (621 ) $ (1,311 ) Lease liability (6,980 ) — (6,980 ) Long-term liability — (550 ) (550 ) Deferred tax liability (16,108 ) — (16,108 ) Net identifiable assets acquired $ 47,697 $ 26,730 $ 74,427 Purchase price allocation Net identifiable assets acquired $ 47,697 $ 26,730 $ 74,427 Goodwill 81,877 4,683 86,560 Total consideration $ 129,574 $ 31,413 $ 160,987 Net cash outflows Cash consideration paid $ (18,774 ) $ (80 ) $ (18,854 ) Cash acquired 1,199 313 1,512 Total $ (17,575 ) $ 233 $ (17,342 ) No goodwill for any acquisition is expected to be deductible for tax purposes. Additionally, per IFRS 3, the Company retrospectively adjusted the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date and, if known, would have affected the measurement of the amounts recognized as of the acquisition date. During the year ended December 31, 2019, the Company recognized additional goodwill of $13 thousand related to the updated valuation of deferred consideration. The measurement period yielded no changes during 2020 and the purchase price allocation has been finalized. (iii) Gloucester Street Capital, LLC On October 8, 2019, the Company announced that it had closed its acquisition of 100% of the membership interests of Gloucester Street Capital, LLC, the parent entity of Valley Agriceuticals, LLC via a merger between Gloucester and a subsidiary of Cresco Labs. As a result of this acquisition, Cresco Labs now holds one of 10 vertically integrated cannabis business licenses granted in the State of New York by the New York State Department of Health. Total consideration for the acquisition was $129.6 million. Total consideration consisted of $18.8 million in cash consideration, equity consideration of $49 thousand which consisted of 8.7 million PVS (as converted), warrants classified as long-term derivative liabilities convertible into 2.0 million PVS (as converted) valued at $5.4 million, $26 thousand in deferred cash consideration, valued at present value, $20.3 million in contingent consideration and settlement of a loan receivable valued at $10.1 million. The maximum payment of contingent consideration is 4.8 million PVS (as converted) (includes potential fractional shares to be paid in cash) of which the ultimate value will fluctuate along with the movement of the Company’s stock price. See section (c) and (d) of this note for discussion of the methodology of the calculation of contingent consideration. See Note 20 for additional detail on liability-classified warrants. The Company calculated, on a pro forma basis, the combined results of the acquired entity as if the Valley Ag acquisition had occurred as of January 1, 2019. These unaudited pro forma results are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of January 1, 2019 or of the future consolidated operating results. Total unaudited pro forma revenue and net loss for the combined company for the year ended December 31, 2019 was $129.8 million and $68.9 million, respectively. Contributed revenue and net loss from the Valley Ag acquisition was $0.8 million and $0.5 million, respectively, from the acquisition date through December 31, 2019. The Company recorded transaction costs of $2.0 million in connection with the Valley Ag acquisition as Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2019. (iv) Hope Heal Health, Inc. (“HHH”) and 1880 West, LLC, (“1880 W”), collectively referred to as (“HHH”) On October 1, 2019, in order to enter the Massachusetts market, Cresco Labs, LLC acquired HHH via certain agreements giving it operational control before cash consideration was settled. HHH holds licenses to cultivate, process and dispense medical and adult-use adult-use Total consideration for the acquisition was $31.4 million consisting of deferred cash consideration, valued at present value, of $26.6 million and settlement of a pre-existing The Company calculated, on a pro forma basis, the combined results of the acquired entity as if the HHH acquisition had occurred as of January 1, 2019. These unaudited pro forma results are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of January 1, 2019 or of the future consolidated operating results. Total unaudited pro forma revenue and net loss for the combined company for the year ended December 31, 2019 was $129.6 million and $68.3 thousand, respectively. Contributed revenue and net income from the HHH acquisition was $2.0 million and $3.0 million, respectively, from the acquisition date through December 31, 2019. The Company recorded transaction costs of $0.6 million in connection with the HHH acquisition in Selling, general and administrative expenses in the Consolidated Statements of Operations for the year ended December 31, 2019. (b) Deferred Consideration, Contingent Consideration and Other Payables The following is a summary of deferred consideration and other payables balances as of December 31, 2020 and 2019, which are classified as short term: ($ in thousands) IFRS 9 classification 2020 2019 MedMar contingent consideration liability for tax payments FVTPL $ — $ 2,000 MedMar contingent consideration liability FVTPL — 1,927 Interest payable - short term Amortized Cost — 1,464 HHH deferred consideration FVTPL — 27,237 Valley Ag deferred consideration Amortized Cost — 18,750 Valley Ag operating cash flows consideration FVTPL — 7,423 Valley Ag make-whole liability FVTPL — 800 Valley Ag contingent consideration FVTPL 19,093 — Liability-classified equity awards FVTPL 22 339 Total Deferred consideration, contingent consideration and other payables $ 19,115 $ 59,940 Decreases in deferred consideration between December 31, 2019 and December 31, 2020 are due to fair value adjustments and payments of deferred consideration related to acquisitions of MedMar, HHH and Valley Ag. For the year ended December 31, 2020, the Company recognized a mark-to-market During the year ended December 31, 2020, the Company paid $27.5 million to settle the HHH deferred consideration and recorded $0.3 million in interest expense. During the year ended December 31, 2020, the Company paid $18.8 million and issued 0.3 million PVS (as-converted), The Valley Ag operating cash flows consideration was reclassified to long-term liabilities as it is expected to be settled in more than 12 months. The Valley Ag make-whole adjustment liability, which compensated previous owners for agreeing to a securities lock-up mark-to-market During the year ended December 31, 2020, the Company recorded a mark-to-market In connection with the Origin House acquisition, the Company acquired deferred consideration liabilities valued at $3.8 million, primarily related to $3.7 million of deferred consideration associated with Origin House’s previous acquisition of Cub City. In May 2020, the Company settled these obligations through issuance of 0.8 million SVS, valued at $2.2 million and cash payment of $1.5 million. In May 2020, the Company issued 0.3 million shares, valued at $1.0 million, in accordance with the post combination remuneration agreement with FloraCal. The Company holds various real estate property approximating $10.0 million in fair value as collateral for certain deferred payment obligations. (c) Long-term Deferred and Contingent Consideration The following is a summary of long-term contingent consideration as of December 31, 2020 and 2019: ($ in thousands) IFRS 9 classification 2020 2019 Valley Ag contingent consideration FVTPL $ — $ 21,901 Valley Ag operating cash flows consideration FVTPL 7,247 — Total Long-term deferred and contingent consideration $ 7,247 $ 21,901 During the year ended December 31, 2020, the Company recorded a $0.2 million decrease to the present value of Valley Ag operating cash flows consideration due to changes in the Company’s incremental borrowing rate and other present value considerations. As of December 31, 2020, the estimated liability of $7.2 million is based on the present value of expected payments associated with future cashflows of the acquired business. |
Long-term Notes and Loans Payab
Long-term Notes and Loans Payable | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Long-term Notes and Loans Payable | NOTE 14. LONG-TERM NOTES AND LOANS PAYABLE The following table represents the Company’s loans payable balances as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 Term Loan $ 180,863 $ — Interest payable 3,658 — HHH Loan — 550 Total borrowings and interest payable $ 184,521 $ 550 Less Short-term borrowings and interest payable (15,046 ) — Total Long-term notes and loans payable $ 169,475 $ 550 (a) Amended Term Loan On February 2, 2020, the Company closed on a senior secured term loan agreement (the “Term Loan”) for an aggregate principal amount of $100 million, with the option to increase the principal amount to $200 million. Of the $100 million Term Loan commitment, $92.4 million was committed by Tranche A lenders (the “Tranche A Commitment”) and $7.6 million was committed by Tranche B lenders (the “Tranche B Commitment”). The Tranche A Commitment accrued interest at a rate of 12.7% per annum, payable in cash quarterly, and had a stated maturity of July 2021. The Tranche B Commitment accrued interest at a rate of 13.2% per annum, payable in cash quarterly, and had a stated maturity of January 2022. The Company’s effective interest rates for the Tranche A Commitment and Tranche B Commitment of the Term Loan were 17.0% and 16.1%, respectively. The Company capitalized $5.5 million and $0.4 million, respectively, of borrowing costs related to the Tranche A Commitment and Tranche B Commitment. On December 11, 2020, the Company entered into an amendment to exercise the mutual option to increase the principal amount to $200 million and refinance the existing Term Loan and the Opaskwayak Cree Nation Loan (the “OCN Loan”), resulting in one amended term loan (the “Amended Term Loan”). As a result of the non-substantial non-extending “Non-Extending The Non-Extending Non-Extending Non-Extending The Amended Term Loan is secured by a guarantee from substantially all material subsidiaries of the Company, as well as by a security interest in certain assets of the Company and such material subsidiaries. The Amended Term Loan also contains negative covenants which restrict the actions of the Company and its subsidiaries during the term of the loan, including restrictions on paying dividends, making investments and incurring additional indebtedness. The Company may prepay in whole or in part the Amended Term Loan at any time prior to the stated maturity date, subject to certain conditions, upon the payment of the outstanding principal amount (plus a specified prepayment premium) and all accrued and unpaid interest and fees. For the year ended December 31, 2020, the Company recognized $16.0 million of interest expense attributable to the Term Loan, including interest expense related to the amortization of the debt issuance costs of $3.6 million. (b) OCN Loan In conjunction with its January 8, 2020 acquisition of Origin House, the Company recorded a short-term liability, the OCN Loan, for an aggregate balance of $22.0 million as of the acquisition date, subject to a 10% interest rate and a stated maturity of June 2020. The weighted average effective interest rate of the OCN Loan was 23.8%. On June 30, 2020, the OCN Loan was amended to extend the maturity date from June 30, 2020 to June 30, 2021 for an extension fee of $0.6 million which was recorded within Accounts payable and other accrued expenses and was amortized over the extended term. Fees, interest and principal payments were made in regular monthly installments through the maturity date. As a result of the non-substantial On September 29, 2020, the OCN Loan was amended to restate the principal repayment terms for an extension fee of $0.1 million which was recorded within Accounts payable and other accrued expenses. Fees, interest and principal payments were made in regular monthly installments through the maturity date. As a result of the non-substantial For the year ended December 31, 2020, the Company recognized interest expense of $4.5 million attributable to the OCN Loan, including interest expense related to the accretion of discount on the OCN Loan of $2.5 million. As discussed above, the OCN Loan was settled in December 2020, in conjunction with the amendment of the Term Loan. (c) Other Loans In conjunction with its October 1, 2019 acquisition of HHH, the Company recorded a long-term liability for the HHH Loan for an aggregate balance of $0.6 million with a stated maturity of June 2021. During June 2020, the Company paid off the $0.6 million outstanding principal balance as part of a sale-leaseback transaction. See Note 7 for additional details on the transaction. |
Revenue and Loyalty Programs
Revenue and Loyalty Programs | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Revenue and Loyalty Programs | NOTE 15. REVENUE AND LOYALTY PROGRAMS (a) Revenue The following table represents the Company’s disaggregated revenue by source, primarily due to the Company’s contracts with its customers, for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Wholesale $ 274,000 $ 79,927 Dispensary 202,251 48,607 Total Revenue $ 476,251 $ 128,534 The Company generates revenue at the point in time the control of the product is transferred to the customer, as the Company has a right to payment, and the customer has assumed significant risks and rewards of such product. The Company does not engage in long-term sales contracts. During the year ended December 31, 2019, the Company recorded $2.1 million of revenue under IFRS 15 related to a bill-and-hold (b) Loyalty Programs The Company has customer loyalty programs where retail customers accumulate points based on their level of spending. These points are recorded as a contract liability until customers redeem their points for discounts on cannabis and vape products as part of an in-store |
Selling, General and Administra
Selling, General and Administrative Expenses | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Selling, General and Administrative Expenses | NOTE 16. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES For the years ended December 31, 2020 and 2019, Selling, general and administrative expenses consisted of the following: ($ in thousands) 2020 2019 Salaries and related $ 81,067 $ 28,519 Consulting and professional fees 24,576 18,091 Advertising and marketing 19,030 12,630 Office 17,696 4,884 Share based compensation 16,659 14,046 Provision expense (Note 19) 13,600 — Excise taxes 13,167 4,341 Technology 7,604 1,989 Insurance 4,358 1,911 Travel and entertainment 3,074 4,154 Rent expense 1,478 286 Business expansion costs 1,586 1,524 Other 2,843 1,743 Total Selling, general and administrative expense $ 206,738 $ 94,118 |
Other (Expense) Income, Net
Other (Expense) Income, Net | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Other (Expense) Income, Net | NOTE 17. OTHER (EXPENSE) INCOME, NET For the years ended December 31, 2020 and 2019, Other (expense) income, net consisted of the following: ($ in thousands) 2020 2019 (Loss) gain on derivative instruments (Note 20) $ (13,319 ) $ (3,236 ) Gain on conversion of loan to investment — 703 Gain (loss) on changes in fair value of deferred and contingent consideration (Note 13) 2,126 (3,186 ) Gain on debt modification (Note 14) 5,409 — Gain on changes in fair value of loans receivable (Note 20) 921 1,515 Impairment on loan receivable (Note 20) (902 ) (3,037 ) Loss on sale leaseback transactions (Note 7) — (670 ) Sale and leaseback settlement costs (Note 7) (479 ) — Dividend income — 97 Unrealized loss on investments held at fair value (Note 8) (160 ) (2,827 ) (Loss) gain on foreign currency (2,394 ) 421 Other (loss) income on investments (1,000 ) — Gain on dissolution of previously held equity investment (Note 8) — 1,309 Other income, net 1,789 264 Total Other (expense) income, net $ (8,009 ) $ (8,647 ) |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Related Party Transactions | NOTE 18. RELATED PARTY TRANSACTIONS (a) Compensation of Key Management Personnel The Company’s key management personnel, consisting of the executive management team and management directors, have the authority and responsibility for planning, directing, and controlling the activities of the Company. The material transactions with related parties and changes in related party balances for the year ended December 31, 2020 are discussed below. Key management personnel compensation for the years ended December 31, 2020 and 2019 was as follows: ($ in thousands) 2020 2019 Management compensation $ 6,234 $ 3,139 Share-based compensation expense 10,992 5,972 Total $ 17,226 $ 9,111 As of December 31, 2020 and 2019, the Company had receivables of $0.2 million and $0.7 million, respectively, with key management personnel. As of December 31, 2020 and 2019, the Company had payables of $2.3 million and $0.1 million, respectively, with key management personnel. Key management personnel hold 109.4 million redeemable units of Cresco Labs, LLC, which is equal to $125.6 million of Non-controlling (b) Related Parties - Debt As of December 31, 2020, the Company had borrowings with related parties of $18.3 million related to the Company’s Term Loan. During the year ended December 31, 2020 and 2019, the Company recorded interest expense related to borrowings with related parties of $1.8 million and $nil, respectively. As of December 31, 2020 and 2019, the Company had interest payable related to borrowings with related parties of $0.1 million and $nil, respectively. See Notes 14 and 23 for additional details. (c) Related Parties - Leases The Company has lease liabilities for real estate lease agreements in which the lessors have minority interest in SLO and MedMar Inc. The lease liabilities were incurred in January 2019 and May 2020 and will expire in 2027 through 2036. The Company has lease liabilities for real estate lease agreements in which the lessor is a member of key management personnel. The lease liabilities were incurred by entering into operating leases and sale and leaseback transactions with lease terms that will expire in 2030 during the year ended December 31, 2020. During the year ended December 31, 2020, the sale and leaseback transactions resulted in net funding of $8.6 million. During the year ended December 31, 2020, the Company received tenant improvement allowance reimbursements of $0.8 million related to these lease agreements and expects to receive further reimbursements of $2.2 million as of December 31, 2020. Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2020 and 2019. 2020 2019 ($ in thousands) Depreciation expense Interest expense Depreciation expense Interest expense Finance lease liability; lessor has minority interest in SLO $ 295 $ 1,494 $ 382 $ 1,650 Finance lease liability; lessor has minority interest in MedMar 209 281 155 177 Finance lease liability; lessor is a member of key management personnel 551 564 — — Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party lease liabilities. 2020 2019 ($ in thousands) ROU asset Lease liability ROU asset Lease liability Finance lease liability; lessor has minority interest in SLO $ 5,219 $ 8,551 $ 9,930 $ 11,727 Finance lease liability; lessor has minority interest in MedMar 2,322 2,552 1,292 1,380 Finance lease liability; lessor is a member of key management personnel 8,371 6,925 — — |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Commitments and Contingencies | NOTE 19. COMMITMENTS AND CONTINGENCIES (a) Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2020, there were no pending or threatened lawsuits, except as disclosed below, that could reasonably be expected to have a material effect on the results of the Company’s operations. There are also no proceedings in which any of the Company’s directors, officers, or affiliates are an adverse party or has a material interest adverse to the Company’s interest. During the year ended December 31, 2020, the Company recorded a provision of $0.1 million related to the Origin House acquisition. The Company subsequently reached an agreement to settle the previously recorded $0.1 million provision. The cash payment to settle the liability was made during the year ended December 31, 2020. During the year ended December 31, 2020, a former executive of the Company commenced proceedings against the Company. On January 29, 2021, the Company commenced an action in the Supreme Court of British Columbia against various parties, including this former executive and a special purpose acquisition entity. On February 1, 2021, a binding settlement was reached and the terms were memorialized in an agreement as of March 1, 2021. The agreed-upon terms included a payment of 1.3 million SVS to the counterparty relating to certain equity awards previously held by the counterparty in exchange for a number of covenants including non-solicitation, non-hire, Provisions, Contingent Liabilities and Contingent Assets Events After the Reporting Period (b) Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management believes that the Company is in substantial compliance with applicable local and state regulations as of December 31, 2020, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future. (c) Commitments As of December 31, 2020, the Company had total commitments related to construction projects of $31.6 million, which will mostly be reimbursed through tenant improvement allowances in 2021. |
Financial Instruments And Fina
Financial Instruments And Financial Risk Management | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Financial Instruments And Financial Risk Management | NOTE 20. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT Financial Instruments The Company’s financial instruments are held at amortized cost (adjusted for impairments or expected credit losses, as applicable) or FVTPL. The carrying values of financial instruments held at amortized cost approximate their fair values as of December 31, 2020 and 2019 due to their nature and relatively short maturity date. Financial assets and liabilities with embedded derivative features are carried at FVTPL. Financial instruments recorded at fair value are classified using a fair value hierarchy that reflects the significance of the inputs to fair value measurements. The three levels of hierarchy are: • Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; and • Level 3 – Inputs for the asset or liability that are not based on observable market data. There have been no transfers between fair value levels valuing these assets during the year. The following tables summarize the Company’s financial instruments as of December 31, 2020 and 2019: 2020 ($ in thousands) Amortized Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 136,339 $ — $ — $ — $ 136,339 Restricted cash 1 4,435 — — — 4,435 Accounts receivable, net 29,266 — — — 29,266 Loans receivable, short-term 921 — 2,237 (720 ) 2,438 Loans receivable, long-term 1,204 — — 20,020 21,224 Investments 2 3,192 — 1,049 119 4,360 Security deposits 3,558 — — — 3,558 Financial Liabilities: Accounts payable and other accrued expenses $ 86,326 $ — $ — $ — $ 86,326 Short-term borrowings 15,046 — — — 15,046 Current portion of lease liabilities 24,742 — — — 24,742 Deferred consideration, contingent consideration and other payables — 22 — 19,093 19,115 Derivative liabilities, long-term — — 30,129 — 30,129 Lease liabilities 145,320 — — — 145,320 Deferred consideration and contingent consideration — — — 7,247 7,247 Long-term notes payable and loans payable 169,475 — — — 169,475 1 Restricted cash balances include various escrow accounts related to investments, acquisitions, facility requirements and building improvements. 2 Investment balances in the amortized cost column represent equity method investments. 2019 ($ in thousands) Amortized Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 49,102 $ — $ — $ — $ 49,102 Restricted cash 1 5,050 — — — 5,050 Accounts receivable, net 16,455 — — — 16,455 Loans receivable, short-term 644 — — — 644 Loans receivable, long-term 390 — 18,243 — 18,633 Investments — — 1,210 68 1,278 Security deposits 1,084 — — — 1,084 Financial Liabilities: Accounts payable and other accrued expenses $ 62,834 $ — $ — $ — $ 62,834 Current portion of lease liabilities 12,019 — — — 12,019 Deferred consideration, contingent consideration and other payables 49,451 339 — 10,150 59,940 Derivative liabilities, short-term — — 178 — 178 Derivative liabilities, long-term — — 15,243 — 15,243 Lease liabilities 82,856 — — — 82,856 Deferred consideration and contingent consideration — — — 21,901 21,901 Long-term notes payable and loans payable 550 — — — 550 1 cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. (a) Loans receivable, short-term The following is a summary of Loans receivable, short-term balances and IFRS 9 classifications (discussed further below) as of December 31, 2020 and 2019: ($ in thousands) IFRS 9 classification 2020 2019 Short-term loans receivable - Lighthouse FVTPL $ 1,517 $ — Interest receivable Amortized cost 921 644 Total Loans receivable, short-term $ 2,438 $ 644 (i) Lighthouse Loan On August 12, 2019, the Company issued a secured convertible promissory note that is convertible, at the Company’s discretion, into additional membership units approximating 1% ownership of the parent company of Lighthouse. At inception, the loan had a maturity of 18 months. This loan is measured at FVTPL and as of December 31, 2020, this loan had a fair value of $1.5 million. As of December 31, 2019, this loan had a fair value of $2.2 million and was classified as Loans receivable, long-term. See Note 8 for discussion of the Company’s investment in Lighthouse Expected Credit Loss The Company calculates ECLs for Loans receivable, short-term by considering cash shortfalls on a discounted basis it would incur in various default scenarios for prescribed future periods and multiplying the shortfalls by the probability of each scenario occurring, which is determined through the exercise of judgment. The Company recognized impairment losses of $0.7 million and $nil during the years ended December 31, 2020 and 2019, respectively, on Loans receivable, short-term. (b) Loans receivable, long-term ($ in thousands) IFRS 9 classification 2020 2019 Long-term loans receivable - Verdant FVTPL $ 20,020 $ 16,007 Long-term loans receivable - Lighthouse FVTPL — 2,236 Long-term loans receivable - Other Amortized cost 367 390 Interest receivable Amortized cost 837 — Total Loans receivable, long-term $ 21,224 $ 18,633 (i) Verdant Loan The Company entered into certain loan arrangements with Verdant Creations, LLC that contained embedded derivatives comprised of a call and put option and a stated interest rate of 5.25%. Settlement of the instruments varies based on contingent events and returns are not fixed. As such, the Company records this loan receivable at FVTPL. Each period, the loan is measured using a probability-weighting analysis of expected outcomes, which utilizes Level 3 inputs. The inputs included market rates ranging from 1.7% to 17.4%, a risk-free rate of 0.1% and expected settlement timing of less than 12 months. Refer to Note 25 for additional information regarding the acquisition of Verdant Creations, LLC. Changes in Level 3 inputs and assumptions utilized resulted in a fair value gain of $0.9 million and $2.0 million for the year ended December 31, 2020 and 2019, respectively. The loan had a fair value of $20.0 million and $16.0 million as of December 31, 2020 and 2019, respectively, with attributable long-term interest receivable of $0.8 million and $nil, respectively, and short-term interest receivable of $0.5 million and $nil, respectively. As of the year ended December 31, 2020, of the $16.9 million maximum loan commitment, $17.1 million was drawn on these loans as the Company allowed the borrower to exceed the maximum loan commitment. The loan arrangements will be effectively settled and included as a part of purchase consideration upon the Company’s acquisition of Verdant Creations, LLC. Refer to Note 25 for additional information regarding the acquisition of Verdant Creations, LLC. (ii) Other Loans In connection with the acquisition of Origin House, the Company assumed a loan receivable with a fair value of $0.4 million and $0.3 million as of December 31, 2020 and the acquisition date, respectively. An outstanding long-term loan receivable with Wellbeings of $0.5 million was effectively settled as a preexisting relationship between the acquirer and acquiree as part of the business combination, resulting in a reversal of the $0.3 million expected credit loss that was previously recorded against the loan balance. Expected Credit Loss The Company calculates ECLs for Loans receivable, long-term by considering cash shortfalls on a discounted basis it would incur in various default scenarios for prescribed future periods and multiplying the shortfalls by the probability of each scenario occurring, which is determined through the exercise of judgment. The Company recognized impairment losses of $0.2 million and $nil, net of reversals, during the year ended December 31, 2020 and 2019 on Loans receivable, long-term. (c) Derivative Liability In conjunction with its acquisition of PDI, the Company recorded a derivative liability of $0.2 million at the acquisition date for an NCI put option, by which the remaining NCI holders could put their shares for a fixed amount of cash within one year of the acquisition legal close/funding date. The derivative was valued using a discount rate of 9.0%. In April 2020, these holders exercised their put option which resulted in the Company paying $0.2 million to purchase the unowned interest of PDI, the Company recorded a $25 thousand mark-to-market (d) Share Purchase Warrants At December 31, 2020, the Company had 6.2 million warrants outstanding classified as Derivative liabilities, long-term, from issuances to underwriters associated with September 2019 financing and sellers from the Valley Ag acquisition. During the year ended December 31, 2020, 43 thousand Valley Ag warrants were exercised for $0.2 million, resulting in a realized loss of $47 thousand and an increase to share capital of $0.4 million. During the year ended December 31, 2020, 18 thousand Randsburg warrants were exercised for $0.1 million, resulting in an increase to share capital of $0.1 million. No additional Randsburg warrants remain outstanding as of December 31, 2020. During the year ended December 31, 2020, the Company recorded a mark-to-market mark-to-market All warrants classified as long-term derivative liabilities are measured at FVTPL. As of December 31, 2020 and 2019, the fair value of liability-classified warrants was determined using the Black-Scholes option-pricing model utilizing the following assumptions: 2020 2019 Risk-free annual interest rate 0.13% 1.58% - 1.61% Expected annual dividend yield 0% 0% Expected stock price volatility 83% 81% Expected life of stock warrants 1.75 - 1.83 years 0.4 - 1.4 years Forfeiture rate 0% 0% Share price at period end $9.86 $6.86 Volatility was estimated by using the average historical volatility of comparable companies from a representative peer group of publicly traded cannabis companies. An increase in volatility would result in an increase in fair value at grant date. The expected life in years represents the period of time before warrants expire. The risk-free rate is based on U.S. treasury bills with a remaining term equal to the expected life of the options. The Company does not expect grantees to forfeit warrants. Financial Risk Management The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board and Company management mitigate these risks by assessing, monitoring and approving the Company’s risk management processes: (a) Credit and Banking Risk Credit risk is the risk of a potential loss to the Company if a customer or a third party to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at December 31, 2020 and 2019 is the carrying amount of cash, accounts receivable, and loans receivable. The Company does not have significant credit risk with respect to its customers or loan counterparties, based on cannabis industry growth in its key markets and the low interest rate environment. Although all deposited cash is placed with U.S. financial institutions in good standing with regulatory authorities, changes in U.S. federal banking laws related to the deposit and holding of funds derived from activities related to the cannabis industry have passed the House of Representatives but have not yet been voted on within the Senate. Given that current U.S. federal law provides that the production and possession of cannabis is illegal, there is a strong argument that banks cannot accept for deposit funds from businesses involved with the cannabis industry. The novel coronavirus (“COVID-19”) The Company’s aging of Accounts receivables as of December 31, 2020 and 2019 was approximately as follows: ($ in thousands) 2020 2019 0 to 60 days $ 27,604 $ 10,276 61 to 120 days 1,134 5,551 120 days + 1,224 899 Total accounts receivable, gross $ 29,962 $ 16,726 For the years ended December 31, 2020 and 2019, the Company recorded bad debt expense of $0.4 million and $0.3 million, respectively, to account for expected credit loss and recorded an additional $0.4 million and $0.2 million, respectively, in bad debt related to invoice write-offs. (b) Asset Forfeiture Risk Because the cannabis industry remains illegal under U.S. federal law, any property owned by participants in the cannabis industry which are either used in the course of conducting such business, or are the proceeds of such business, could be subject to seizure by law enforcement and subsequent civil asset forfeiture. Even if the owner of the property was never charged with a crime, the property in question could still be seized and subject to an administrative proceeding by which, with minimal due process, it could be subject to forfeiture. (c) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations associated with financial liabilities. The Company primarily manages liquidity risk through the management of its capital structure by ensuring that it will have sufficient liquidity to settle obligations and liabilities when due. As of December 31, 2020, the Company had working capital (defined as current assets less current liabilities) of $167.1 million, which reflects the amendment of the Term Loan as discussed in Note 14. In December, 2020 the Company amended the existing term loan facility increasing the total principal outstanding to $200 million. In December 2019, the Company entered into the ATM Offering for subordinated voting shares in the Company to be issued at the discretion of management to raise up to C$55 million to fund corporate operations. See Note 11 for further information. Additionally, the Company expects to receive tenant improvement allowances of $47.7 million to fund further expansion. Information about tenant improvement allowances and the maturity analysis for lease obligations is located in Note 7. The Company will continue to raise capital as needed to fund operations and expansion. In addition to the commitments outlined in Note 7, the Company has the following contractual obligations as of December 31, 2020: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable & other accrued expenses $ 86,326 $ — $ — $ 86,326 Deferred consideration, contingent consideration and other payables 19,115 — — 19,115 Deferred consideration and contingent consideration — 7,247 — 7,247 Long-term notes payable and loans payable and Short-term borrowings 15,046 169,475 — 184,521 Total obligations as of December 31, 2020 $ 120,487 $ 176,722 $ — $ 297,209 In addition to the commitments outlined in Note 7, the Company has the following contractual obligations as of December 31, 2019: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable and other accrued expenses $ 62,834 $ — $ — $ 62,834 Deferred consideration, contingent consideration and other payables 59,940 — — 59,940 Deferred consideration and contingent consideration — 21,901 — 21,901 Other long-term liabilities — 550 — 550 Total obligations as of December 31, 2019 $ 122,774 $ 22,451 $ — $ 145,225 (d) Market Risk (i) Currency Risk The operating results and financial position of the Company are reported in U.S. dollars. As of December 31, 2020 and 2019, the Company’s financial assets and liabilities are denominated primarily in U.S. dollars. However, from time to time some of the Company’s financial transactions are denominated in currencies other than the U.S. dollar. The results of the Company’s operations are subject to currency transaction and translation risks. The Company recorded a $2.4 million foreign exchange loss and a $0.4 million foreign exchange gain during the years ended December 31, 2020 and 2019, respectively. See Note 17 for additional details. As of December 31, 2020 and 2019, the Company had no hedging agreements in place with respect to foreign exchange rates. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks at this time. (ii) Interest Rate Risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. An increase or decrease in the Company’s incremental borrowing rate by 10% would result in an associated increase or decrease in Deferred consideration, contingent consideration and other payables and Interest expense, net of $0.2 million. The Company’s effective interest rates for its Term Loan range from 17.6% to 18.1% and the stated interest rate varies from 12.0% to 12.7% based on the term elected by the lender. See Note 14 for further information. (iii) Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company is subject to price risk related to derivative liabilities and contingent consideration that are valued based on the Company’s own stock price. An increase or decrease in stock price by 10% would result in an associated increase or decrease of $6.7 million or $6.5 million, respectively, in both the fair value of derivative liabilities and contingent consideration and Other (expense) income, net. (iv) Tax Risk Tax risk is the risk of changes in the tax environment that would have a material adverse effect on the Company’s business, results of operations, and financial condition. Currently, state licensed marijuana businesses are assessed a comparatively high effective federal tax rate due to section 280E, which bars businesses from deducting all expenses except their cost of sales when calculating federal tax liability. Any increase in tax levies resulting from additional tax measures may have a further adverse effect on the operations of the Company, while any decrease in such tax levies will be beneficial to future operations. See Note 24 for the Company’s disclosure of uncertain tax positions. (v) Regulatory Risk Regulatory risk pertains to the risk that the Company’s business objectives are contingent, in part, upon the compliance of regulatory requirements. Due to the nature of the industry, the Company recognizes that regulatory requirements are more stringent and punitive in nature. Any delays in obtaining, or failure to obtain regulatory approvals can significantly delay operational and product development and can have a material adverse effect on the Company’s business, results of operation, and financial condition. The Company is cognizant of the advent of regulatory changes occurring in the cannabis industry on the city, state, and national levels. Although regulatory outlook on the cannabis industry has been moving in a positive trend, the Company is aware of the effect that unforeseen regulatory changes could have on the goals and operations of the business as a whole. |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Segment Information | NOTE 21. SEGMENT INFORMATION The Company operates in one segment, the cultivation, manufacturing, distribution, and sale of cannabis. For the year ended December 31, 2020, the Company generated 98% of its revenue in the United States with the remainder generated in Canada. For the year ended December 31, 2019, all revenues were generated in the United States. |
Earnings (Loss) Per Share
Earnings (Loss) Per Share | 12 Months Ended |
Dec. 31, 2020 | |
Earnings per share [abstract] | |
Earnings (Loss) Per Share | NOTE 22. EARNINGS (LOSS) PER SHARE Earnings (loss) per share (“EPS”) is calculated by dividing the net earnings or loss attributable to shareholders by the weighted average shares outstanding. Potentially dilutive securities of approximately 146.2 million and 152.1 million for the years ended December 31, 2020 and 2019, respectively, were excluded in the calculation of diluted EPS for these periods as their impact would have been anti-dilutive due to net losses in the periods. The following is a reconciliation for the calculation of basic and diluted loss per share for the years ended December 31, 2020 and 2019: (in thousands, except per share data) 2020 2019 Basic and diluted loss per share Net loss attributable to Cresco Labs Inc. shareholders $ (81,925 ) $ (43,201 ) Weighted-average number of shares outstanding 210,466 118,318 Loss per share – basic and diluted $ (0.39 ) $ (0.37 ) |
Interest (Expense) Income, Net
Interest (Expense) Income, Net | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Interest (Expense) Income, Net | NOTE 23. INTEREST (EXPENSE) INCOME, NET Interest expense, net consisted of the following for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Interest expense – leases $ (20,375 ) $ (7,078 ) Interest expense – notes and loans payable (14,353 ) — Accretion of debt discount and amortization of deferred financing fees (6,139 ) — Other interest expense (40 ) (2,380 ) Interest income 1,414 1,583 Total Interest expense, net $ (39,493 ) $ (7,875 ) See Note 7 for additional information regarding Interest expense – leases and Note 14 for additional information on Interest expense – notes and loans payable and Accretion of debt discount and amortization of deferred financing fees. |
Provision For Income Taxes And
Provision For Income Taxes And Deferred Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Provision For Income Taxes And Deferred Income Taxes | NOTE 24. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES The Company accounts for income taxes in accordance with IAS 12 Income Taxes As the Company operates in the legal cannabis industry, the Company is subject to the limits of Internal Revenue Code (“IRC”) Section 280E for US federal income tax purposes as well as state income tax purposes for all states except for California. Under IRC Section 280E, the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable The Company is treated as a United States corporation for US federal income tax purposes under IRC Section 7874 and is subject to US federal income tax on its worldwide income. However, for Canadian tax purposes, the Company, regardless of any application of IRC Section 7874, is treated as a Canadian resident company (as defined in the Income Tax Act (Canada) (the “ITA”) for Canadian income tax purposes. As a result, the Corporation is subject to taxation both in Canada and the United States. As of December 31, 2020, the Company has $nil million of non-capital non-Capital As of December 31, 2019, the Company had $1.7 million of non-capital The Company determined that the tax impact of certain arrangements between its management companies and operating companies is not probable of being sustained under IFRIC 23 due to the evolving interpretations of IRC Section 280E. As a result, the Company recorded a reserve for an uncertain tax position of $15.5 million and $7.5 million as of December 31, 2020 and 2019, respectively. Of this amount, $0.6 million relates to penalties and $0.5 million relates to interest as of December 31, 2020, and $0.5 million relates to penalties and $0.2 million relates to interest as of December 31, 2019. The amounts above may differ from the amounts recorded in Deferred tax asset and Deferred tax liability in the Consolidated Statements of Financial Position due to netting for tax filing groups for which the company has the legal right and intention to settle on a net basis as allowable under IAS 12.71. Provision for income taxes consists of the following for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Current Federal $ 35,784 $ 10,455 State 12,383 2,830 Total current $ 48,167 $ 13,285 Deferred Federal $ (2,566 ) $ 1,124 State (1,881 ) 52 Total deferred $ (4,447 ) $ 1,176 Total $ 43,720 $ 14,461 As of December 31, 2020 and 2019, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2020 2019 Deferred tax assets Share-based compensation $ 2,080 $ 1,177 Net operating losses 12,440 1,285 Lease liabilities 20,146 13,202 Inventory — 188 Other 817 425 Total deferred tax assets $ 35,483 $ 16,277 Deferred tax liabilities Biological assets $ (7,396 ) $ (4,213 ) ROU assets (8,699 ) (6,488 ) Inventory (8,026 ) — Property, plant and equipment (8,407 ) (7,923 ) Intangible assets (48,517 ) (18,877 ) Other (137 ) (227 ) Total deferred tax liabilities $ (81,182 ) $ (37,728 ) Net deferred tax liabilities $ (45,699 ) $ (21,451 ) The amounts above may differ from the amounts recorded in Deferred tax asset and Deferred tax liability in the Consolidated Statements of Financial Position due to netting for tax filing groups for which the company has the legal right and intention to settle on a net basis as allowable under IAS 12.71. The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2020 2019 Expected income tax (recovery) expense at statutory tax rate $ 4,833 $ (10,783 ) Tax rate differences 76 (5,383 ) Pass through and non-controlling (13,559 ) 186 State tax expense, net 11,148 1,726 Permanently non-deductible 29,635 16,382 Uncertain tax treatment 7,598 4,875 Share-based compensation 3,349 3,869 Change in tax status — 3,102 Return-to-provision (4,301 ) — Net changes in deferred tax assets not recognized 5,586 608 Other (645 ) (121 ) Income tax expense $ 43,720 $ 14,461 Effective tax rate 206.8 % (28.4 %) Movement in net deferred tax liabilities: ($ in thousands) 2020 2019 Balance at the beginning of the year $ (21,451 ) $ (4,459 ) Recognized in profit/loss 4,447 (1,176 ) Recognized in goodwill (30,199 ) (16,108 ) Recognized in equity 1,504 292 Balance at the end of the year $ (45,699 ) $ (21,451 ) For the year ended December 31, 2020, the Company recognized in equity a deferred tax asset of $1.5 million comprised of $0.3 million related to the previous adoption IFRS 16 and a deferred tax asset of $0.2 million related to share-based compensation reserve and other transactions with shareholders. In 2020, the Company recorded a deferred tax asset of $1.0 million related to the step-up The Company also recognized in equity other activity in addition to the deferred tax asset. This includes the tax receivable agreement liability of $0.8 million related to estimated payables to certain shareholders, and $0.1 million related to permanent adjustments to the share based compensation reserve. For the year ended December 31, 2019, the Company recognized in equity a deferred tax asset of $0.3 million comprised of $0.4 million related to the adoption of IFRS 16 partially offset by $0.1 million related to share-based compensation reserve and other transactions with shareholders. Deferred tax assets have not been recognized in respect of the following deductible temporary differences: ($ in thousands) 2020 2019 Unrecognized deductible temporary differences: Canadian non-capital $ 55,552 $ 1,677 Canadian capital losses carried forward — 809 U.S. non-capital 7,637 — California non-capital 25,864 — U.S. and California amortization of intangible assets 1,763 — Capital raise expenses 10,375 2,332 Other 6,548 63 Total $ 107,739 $ 4,881 The loss carryforwards will expire if they are not used within certain periods. Management has determined that it is more likely than not that the benefit from these deferred tax assets will not be realized as there may not be sufficient earnings. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Subsequent Events | NOTE 25. SUBSEQUENT EVENTS The Company has evaluated subsequent events through March 26, 2021, which is the date on which these financial statements were issued. On January 14, 2021, the Company entered into a definitive agreement with Bluma Wellness Inc. (“Bluma”)(the “Bluma Agreement”), pursuant to which Cresco will acquire all of the issued and outstanding shares of Bluma in an all-share On January 14, 2021, the Company announced the commencement of a best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Securities”) of the Company. On January 15, 2021, the Company closed the Offering of 9.9 million subordinate voting shares at a price of C$16.00 per share for total gross proceeds of approximately US$125.0 million. The Securities were offered in each of the Provinces of Canada, other than Québec, pursuant to a prospectus supplement dated January 19, 2021 to the Company’s base shelf prospectus dated July 25, 2019 and in the United States on a private placement basis to “qualified institutional buyers.” On February 16, 2021, the Company closed its acquisition of four Ohio dispensaries previously operated by Verdant Creations, LLC and its affiliates (collectively “Verdant”) pursuant to the agreements previously announced on May 26, 2020. The Company acquired the four dispensaries for cash consideration of US$11.5 million and 127,065 Cresco shares at a price of C$20 per share share for total equity consideration of US$2.0 million. As of the date of issuance of this report, the Company is still in the process of determining the fair value of acquired assets and liabilities and calculation of the associated goodwill. On February 22, 2021, the Company entered into a share purchase agreement with Spyder Cannabis Inc. and agreed to the terms of a debt assignment agreement with Plant-Based Investment Corp (“PBIC”) (collectively, the “180 Smoke Agreement”), pursuant to which Cresco will sell all of the equity interests of 180 Smoke in a cash transaction that values 180 Smoke at an equity value of $0.000001 on a cash-free basis, and Cresco will sell its outstanding debt receivables with 180 Smoke of approximately C$11.6M to PBIC for C$1.0M cash (collectively, the “180 Smoke Transaction”). The 180 Smoke Transaction is expected to close in the first half of 2021. On March 18, 2021, the Company entered into a definitive agreement to acquire all of the issued and outstanding equity interests in Cultivate Licensing LLC and BL Real Estate LLC (collectively, “Cultivate”), a vertically integrated Massachusetts operator, for maximum consideration of up to $158.0 million (the “Purchase Price”). A portion of the Purchase Price is payable upon closing of $15.0 million cash consideration and Cresco shares having an equity value equal to $75.0 million. The remaining portion of the Purchase Price will be structured as an earnout of up to $68.0 million in which approximately 12.5% of earnout payments shall be paid in cash and the remaining portion satisfied through issuance of Cresco shares (the “Cultivate Transaction”). The Cultivate Transaction is expected to close in the fourth quarter of 2021. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Basis of Preparation | (a) Basis of Preparation The accompanying consolidated financial statements of the Company have been prepared under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations of the IFRS Interpretations Committee (“IFRIC”) in effect for the years ended December 31, 2020 and 2019. The consolidated financial statements were approved and authorized for issue by the Board of Directors of the Company on March 26, 2021. |
Basis of Measurement | (b) Basis of Measurement The accompanying consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for biological assets which are measured at fair value less cost to sell; certain investments in associates, which are accounted for under the equity method; loans receivable measured at fair value through profit or loss (“FVTPL”); and certain investments, derivative instruments, and contingent consideration, which are recorded at fair value. Historical cost is generally based upon the fair value of the consideration given in exchange for assets and the contractual obligation for liabilities. Management has applied judgment in concluding that there remain no material uncertainties related to events or conditions that may cast doubt upon the entity’s ability to continue as a going concern, which includes judgment of the effects of subsequent events (see Note 25); and the Company’s ability to realize its assets and settle its obligations in the normal course of operations for at least twelve months from the date of the financial statements. |
Functional and Presentation Currency | (c) Functional and Presentation Currency The Company’s functional currency and that of the majority of its subsidiaries, as determined by management, is the United States (“U.S.”) dollar. The Company’s presentation currency is the U.S. dollar. As such, the accompanying consolidated financial statements are presented in U.S. dollars. All references to “C$” refer to Canadian dollars. Foreign currency denominated assets and liabilities are re-measured period-end Assets and liabilities of foreign operations having a functional currency other than the U.S. dollar are translated at the rate of exchange prevailing at the reporting date; revenues and expenses are translated at the monthly average rate of exchange during the period. Gains or losses on translation of foreign subsidiaries and net investments in foreign operations are included in other comprehensive loss. |
Basis of Consolidation | (d) Basis of Consolidation The consolidated financial statements include the accounts of the Company and its subsidiaries with intercompany balances and transactions eliminated upon consolidation. Subsidiaries are those entities over which the Company has the power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee, and has the ability to use its power to affect its returns. The following are Cresco’s wholly owned or effectively controlled subsidiaries and entities over which the Company has control as of December 31, 2020. Entity Location Purpose Percentage Held Cresco Labs Inc. British Columbia, Canada Parent Company Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100 % Cresco Labs, LLC Illinois Operating Entity 49.98 % Cresco Labs Notes Issuer, LLC Illinois Holding Company 100 % Gloucester Street Capital, LLC New York Holding Company 100 % Valley Agriceuticals, LLC New York Operating Entity 100 % MedMar Inc. Illinois Holding Company 100 % MedMar Lakeview, LLC (Sunnyside - Lakeview and Sunnyside - River North) Illinois Dispensary 87.6 % MedMar Rockford, LLC (Sunnyside - Rockford and Sunnyside - South Beloit) Illinois Dispensary 75 % CannaRoyalty Corp. (Origin House) Ontario, Canada Holding Company 100 % Cali-AntiFragile Corp. California Holding Company 100 % Alta Supply Inc. (Continuum) California Distribution 100 % Kaya Management Inc. California Production 100 % RPE Inc. (Continuum) California Distribution 100 % FloraCal California Cultivation 100 % Cub City, LLC California Distribution 100 % CRHC Holdings Corp. Ontario, Canada Holding Company 100 % 2360149 Ontario Inc. (180 Smoke) Ontario, Canada Nicotine Vape Company 100 % Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85 % (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company. Entity Location Purpose Percentage Held Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 98.77 % Wellbeings, LLC Delaware CBD Wellness Product Development 100 % Cresco Labs SLO, LLC California Holding Company 100 % SLO Cultivation Inc. California Cultivation and Production Facility 80 % Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs PA, LLC Pennsylvania; Registered: Illinois Holding Company 100 % Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100 % Cresco Labs Arizona, LLC Arizona Holding Company 100 % Arizona Facilities Supply, LLC Arizona/Maryland Cultivation, Production and Dispensary Facility 100 % Cresco Labs Tinad, LLC Illinois Holding Company 100 % PDI Medical III, LLC (Sunnyside - Buffalo Grove and Sunnyside - Naperville) Illinois Dispensary 100 % Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100 % Phoenix Farms of Illinois, LLC (Sunnyside - Champaign and Sunnyside - Danville) Illinois Dispensary 100 % JDC Elmwood, LLC Illinois Holding Company 100 % FloraMedex, LLC (Sunnyside - Elmwood Park and Sunnyside - Schaumburg) Illinois Dispensary 100 % Cresco Edibles, LLC Illinois Holding Company 100 % TSC Cresco, LLC Illinois Licensing 75 % Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% Cresco U.S. Corp., which is wholly owned by the Company, is the sole manager of Cresco Labs, LLC; Cresco Labs, LLC is the sole owner and manager of Cresco Labs Notes Issuer, LLC. Therefore, the Company controls Cresco Labs Notes Issuer, LLC and has consolidated its results into the consolidated financial statements. Non-controlling |
Cash and Cash Equivalents | (e) Cash and Cash Equivalents Cash and cash equivalents include cash deposits in financial institutions, other deposits that are readily convertible into cash and cash on hand. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. |
Restricted Cash | (f) Restricted Cash Restricted cash represents amounts held in escrow related to investments, acquisitions, facility requirements and building improvements. The Company held $4.4 million and $5.1 million of restricted cash as of December 31, 2020 and 2019, respectively. |
Accounts Receivable | (g) Accounts Receivable Accounts receivables are classified as financial assets initially recognized at fair value and subsequently measured at amortized cost, less any provisions for impairment. When a receivable is uncollectible, it is written off against the provision. Subsequent recoveries of amounts previously written off are credited to the Consolidated Statements of Operations. |
Biological Assets | (h) Biological Assets The Company’s biological assets consist of cannabis plants and are valued at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of internally produced Work-in-process All production costs related to biological assets are expensed as incurred and are included as Cost of sales – production costs. They include the direct cost of seeds and growing materials as well as other indirect costs such as utilities and supplies used in the growing process. Indirect labor for individuals involved in the growing and quality control process is also included, as well as depreciation on production equipment and overhead costs such as rent to the extent it is associated with the growing space. Unrealized fair value gains/losses on growth of biological assets are recorded in a separate line in the Consolidated Statements of Operations. The Company capitalizes cost incurred after harvest to bring the products to their present location and condition in accordance with International Accounting Standards (“IAS”) 2 Inventories |
Inventory | (i) Inventory Inventories of purchased finished goods and packing materials are initially valued at cost and subsequently at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell at harvest which becomes the deemed cost. Any subsequent post-harvest costs are capitalized to inventory. Post-harvest costs include costs such as materials, labor and depreciation expense on equipment involved in manufacturing, packaging, labeling, inspection and testing. Cost of sales - production costs also includes certain excise taxes and community benefit fees. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Products for resale and supplies and consumables are valued at lower of cost and net realizable value. The Company reviews inventory for obsolete, redundant and slow-moving goods and any such inventory is written down to net realizable value. |
Property and Equipment | (j) Property and Equipment Property and equipment is stated at cost, net of accumulated depreciation. Land is recorded at cost. Depreciation is calculated using the straight-line method over the useful life of the asset. The assets’ residual values, useful lives and methods of depreciation are reviewed at each financial year-end Category Methodology Estimated Useful Life Leasehold Improvements Amortized over the lesser of the life of the lease or estimated useful life of the improvement 1 - 15 years Machinery and Equipment Over the estimated useful life of the asset 5 - 15 years Furniture and Fixtures Over the estimated useful life of the asset 3 - 8 years Vehicles Over the estimated useful life of the asset 5 years Website and Software Over the estimated useful life of the asset 3 - 7 years Computer Equipment Over the estimated useful life of the asset 3 - 7 years Buildings and Building Improvements Over the estimated useful life of the asset 5 - 39 years Repairs and maintenance that do not improve efficiency or extend economic life are charged to expense as incurred. |
Intangible Assets | (k) Intangible Assets Intangible assets are recorded at cost, less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date or date of consolidation/control. Amortization of definite-lived intangible assets is recorded on a straight-line basis over their estimated useful lives, which do not exceed the contractual period, if any, over the following terms: Category Estimated Useful Life Market-Related Intangibles 12 - 18 months Customer Relationships 7 - 19 years Non-Compete 4 - 5 years Internally Developed Software 10 years Trade Names 10 years Permit Application Fees 1 - 2 years The estimated useful lives and residual values are reviewed at each year end, and any changes in estimates are accounted for prospectively. Intangible assets that have an indefinite useful life are not subject to amortization. The Company’s indefinite-lived intangible assets consist of licenses, which, for valuation purposes, represent the future benefits associated with the Company’s cultivation, processing, and dispensary licenses. Absent such license intangibles, the Company cannot continue as a going concern and as such, there is no foreseeable limit to the period over which these assets are expected to generate future cash inflows to the Company. Definite-lived intangible assets are tested for impairment when there is an indication of impairment. Indefinite-lived intangible assets are tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment (refer to Note 9 for additional details on impairment testing). During the year ended December 31, 2020, the Company recorded an impairment charge of $1.2 million on a market-related intangible asset due to changing market conditions. The Company fully recovered the value of this intangible asset and recorded an impairment reversal of $1.2 million. For the years ended December 31, 2020 and 2019, the Company did not recognize any impairment losses. |
Investments in Associates | (l) Investments in Associates The Company determines how to account for investments based on the level of control it has over the investment. If it is determined that the Company has control, then the investment should be consolidated. Investments in which the Company has significant influence, but no control, are considered investments in associates. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but without control or joint control over those policies. Investments in associates are accounted for using the equity method of accounting. Interests in associates accounted for using the equity method are initially recognized at cost. The carrying value is then adjusted for the Company’s share of comprehensive loss, additional contributions to the investee and additional distributions from the investee. The carrying value of associates is assessed for impairment at each balance sheet date. The Company’s investments in equity-accounted investees are classified within Investments in the Consolidated Statements of Financial Position. Investments in which the Company does not have significant influence or control are first recognized at cost. At each reporting period, changes from the initial cost and fair value are recognized through profit and loss and balances are classified within Investments in the Consolidated Statements of Financial Position. Refer to Note 8 for additional information on the Company’s Investments in Associates. |
Goodwill | (m) Goodwill Goodwill represents the excess of the purchase price paid for the acquisition of a business over the fair value of the net tangible and intangible assets acquired. Goodwill is allocated to the cash-generating unit (“CGU”) or CGUs which are expected to benefit from the synergies of the combination. Goodwill is tested for impairment annually or more frequently as warranted if events or changes in circumstances indicate impairment. For the purpose of impairment testing, goodwill and indefinite-lived intangible assets have been allocated to CGUs or groups of CGUs representing the lowest level that the assets are monitored for internal reporting purposes. Goodwill and indefinite-lived intangible assets are tested for impairment by comparing the carrying value of each CGU containing the assets to its recoverable amount (the higher of the asset’s fair value less costs of disposal and value-in-use); |
Income Taxes | (n) Income Taxes Tax expense recognized in profit or loss is comprised of the sum of current and deferred taxes not recognized in other comprehensive income (loss) or directly in equity. (i) Current Tax Current tax assets and/or liabilities are comprised of claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred Tax Deferred taxes are calculated using the liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive income (loss) or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income (loss) or equity, respectively. |
Financial Instruments | (o) Financial Instruments The Company recognizes all financial instruments in accordance with IFRS 9 Financial Instruments Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are incremental and are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities measured at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expires, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. The classification of financial instruments dictates how these assets and liabilities are measured subsequently in the Company’s consolidated financial statements. (i) Financial Instruments Measured at Fair Value Through Profit or Loss Financial instruments are classified as FVTPL when they are held for trading. A financial instrument is held for trading if it was acquired for the purpose of sale in the near term. Derivative financial instruments that are not designated and effective as hedging instruments are also classified as FVTPL. Financial instruments classified as FVTPL are stated at fair value with any changes in fair value recognized in earnings for the period. Financial assets in this category include certain short-term investments, derivatives and contingent consideration. Loans receivable primarily consist of loans to entities in which the Company has a potential future investment. These loans are measured at either FVTPL if they have derivative qualities or at amortized cost, less expected credit losses. Refer to Note 20 for additional information on the inputs utilized in the determination of fair values, including fair value hierarchy considerations. (ii) Financial Assets Measured at Amortized Cost Financial assets measured at amortized cost are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial assets are measured at amortized cost using the effective interest method, less any impairment losses. Financial assets in this category include cash and cash equivalents, trade receivables, other receivables, and loans receivable. (iii) Impairment of Financial Assets The Company assesses at each statement of financial position date whether there is objective evidence that a financial asset or group of financial assets is impaired. The Company recognizes expected credit losses (“ECL”) for trade receivables based on the simplified approach under IFRS 9. The simplified approach to the recognition of expected losses does not require the Company to track the changes in credit risk; rather, the Company recognizes a loss allowance based on lifetime ECLs at each reporting date from the date of the trade receivable. Evidence of impairment may include indications that a debtor or a group of debtors is experiencing significant financial difficulty such as defaulting or delinquency in interest or principal payments; likely to enter bankruptcy or other financial reorganization; or experiencing a measurable decrease in the estimated future cash flows according to observable data such as changes in arrears or economic conditions that correlate with defaults. Trade receivables are reviewed qualitatively on a case-by-case For financial assets carried at amortized cost, the Company recognizes loss allowances for ECLs on its financial assets measured at amortized cost. ECLs are a probability-weighted estimate of credit losses. The Company applies a three-stage approach to measure ECLs. The Company measures loss allowance at an amount equal to twelve months of expected losses for performing loans receivable if the credit risk at the reporting date has not increased significantly since initial recognition (Stage 1) and at an amount equal to lifetime expected losses on loans receivable that have experienced a significant increase in credit risk since origination (Stage 2) and at an amount equal to lifetime expected losses which are credit impaired (Stage 3). The Company considers a significant increase in credit risk to have occurred if contractual payments are more than 30 days past due and considers the loans receivable to be in default if they are 90 days past due. A significant increase in credit risk or default may have also occurred if there are other qualitative factors (including forward looking information) to consider; such as borrower specific information (i.e., change in credit assessment). Objective evidence of impairment of financial assets carried at amortized cost exists if the counterparty is experiencing significant financial difficulty, there is a breach of contract, concessions are granted to the counterparty that would not normally be granted, or it is probable the counterparty will enter into bankruptcy or a financial reorganization. Refer to Note 3 for additional information on the impact of allowance for doubtful accounts and refer to Note 20 for additional information on the impact of ECLs. (iv) Financial Liabilities Measured at Amortized Cost Financial liabilities measured at amortized cost are recognized initially at fair value net of any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. Other financial liabilities are de-recognized Summary of the Company’s Classification and Measurements of Financial Assets and Liabilities IFRS 9 Account Classification Measurement Cash and cash equivalents Amortized cost Amortized cost Restricted cash Amortized cost Amortized cost Accounts receivable Amortized cost Amortized cost Loans receivable Amortized cost or FVTPL Amortized cost or fair value Investments FVTPL Fair value Accounts payable and accrued expenses and Other long-term liabilities Amortized cost Amortized cost Deferred consideration, contingent consideration and other payables FVTPL Fair value Derivative liabilities FVTPL Fair value Short-term borrowings Amortized cost Amortized cost Lease liabilities Amortized cost Amortized cost Long-term notes payable and loans payable Amortized cost Amortized cost |
Leases | (p) Leases The Company adopted IFRS 16 Leases IFRS 16 permits entities to elect practical expedients to simplify the ongoing application of IFRS 16. On an ongoing basis, the Company elected to adopt the following practical expedient: (i) The Company has elected not to recognize right-of-use The Company has entered into leases primarily for its corporate office, cultivation and processing facilities and dispensaries. At inception of a contract, the Company determines whether the contract includes a lease. A contract contains a lease if it includes enforceable rights and obligations under which the right to control the use of an identified asset is conveyed for a period of time in exchange for consideration. The Company recognizes an ROU asset and a lease liability at the commencement date – the date when the asset is available for use by the lessee. The Company assesses at lease commencement whether it is reasonably certain to exercise extension or termination options. The Company reassesses its lease portfolio to determine whether it is reasonably certain to exercise the options if there is a significant event or significant change in circumstances within its control. The extension options which are considered reasonably certain to be exercised are mainly those for which operational decisions have been made which make the leased assets vital to the continued relevant business activities. Liabilities arising from a lease are initially measured at the present value of the lease payments not yet paid which are then discounted using the Company’s incremental borrowing rate. Lease liabilities include the value of the following payments: (i) Fixed payments, including in-substance (ii) The exercise price of a purchase option if the Company is reasonably certain to exercise that option; and (iii) Penalties for early termination of the lease, if the lease term reflects the Company exercising an option to terminate the lease. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is decreased by cash paid less interest expense incurred. The lease liability is remeasured when there is a change in future lease payments, or if the Company changes its assessment of whether it will exercise an extension, purchase, or termination option. ROU assets are measured at cost and are comprised of the following: (i) The amount of the initial measurement of lease liability; (ii) Lease payments made at or before the commencement date less any lease incentives received; (iii) Any initial direct costs; and (iv) An estimate of costs of dismantling and removing the underlying asset, restoring the site on which it is located or the underlying asset, if applicable. The ROU asset is depreciated on a straight-line basis from the commencement date to the end of the lease term. The depreciation expense on ROU assets replaces rent expense. The value of the ROU asset is periodically reduced by impairment losses, if any, and adjusted for certain revaluations of the lease liability. Upon adoption on January 1, 2019, the Company recognized ROU assets of $32.5 million and lease liabilities of $37.7 million, accumulated deficit of $1.5 million, a reduction of deferred rent of $2.2 million and a reduction of non-controlling The following reconciliation to the opening balance for lease liabilities under IFRS 16 as of January 1, 2019 is based on leases at December 31, 2018: ($ in thousands) Lease obligations in accordance with IAS 17 at December 31, 2018 $ 60,451 Leases not commenced at January 1, 2019 (929 ) Exemption for short-term leases (133 ) Lease extension options 34,841 Other 1,149 Obligations from lease arrangements (undiscounted) $ 95,379 Effect of discounting (57,672 ) Lease liability recognized as of January 1, 2019 $ 37,707 Refer to Note 7 for additional information on leases. |
Revenue Recognition | (q) Revenue Recognition The Company’s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. IFRS 15 Revenue from Contracts with Customers 1. Identify the contract with a customer; 2. Identify the performance obligations in the contract; 3. Determine the transaction price, which is the total consideration provided by the customer; 4. Allocate the transaction price among the performance obligations in the contract based on their relative fair values; and 5. Recognize revenue when the relevant criteria are met for each unit (at a point in time or over time). The Company recognizes revenue upon satisfaction of the performance obligation, when control of the promised goods is transferred to the Company’s customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods, upon delivery and acceptance by wholesale customers and upon sale to retail customers. Revenue is presented net of sales tax and other related taxes. The company satisfies the following criteria prior to deeming control to have transferred to customers in bill-and-hold 1. The reason for the bill-and-hold 2. Products is identified separately as belonging to the customer; 3. Products currently are ready for physical transfer to the customer; and 4. Products cannot be used or directed to another customer. Contract Costs In accordance with IFRS 15, incremental costs to obtain a contract are capitalized and amortized over the contract term if the cost are expected to be recoverable. The Company does not capitalize incremental costs to obtain a contract where the contract duration is expected to be one year or less. As of December 31, 2020 and 2019, the Company did not have any costs capitalized. |
Classification of Expenses | (r) Classification of Expenses The expenses in the accompanying Consolidated Statements of Operations are presented by function. The Company recognizes excise tax as Cost of sales—production costs or Selling, general and administrative expense based on whether the tax is generated on production of cannabis or as part of selling costs, respectively. See Note 16 for details of expenses by nature. |
Share-Based Compensation | (s) Share-Based Compensation The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Expected forfeitures are estimated at the date of grant and subsequently adjusted if further information indicates actual forfeitures may vary from the original estimate. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For share-based payments granted to non-employees, non-employees re-measured For awards where the holder has the election of settling their award in either cash or equity, the fair value of share-based compensation is remeasured at the end of each reporting period until the corresponding awards are settled. |
Earnings (Loss) Per Share | (t) Earnings (Loss) Per Share The Company presents basic and diluted earnings (loss) per share. Basic earnings (loss) per share is calculated by dividing the profit or loss attributable to shareholders by the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share is determined by adjusting the profit or loss attributable to shareholders and the weighted average number of shares outstanding, for the effects of all dilutive potential shares, which are comprised of redeemable LLC shares, warrants, options and restricted stock units (“RSUs”) issued. Items with an anti-dilutive impact are excluded from the calculation. The number of shares included with respect to options, warrants, redeemable shares and RSUs is computed using the treasury stock method. |
Significant Accounting Judgments, Estimates, and Assumptions | (u) Significant Accounting Judgments, Estimates, and Assumptions The preparation of the Company’s consolidated financial statements under IFRS requires management to make judgments, estimates, and assumptions about the carrying amounts of certain assets and liabilities. Estimates and related assumptions are based on historical experience and other relevant factors. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis for reasonableness and relevancy. Where revisions are required, they are recognized in the period in which the estimate is revised for the current as well as future periods that are affected. Significant judgements, estimates, and assumptions that have the most significant effect on the amounts recognized in the accompanying consolidated financial statements are described below. (i) ECL on Loan Receivables and Trade Receivables The Company calculates ECLs for trade receivables based on the historical default rates over the expected life of the trade receivable and adjusts for forward-looking estimates, which are determined through the exercise of judgement. The Company calculates ECLs for loan receivables by considering cash shortfalls on a discounted basis it would incur in various default scenarios for prescribed future periods and multiplying the shortfalls by the probability of each scenario occurring, which is determined through the exercise of judgement. The Company’s ECL models rely on forward looking information and economic inputs, such as default rates, industry growth rate, licensing rules, etc. The inputs and models used for calculating expected credit losses may not always capture all characteristics of the market at the date of the financial statements. To reflect this, qualitative adjustments or overlays may be made as temporary adjustments using expert credit judgement. The allowance the Company records, if any, is the sum of these probability weighted outcomes. (ii) Biological Assets and Inventory The valuation of biological assets at the point of harvest is the cost basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable for inventory. In calculating the value of the biological assets and inventory, the estimates management make include: estimating the stage of growth of the cannabis up to the point of harvest, the likelihood cannabis plants will grow to full maturity, harvesting costs, selling costs, average or expected selling prices and expected yields for the cannabis plants. In calculating final inventory values, management compares the inventory cost to estimated net realizable value. The Company must also determine if the cost of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged. See Note 4 for additional information. (iii) Estimated Useful Lives, Depreciation of Property and Equipment, and Amortization of Intangible Assets Depreciation of property and equipment and amortization of intangible assets is dependent upon estimates of useful lives which are determined through the exercise of judgement. (iv) Property and Equipment Impairment The Company evaluates the carrying value of long-lived assets at the end of each reporting period whenever there is any indication that a long-lived asset is impaired. Such indicators include evidence of physical damage, indicators that the economic performance of the asset is worse than expected, or that the decline in asset value is more than the passage of time or normal use, or significant changes occur with an adverse effect on the Company’s business. If any such indication exists, the Company estimates the recoverable amount of the asset. An asset is impaired when its carrying amount exceeds its recoverable amount. The Company measures impairment based on the amount by which the carrying value exceeds the estimated fair value of the long-lived asset. The fair value is determined primarily by using the projected future cash flows discounted at a rate commensurate with the risk involved as well as market valuations. Losses on long-lived assets to be disposed of are determined in a similar manner, except that the fair values are reduced for an estimate of the cost to dispose or abandon. (v) Goodwill and Indefinite-Lived Intangible Asset Impairment Goodwill and indefinite-lived intangible assets are tested for impairment annually during the fourth quarter and whenever events or changes in circumstances indicate that the carrying amount of these assets has been impaired. In order to determine if the value of these assets might be impaired, the CGU to which the assets have been allocated must be valued using present value techniques. When applying this valuation technique, the Company relies on a number of factors, including historical results, business plans, forecasts, market data and discount rates. Changes in the conditions for these judgements and estimates can significantly affect the assessed value of goodwill and indefinite-lived intangibles. The Company has determined that the goodwill associated with all acquisitions belongs to each respective state as this is the lowest level at which management monitors goodwill and indefinite-lived intangibles. See Note 9 for additional details. (vi) Business Combinations and Asset Acquisitions Determination of an acquisition as a business combination or an asset acquisition depends on whether the assets acquired constitute a business. The classification can have a significant impact on the accounting on and subsequent to the acquisition date. a. Business Combinations A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for by applying the acquisition method. The total consideration transferred in a business combination is the sum of the fair values of assets transferred, liabilities assumed and equity interests issued by the acquirer in exchange for control of the acquiree. The acquisition date is the date on which the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS 3 Business Combinations In determining the fair value of all identifiable assets, liabilities and contingent liabilities acquired, the most significant estimates relate to contingent consideration and intangible assets. Management exercises judgement in estimating the probability and timing of when contingent payments are expected to be made and at what amounts, which is used as the basis for estimating fair value. For any intangible asset identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent valuation expert or management may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Non-controlling non-controlling acquisition-by-acquisition non-controlling b. Asset Acquisitions Acquisitions that do not meet the definition of a business combination are accounted for as an asset acquisition. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Goodwill is not recorded as a result of an asset acquisition. (vii) Control Over the Investee, Principles of Consolidation The Company examines three elements to determine whether control exists. When all of these three elements of control are present, then an investor is considered to have control over an investee and consolidation is required. When one or more of the elements is not present, an investor will not consolidate, but instead will be required to determine the nature of its relationship with the investee. The three elements of control that serve as the basis of consolidation include: identify the investee, understand the purpose and design of the investee, and identify the relevant activities of the investee and how decisions about these relevant activities are made. The Company exercises its judgement when determining control over an investee when it has all of the following attributes: power over the investee, such as the ability to direct relevant activities of the investee; exposure or rights to variable returns from its involvement with the investee, such as returns that are not fixed and have the potential to vary with performance of the investee; and the ability to use its power over the investee to affect the amount of the investor’s returns, such as identifying the link between power and returns. Cresco Labs Inc. through Cresco U.S. Corp has control over Cresco Labs, LLC. Despite holding a minority interest, the Company has the full decision-making power over Cresco Labs. According to IFRS 10 Consolidated Financial Statements, (viii) Share-Based Compensation In calculating share-based compensation expense, key estimates such as the rate of forfeiture of awards granted, the expected life of options, the volatility of the Company’s stock price and the risk-free interest rate are used. (ix) Income Tax Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. Further, to the extent that there are any uncertain tax positions where it is “probable” that a taxing authority would not accept such tax position, the Company reflects the measurement of that uncertainty in its current and deferred taxes in the financial statement. (x) Sale and Leaseback Accounting A sale and leaseback transaction involves the transfer of an asset to another entity and the leaseback of the same asset. The Company applies IFRS 15 and IFRS 16 when accounting for sale and leaseback transactions. Significant estimates and judgements applied include determination of the fair value of the underlying asset, transfer of control, and determination of the implicit interest rate. The Company recognizes gains or losses related to the transfer of rights of the asset to the buyer-lessor and measures the ROU asset arising from the leaseback at the retained portion of the previous carrying amount. (xi) Fair Value Measurements Fair value is defined as a price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on a specified date. The Company calculates the estimated fair value of financial instruments using quoted market prices whenever available and utilizes standard pricing models in situations where quoted market prices are not available. Refer to Note 20 for additional information on the inputs utilized in the determination of fair values, including fair value hierarchy considerations. |
Reclasses and Adjustments | (v) Reclasses and Adjustments Certain prior period amounts have been reclassified for comparability with the current year presentation. |
Recently Issued Accounting Standards | (w) Recently Issued Accounting Standards The Company does not believe any recently issued, but not yet effective IFRS standards that have been issued by the IASB will have a material impact on the Company’s financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Significant Investments in Subsidiaries | The following are Cresco’s wholly owned or effectively controlled subsidiaries and entities over which the Company has control as of December 31, 2020. Entity Location Purpose Percentage Held Cresco Labs Inc. British Columbia, Canada Parent Company Cresco U.S. Corp. Illinois Manager of Cresco Labs, LLC 100 % Cresco Labs, LLC Illinois Operating Entity 49.98 % Cresco Labs Notes Issuer, LLC Illinois Holding Company 100 % Gloucester Street Capital, LLC New York Holding Company 100 % Valley Agriceuticals, LLC New York Operating Entity 100 % MedMar Inc. Illinois Holding Company 100 % MedMar Lakeview, LLC (Sunnyside - Lakeview and Sunnyside - River North) Illinois Dispensary 87.6 % MedMar Rockford, LLC (Sunnyside - Rockford and Sunnyside - South Beloit) Illinois Dispensary 75 % CannaRoyalty Corp. (Origin House) Ontario, Canada Holding Company 100 % Cali-AntiFragile Corp. California Holding Company 100 % Alta Supply Inc. (Continuum) California Distribution 100 % Kaya Management Inc. California Production 100 % RPE Inc. (Continuum) California Distribution 100 % FloraCal California Cultivation 100 % Cub City, LLC California Distribution 100 % CRHC Holdings Corp. Ontario, Canada Holding Company 100 % 2360149 Ontario Inc. (180 Smoke) Ontario, Canada Nicotine Vape Company 100 % Cresco Labs Michigan, LLC (a) Michigan Cultivation and Production Facility 85 % (a) Cresco Labs Michigan, LLC is 85% owned by related parties within management of the Company. Entity Location Purpose Percentage Held Cresco Labs Notes Issuer, LLC Illinois Holding Company Cresco Labs Ohio, LLC Ohio Cultivation, Production and Dispensary Facility 98.77 % Wellbeings, LLC Delaware CBD Wellness Product Development 100 % Cresco Labs SLO, LLC California Holding Company 100 % SLO Cultivation Inc. California Cultivation and Production Facility 80 % Cresco Labs Joliet, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Kankakee, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs Logan, LLC Illinois Cultivation and Production Facility 100 % Cresco Labs PA, LLC Pennsylvania; Registered: Illinois Holding Company 100 % Cresco Yeltrah, LLC Pennsylvania Cultivation, Production and Dispensary Facility 100 % Cresco Labs Arizona, LLC Arizona Holding Company 100 % Arizona Facilities Supply, LLC Arizona/Maryland Cultivation, Production and Dispensary Facility 100 % Cresco Labs Tinad, LLC Illinois Holding Company 100 % PDI Medical III, LLC (Sunnyside - Buffalo Grove and Sunnyside - Naperville) Illinois Dispensary 100 % Cresco Labs Phoenix Farms, LLC Illinois Holding Company 100 % Phoenix Farms of Illinois, LLC (Sunnyside - Champaign and Sunnyside - Danville) Illinois Dispensary 100 % JDC Elmwood, LLC Illinois Holding Company 100 % FloraMedex, LLC (Sunnyside - Elmwood Park and Sunnyside - Schaumburg) Illinois Dispensary 100 % Cresco Edibles, LLC Illinois Holding Company 100 % TSC Cresco, LLC Illinois Licensing 75 % Cresco HHH, LLC Massachusetts Cultivation, Production and Dispensary Facility 100% |
Summary of Estimated Useful Lives of Property Plant and Equipment | Category Methodology Estimated Useful Life Leasehold Improvements Amortized over the lesser of the life of the lease or estimated useful life of the improvement 1 - 15 years Machinery and Equipment Over the estimated useful life of the asset 5 - 15 years Furniture and Fixtures Over the estimated useful life of the asset 3 - 8 years Vehicles Over the estimated useful life of the asset 5 years Website and Software Over the estimated useful life of the asset 3 - 7 years Computer Equipment Over the estimated useful life of the asset 3 - 7 years Buildings and Building Improvements Over the estimated useful life of the asset 5 - 39 years |
Summary of Useful Lives of Finite Lived Intangible Assets Other Than Goodwill | Category Estimated Useful Life Market-Related Intangibles 12 - 18 months Customer Relationships 7 - 19 years Non-Compete 4 - 5 years Internally Developed Software 10 years Trade Names 10 years Permit Application Fees 1 - 2 years |
Summary of Measurement Category of Financial Assets and Financial Liabilities | IFRS 9 Account Classification Measurement Cash and cash equivalents Amortized cost Amortized cost Restricted cash Amortized cost Amortized cost Accounts receivable Amortized cost Amortized cost Loans receivable Amortized cost or FVTPL Amortized cost or fair value Investments FVTPL Fair value Accounts payable and accrued expenses and Other long-term liabilities Amortized cost Amortized cost Deferred consideration, contingent consideration and other payables FVTPL Fair value Derivative liabilities FVTPL Fair value Short-term borrowings Amortized cost Amortized cost Lease liabilities Amortized cost Amortized cost Long-term notes payable and loans payable Amortized cost Amortized cost |
Summary of Reconciliation of Lease Liabilities | The following reconciliation to the opening balance for lease liabilities under IFRS 16 as of January 1, 2019 is based on leases at December 31, 2018: ($ in thousands) Lease obligations in accordance with IAS 17 at December 31, 2018 $ 60,451 Leases not commenced at January 1, 2019 (929 ) Exemption for short-term leases (133 ) Lease extension options 34,841 Other 1,149 Obligations from lease arrangements (undiscounted) $ 95,379 Effect of discounting (57,672 ) Lease liability recognized as of January 1, 2019 $ 37,707 |
Accounts Receivable (Tables)
Accounts Receivable (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Accounts Receivable | As of December 31, 2020 and 2019, Accounts receivable, net consisted of the following: ($ in thousands) 2020 2019 Accounts receivable, gross $ 29,962 $ 16,726 Allowance for doubtful accounts (696 ) (271 ) Total Accounts receivable, net $ 29,266 $ 16,455 |
Biological Assets (Tables)
Biological Assets (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of detailed information about biological assets [abstract] | |
Summary of Changes in the Carrying Value of Biological Assets | The changes in the carrying value of Biological assets for the periods ended December 31, 2020 and 2019, consisted of the following: ($ in thousands) Biological assets at January 1, 2019 $ 17,673 Biological Assets Acquired (Note 13) 1,436 Transferred to inventory upon harvest (96,849 ) Changes in fair value of biological assets 109,531 Biological assets at December 31, 2019 $ 31,791 Biological assets acquired (Note 13) 2,002 Transferred to inventory upon harvest (280,863 ) Changes in fair value of biological assets 293,119 Biological assets at December 31, 2020 $ 46,049 |
Summary of Sensitivity of the Inputs in Relation to Biological Assets | The Company has quantified the sensitivity of the inputs in relation to biological assets as of December 31, 2020 and 2019 and expects the following effect on fair value as shown in the table below: ($ in thousands, except inputs) Effect on fair value Significant inputs & assumptions Range of inputs (as of December 31, 2020) Sensitivity 2020 2019 Selling price per gram, less cost to sell $1.25 to $6.23 Increase 5% $ 2,292 $ 6,360 Decrease 5% (2,292 ) (6,360 ) Attrition rate 7% to 15% Increase 5% (2,425 ) (1,602 ) Decrease 5% 1,729 1,298 Average yield per plant 43 grams to 136 grams Increase 5% 2,292 1,590 Decrease 5% (2,292 ) (1,590 ) Cumulative stage of completion 35% - 55% complete Increase 5% 5,330 3,177 Decrease 5% (5,326 ) (3,177 ) |
Inventory (Tables)
Inventory (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Inventory | Inventory as of December 31, 2020 and 2019, consisted of the following: ($ in thousands) 2020 2019 Raw materials $ 67,176 $ 16,521 Raw materials—non-cannabis 15,496 5,820 Work-in-process 24,906 14,100 Finished goods 29,027 13,114 Total Inventory $ 136,605 $ 49,555 |
Property And Equipment (Tables)
Property And Equipment (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Property and Equipment | As of December 31, 2020 and 2019, Property and equipment consisted of the following: ($ in thousands) Land and Machinery Furniture Lesaehold Website, Vehicles Contruction Total Cost Balance as of January 1, 2019 $ 11,125 $ 4,449 $ 2,088 $ 17,828 $ 1,096 $ 386 $ 4,378 $ 41,350 Additions 3,683 9,473 7,635 36,793 1,446 295 46,103 105,428 Transfers 5,397 694 — 4,837 — — (10,928 ) — Purchase related to sale-leaseback transactions 37,062 — — — — — — 37,062 Sales related to sale-leaseback transactions (37,062 ) — — — — — — (37,062 ) Business acquisitions 7,802 1,034 735 3,507 173 34 2,495 15,780 As of December 31, 2019 $ 28,007 $ 15,650 $ 10,458 $ 62,965 $ 2,715 $ 715 $ 42,048 $ 162,558 Additions 1,055 5,908 4,804 10,415 2,409 878 45,225 70,694 Transfers 1,728 1,290 2,191 56,401 125 21 (61,756 ) — Disposals — (110 ) (33 ) (214 ) (24 ) — — (381 ) Sales related to sale-leaseback transactions (22,083 ) — — — — — (11,403 ) (33,486 ) Additions from acquisition — 455 473 11,615 585 331 5,166 18,625 Effect of foreign exchange and other adjustments — 6 (273 ) 130 (43 ) — (50 ) (230 ) As of December 31, 2020 $ 8,707 $ 23,199 $ 17,620 $ 141,312 $ 5,767 $ 1,945 $ 19,230 $ 217,780 Accumulated depreciation Balance as of January 1, 2019 $ (50 ) $ (335 ) $ (234 ) $ (633 ) $ (327 ) $ (50 ) $ — $ (1,629 ) Depreciation (382 ) (913 ) (760 ) (2,509 ) (416 ) (110 ) — (5,090 ) As of December 31, 2019 $ (432 ) $ (1,248 ) $ (994 ) $ (3,142 ) $ (743 ) $ (160 ) $ — $ (6,719 ) Depreciation (315 ) (1,985 ) (2,203 ) (10,189 ) (1,262 ) (333 ) — (16,287 ) Sales related to sale-leaseback transactions — — — 457 — — — 457 As of December 31, 2020 $ (747 ) $ (3,233 ) $ (3,197 ) $ (12,874 ) $ (2,005 ) $ (493 ) $ — $ (22,549 ) Net book value As of December 31, 2019 $ 27,575 $ 14,402 $ 9,464 $ 59,823 $ 1,972 $ 555 $ 42,048 $ 155,839 As of December 31, 2020 $ 7,960 $ 19,966 $ 14,423 $ 128,438 $ 3,762 $ 1,452 $ 19,230 $ 195,231 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of quantitative information about right-of-use assets [abstract] | |
Summary of Right-of-use Assets | As of December 31, 2020 and 2019, the Company’s leases include the following ROU assets: ($ in thousands) 2020 2019 Real estate $ 92,159 $ 46,696 Vehicles 10 — Total ROU assets $ 92,169 $ 46,696 |
Summary of Maturities of Lease Liabilities | As of December 31, 2020, maturities of lease liabilities were as follows: ($ in thousands) 2021 $ 33,207 2022 33,560 2023 34,265 2024 35,528 2025 36,324 Thereafter 354,986 Total lease payments $ 527,870 Less: imputed interest (310,142 ) Less: tenant improvement allowance (47,666 ) Present value of lease liabilities 170,062 Less: current lease liabilities (24,742 ) Present value of long-term lease liabilities $ 145,320 |
Summary of Contractual Receipts for Lease Contract Due | As of December 31, 2020, contractual receipts due to the Company for lease contracts in which the Company is the lessor were as follows: ($ in thousands) 2021 $ 642 2022 591 2023 609 2024 642 2025 646 Thereafter 2,783 Total lease payments $ 5,913 |
Investments (Tables)
Investments (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Investments at Fair Value | The following is a summary of the investments at fair value held as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 420 Capital $ 68 $ 68 Lighthouse 1,049 1,209 Fleurish 51 — MassRoots, Inc. — 1 Total Investments $ 1,168 $ 1,278 |
Summary of Investment in Associates Accounted for as an Equity Method Investment | The following is a summary of the investment in associates accounted for as an equity method investment and held as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 Trichome $ 3,192 $ — Total Investment $ 3,192 $ — |
Intangible Assets and Goodwill
Intangible Assets and Goodwill (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Detailed information of Intangible assets and Goodwill | As of December 31, 2020 and 2019, Intangible assets and Goodwill consisted of the following: ($ in thousands) Customer Trade Permit Licenses Other Goodwill Total Cost Balance at January 1, 2019 $ 5,429 $ — $ 2,389 $ 18,047 $ 1,833 $ 51,146 $ 78,844 Additions — — 4,453 — — 13 4,466 Additions from acquisitions 1,500 — — 65,400 300 86,560 153,760 Balance at December 31, 2019 $ 6,929 $ — $ 6,842 $ 83,447 $ 2,133 $ 137,719 $ 237,070 Additions — — 1,886 — 2,722 — 4,608 Additions from acquisitions 52,200 41,800 — 5,900 2,865 320,552 423,317 Foreign exchange — — — — — 4 4 Measurement period adjustments 11,400 (2,100 ) — — (111 ) (6,414 ) 2,775 Balance at December 31, 2020 $ 70,529 $ 39,700 $ 8,728 $ 89,347 $ 7,609 $ 451,861 $ 667,774 Accumulated amortization Balance at January 1, 2019 $ (130 ) $ — $ (1,866 ) $ — $ (238 ) $ — $ (2,234 ) Amortization (728 ) — (1,399 ) — (784 ) — (2,911 ) Balance at December 31, 2019 $ (858 ) $ — $ (3,265 ) $ — $ (1,022 ) $ — $ (5,145 ) Amortization (4,271 ) (3,970 ) (3,853 ) — (3,156 ) — (15,250 ) Balance at December 31, 2020 $ (5,129 ) $ (3,970 ) $ (7,118 ) $ — $ (4,178 ) $ — $ (20,395 ) Net book value December 31, 2019 $ 6,071 $ — $ 3,577 $ 83,447 $ 1,111 $ 137,719 $ 231,925 December 31, 2020 $ 65,400 $ 35,730 $ 1,610 $ 89,347 $ 3,431 $ 451,861 $ 647,379 (a) Other Intangibles includes market-related intangibles, non-compete |
Accounts Payable And Other Ac_2
Accounts Payable And Other Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of accounts payable and other accrued expenses | ($ in thousands) 2020 2019 Accounts payable $ 26,170 $ 32,463 Accrued expenses 34,843 24,133 Payroll liabilities 14,858 5,195 Excise taxes payable 8,675 540 Contract liability 1,182 — Tax penalty 578 455 Property taxes payable 20 48 Total Accounts payable and other accrued expenses $ 86,326 $ 62,834 |
Share Capital (Tables)
Share Capital (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of issued and outstanding shares | As of December 31, 2020 and 2019, issued and outstanding shares and units consisted of the following: (in thousands) Notes Redeemable Units Subordinate Voting Shares (SVS) Super Proportionate Special Shares Beginning balance, January 1, 2019 143,844 26,711 500 82,803 — 3,020 Stock options exercised — 575 — 342 — — Warrants exercised Note 11(c) — 170 — — — — Issuance of MedMar shares Note 11(b)(vi) — — — 3,020 — (3,020 ) Issuance of Valley Ag shares Note 11(b)(vi) — — — 8,660 — — PVS converted to SVS and adjustments Note 11(a) — 37,122 — (36,888 ) — — Cresco LLC redemption Note 11(e) (1,672 ) 1,672 — — — — Share issuance from equity raise Note 11(b)(vi) — 7,350 — — — — Ending balance, December 31, 2019 142,172 73,600 500 57,937 — — Beginning balance, January 1, 2020 142,172 73,600 500 57,937 — — Options and warrants exercised Note 11(c), 12 — 1,688 — 12 — 23 RSUs issued Note 12 — 2,034 — — — 28 Issuance of shares related to acquisitions Note 11(b)(ii-v) — 70,084 — 233 — (155 ) Issuance of shares related to distribution agreements Note 11(b)(ii) — — — — — 249 Cresco LLC redemption Note 11(e) (15,834 ) 15,681 — — — — PVS converted to SVS Note 11(a) — 28,871 — (28,871 ) — — Issuances related to employee taxes on certain share-based payment arrangements Note 12 — 1,336 — — — — Share issuances Note 11(b)(i) — 792 — — 1 — Ending balance, December 31, 2020 126,338 194,086 500 29,311 1 145 * PVS presented on an “as-converted” (1-to-200) ** SSVS presented on an “as-converted” (1-to-0.00001) |
Summary of warrants outstanding | A summary of the status of the warrants outstanding is as follows: Number of Weighted- average Balance as of January 1, 2019 397,079 $ 5.35 Issued 6,226,250 7.78 Exercised (169,545 ) 6.16 Balance as of December 31, 2019 6,453,784 $ 7.73 Exercised (270,635 ) 6.05 Balance as of December 31, 2020 6,183,149 $ 7.80 * PVS presented on an “as-converted” (1-to-200) |
Summary of changes in ownership and non-controlling interests | As of and for the year ended December 31, 2020, non-controlling ($ in thousands) TSC MedMar Inc. MedMar Inc. Cresco Labs Ohio, SLO Inc. Other 1 Eliminations Total Non-current $ 4,064 $ 32,680 $ 20,634 $ 11,392 $ 23,848 $ 878,752 $ — $ 971,370 Current assets 31,489 26,199 37,996 41,258 79,822 298,846 (153,856 ) 361,754 Non-current — (11,942 ) (2,279 ) (7,113 ) (10,643 ) (381,749 ) — (413,726 ) Current liabilities (24,209 ) (31,706 ) (26,686 ) (47,512 ) (120,195 ) (107,753 ) 163,421 (194,640 ) Net assets $ 11,344 $ 15,231 $ 29,665 $ (1,975 ) $ (27,168 ) $ 688,096 $ 9,565 $ 724,758 Net assets attributable to NCI $ 3,197 $ 3,264 $ 4,468 $ 70 $ (5,383 ) $ 144,695 3 $ — $ 150,311 Revenue $ 16,874 $ 31,320 $ 38,417 $ 14,646 $ 19,772 $ 386,257 $ (31,035 ) $ 476,251 Gross profit 9,882 16,404 20,136 3,332 (4,901 ) 243,674 (4,587 ) 283,940 Total comprehensive income (loss) $ 8,440 $ 3,559 $ 10,738 $ (7,996 ) $ (12,214 ) $ (39,089 ) $ — $ (36,562 ) Comprehensive income (loss) allocated to NCI $ 2,110 $ 441 $ 2,684 $ (80 ) $ (2,443 ) $ 42,651 $ — $ 45,363 NCI percentage at December 31, 2020 25.0 % 1 12.4 % 2 25.0 % 2 1.0 % 1 20.0 % 1 50.02 % 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 50.02% NCI related to NCI for Cresco Labs Inc. 2 The NCI percentage reflects the NCI that exists at Cresco Labs Inc. 3 Includes the effect of LLC unit redemptions and other adjustments As of and for the year ended December 31, 2019, non-controlling ($ in thousands) TSC MedMar Inc. MedMar Inc. Cresco Labs Ohio, SLO Other 1 Eliminations Total Non-current $ 3,185 $ 16,667 $ 21,419 $ 12,575 $ 23,317 $ 380,053 $ — $ 457,216 Current assets 14,081 750 1,644 30,949 47,529 116,472 (52,087 ) 159,338 Non-current — (1,634 ) (1,993 ) (95 ) (13,940 ) (126,100 ) — (143,762 ) Current liabilities (13,442) (1,479) (2,172) (37,660) (68,822) (78,522) 51,928 (150,169) Net assets $ 3,824 $ 14,304 $ 18,898 $ 5,769 $ (11,916 ) $ 291,903 $ (159 ) $ 322,623 Net assets attributable to NCI $ 1,567 $ 2,907 $ 2,081 $ 150 $ (2,940 ) $ 131,776 $ — $ 135,541 Revenue $ 6,417 $ 4,088 $ 5,310 $ 7,759 $ 21,148 $ 99,290 $ (15,478 ) $ 128,534 Gross profit 5,037 1,999 2,565 2,210 (505 ) 61,935 (9,160 ) 64,081 Total comprehensive income (loss) $ 5,747 $ (980 ) $ (555 ) $ (6,259 ) $ (15,295 ) $ (47,960 ) $ — $ (65,302 ) Comprehensive income (loss) allocated to NCI $ 1,437 $ (121 ) $ (139 ) $ (63 ) $ (3,059 ) $ (20,156 ) $ — $ (22,101 ) NCI percentage at December 31, 2019 25.0 % 1 12.4 % Holders 25.0 % Holders 1.0 % Holders 20.0 % Holders 56.2 % Holders Holders 1 The NCI percentage reflects the NCI that exists at Cresco Labs, LLC. There is a further 56.2% NCI related to NCI for Cresco Labs Inc. |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of the status of the stock options outstanding | A summary of the status of the options outstanding consisted of the following: Number of Weighted- Outstanding – January 1, 2019 19,500,000 $ 2.11 Granted 4,474,000 7.48 Exercised (934,682 ) 1.37 Forfeited (669,150 ) 2.88 Outstanding – December 31, 2019 22,370,168 $ 3.19 Granted 7,278,021 5.04 Exercised (1,945,401 ) 2.12 Origin House replacement awards 629,275 4.24 Forfeited (5,845,350 ) 2.77 Outstanding - December 31, 2020 22,486,713 $ 3.96 Exercisable - December 31, 2020 9,550,535 $ 3.25 |
Summary of stock options outstanding | The following table summarizes the stock options outstanding as of December 31, 2020: Expiration date Stock Exercise 1 Stock October 2022 17,578 $ 3.13 17,578 April 2025 1,758 4.49 879 May 2025 3,516 6.01 2,636 June 2025 205,273 0.50 - 5.80 203,954 July 2025 3,515 5.43 2,637 September 2025 250,000 1.00 — January - February 2026 75,000 1.00 75,000 May - June 2026 600,000 1.00 600,000 November - December 2026 17,500 1.00 17,500 January 2027 5,000 1.00 3,750 October 2027 200,000 1.00 200,000 November 2027 250,000 1.00 - 1.14 162,500 December 2027 328,120 1.14 - 4.17 265,620 March 2028 254,028 1.14 121,250 May - June 2028 610,000 2.25 235,000 July 2028 235,000 2.25 - 3.75 125,139 August 2028 403,120 3.75 - 6.31 240,620 September 2028 7,014,374 1.13 - 3.75 3,818,541 October - November 2028 1,788,750 3.75 868,750 December 2028 220,000 6.50 110,000 January 2029 149,876 6.67 149,876 February 2029 85,000 6.50 21,250 March 2029 272,000 11.25 68,000 June 2029 1,171,250 10.28 297,500 September 2029 1,186,250 5.90 293,750 December 2029 582,000 6.86 145,500 March 2030 597,000 2.99 — May 2030 3,812,023 4.56 1,312,023 June 2030 885,000 4.11 — July 2030 19,544 5.39 19,544 September 2030 555,000 6.00 — December 2030 689,238 9.86 - 10.19 171,738 22,486,713 9,550,535 |
Summary of fair value of stock options granted under the plan | The fair value of stock options granted under the Plan during the years ended December 31, 2020 and 2019, was determined using the Black-Scholes option-pricing model with the following range of assumptions at the time of the grant: 2020 2019 Risk-free annual interest rate 0.54% - 1.79 % 1.97% to 2.49 % Expected annual dividend yield — — Expected stock price volatility 65% to 81 % 77% to 88 % Expected life of stock options 5 to 7 years 5.5 to 7 years Forfeiture rate 5% - 15 % 0% to 3% Fair value at grant date $1.84 to $6.48 $3.88 to $8.26 Stock price at grant date $2.99 to $10.19 $5.90 to $11.25 Exercise price range $2.99 to $10.19 $5.90 to $11.25 |
Summary of outstanding RSUs | A summary of outstanding RSUs is provided below: Number of Weighted Outstanding - January 1, 2019 — $ — Granted 404,215 8.58 Outstanding – December 31, 2019 404,215 $ 8.58 Granted 661,190 6.00 Origin House replacement awards 3,430,456 5.96 Vested and settled (3,435,527 ) 5.23 Forfeited (66,005 ) 8.91 Outstanding - December 31, 2020 994,329 $ 6.54 Liability classified as of December 31, 2020 2,210 $ 9.86 |
Acquisitions (Tables)
Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of significant business combinations | The table below summarizes significant business combinations completed during the year ended December 31, 2020: Completed during the year ended December 31, 2020 Origin House (ii) ($ in thousands) Total consideration Common shares issued $ 396,575 Replacement awards 31,671 Total consideration $ 428,246 Net identifiable assets (liabilities) acquired Cash $ 32,984 Accounts receivable 7,565 Inventory 14,658 Biological assets 2,002 Other current assets 2,197 Property and equipment 18,625 Right-of-use 17,984 Loans receivable, long-term 331 Investment in associate 4,302 Investments 139 Customer relationships 63,600 Trade names 39,700 Licenses 5,900 Market related intangibles 2,374 Internally developed software 380 Total identifiable assets acquired $ 212,741 Short-term liabilities $ (24,349 ) Lease liabilities (18,002 ) Deferred and contingent consideration (3,807 ) Notes payable (22,045 ) Deferred tax liabilities (30,200 ) Net identifiable assets acquired $ 114,338 Purchase price allocation Net identifiable assets acquired $ 114,338 Goodwill 313,908 Total consideration $ 428,246 The table below summarizes business combinations completed during the year ended December 31, 2019: Completed during the year ended December 31, 2019 Valley Ag (iii) HHH (iv) Total ($ in thousands) Total consideration Cash $ 18,774 $ — $ 18,774 Deferred cash consideration 25,990 26,606 52,596 Common shares issued 48,881 — 48,881 Derivative liability consideration 5,437 — 5,437 Contingent consideration 20,346 — 20,346 Loan settlement 10,146 4,807 14,953 $ 129,574 $ 31,413 $ 160,987 Net identifiable assets (liabilities) acquired Cash $ 1,199 $ 313 $ 1,512 Accounts receivable 145 306 451 Inventory 800 4,703 5,503 Biological assets — 1,436 1,436 Other current assets 558 18 576 Property & equipment 7,256 8,524 15,780 Right-of-use 6,836 — 6,836 Other non-current 81 1 82 Customer relationships 1,200 300 1,500 Non-compete — 300 300 License 53,400 12,000 65,400 Total identifiable assets acquired $ 71,475 $ 27,901 $ 99,376 Short-term liabilities $ (690 ) $ (621 ) $ (1,311 ) Lease liability (6,980 ) — (6,980 ) Long-term liability — (550 ) (550 ) Deferred tax liability (16,108 ) — (16,108 ) Net identifiable assets acquired $ 47,697 $ 26,730 $ 74,427 Purchase price allocation Net identifiable assets acquired $ 47,697 $ 26,730 $ 74,427 Goodwill 81,877 4,683 86,560 Total consideration $ 129,574 $ 31,413 $ 160,987 Net cash outflows Cash consideration paid $ (18,774 ) $ (80 ) $ (18,854 ) Cash acquired 1,199 313 1,512 Total $ (17,575 ) $ 233 $ (17,342 ) |
Summary of deferred consideration and other payables balances classified as short term | The following is a summary of deferred consideration and other payables balances as of December 31, 2020 and 2019, which are classified as short term: ($ in thousands) IFRS 9 classification 2020 2019 MedMar contingent consideration liability for tax payments FVTPL $ — $ 2,000 MedMar contingent consideration liability FVTPL — 1,927 Interest payable - short term Amortized Cost — 1,464 HHH deferred consideration FVTPL — 27,237 Valley Ag deferred consideration Amortized Cost — 18,750 Valley Ag operating cash flows consideration FVTPL — 7,423 Valley Ag make-whole liability FVTPL — 800 Valley Ag contingent consideration FVTPL 19,093 — Liability-classified equity awards FVTPL 22 339 Total Deferred consideration, contingent consideration and other payables $ 19,115 $ 59,940 |
Summary of long-term contingent consideration | (c) Long-term Deferred and Contingent Consideration The following is a summary of long-term contingent consideration as of December 31, 2020 and 2019: ($ in thousands) IFRS 9 classification 2020 2019 Valley Ag contingent consideration FVTPL $ — $ 21,901 Valley Ag operating cash flows consideration FVTPL 7,247 — Total Long-term deferred and contingent consideration $ 7,247 $ 21,901 |
Long-term Notes and Loans Pay_2
Long-term Notes and Loans Payable - (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Loans Payable Balances is Follows | The following table represents the Company’s loans payable balances as of December 31, 2020 and 2019: ($ in thousands) 2020 2019 Term Loan $ 180,863 $ — Interest payable 3,658 — HHH Loan — 550 Total borrowings and interest payable $ 184,521 $ 550 Less Short-term borrowings and interest payable (15,046 ) — Total Long-term notes and loans payable $ 169,475 $ 550 |
Revenue and Loyalty Programs (T
Revenue and Loyalty Programs (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Disaggregated Revenue by Source | The following table represents the Company’s disaggregated revenue by source, primarily due to the Company’s contracts with its customers, for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Wholesale $ 274,000 $ 79,927 Dispensary 202,251 48,607 Total Revenue $ 476,251 $ 128,534 |
Selling, General and Administ_2
Selling, General and Administrative Expenses (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Selling General and Administrative Expense | For the years ended December 31, 2020 and 2019, Selling, general and administrative expenses consisted of the following: ($ in thousands) 2020 2019 Salaries and related $ 81,067 $ 28,519 Consulting and professional fees 24,576 18,091 Advertising and marketing 19,030 12,630 Office 17,696 4,884 Share based compensation 16,659 14,046 Provision expense (Note 19) 13,600 — Excise taxes 13,167 4,341 Technology 7,604 1,989 Insurance 4,358 1,911 Travel and entertainment 3,074 4,154 Rent expense 1,478 286 Business expansion costs 1,586 1,524 Other 2,843 1,743 Total Selling, general and administrative expense $ 206,738 $ 94,118 |
Other (Expense) Income, net (Ta
Other (Expense) Income, net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of Other expense income [Abstract] | |
Summary of Other (expense) income | For the years ended December 31, 2020 and 2019, Other (expense) income, net consisted of the following: ($ in thousands) 2020 2019 (Loss) gain on derivative instruments (Note 20) $ (13,319 ) $ (3,236 ) Gain on conversion of loan to investment — 703 Gain (loss) on changes in fair value of deferred and contingent consideration (Note 13) 2,126 (3,186 ) Gain on debt modification (Note 14) 5,409 — Gain on changes in fair value of loans receivable (Note 20) 921 1,515 Impairment on loan receivable (Note 20) (902 ) (3,037 ) Loss on sale leaseback transactions (Note 7) — (670 ) Sale and leaseback settlement costs (Note 7) (479 ) — Dividend income — 97 Unrealized loss on investments held at fair value (Note 8) (160 ) (2,827 ) (Loss) gain on foreign currency (2,394 ) 421 Other (loss) income on investments (1,000 ) — Gain on dissolution of previously held equity investment (Note 8) — 1,309 Other income, net 1,789 264 Total Other (expense) income, net $ (8,009 ) $ (8,647 ) |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Key Management Personnel Compensation | Key management personnel compensation for the years ended December 31, 2020 and 2019 was as follows: ($ in thousands) 2020 2019 Management compensation $ 6,234 $ 3,139 Share-based compensation expense 10,992 5,972 Total $ 17,226 $ 9,111 |
Summary of Expense Resulting from the Related Party Transactions | Below is a summary of the expense resulting from the related party lease liabilities for the years ended December 31, 2020 and 2019. 2020 2019 ($ in thousands) Depreciation expense Interest expense Depreciation expense Interest expense Finance lease liability; lessor has minority interest in SLO $ 295 $ 1,494 $ 382 $ 1,650 Finance lease liability; lessor has minority interest in MedMar 209 281 155 177 Finance lease liability; lessor is a member of key management personnel 551 564 — — |
Summary of ROU Assets and Lease Liabilities Attributable to Related Party Transactions | Additionally, below is a summary of the ROU assets and lease liabilities attributable to related party lease liabilities. 2020 2019 ($ in thousands) ROU asset Lease liability ROU asset Lease liability Finance lease liability; lessor has minority interest in SLO $ 5,219 $ 8,551 $ 9,930 $ 11,727 Finance lease liability; lessor has minority interest in MedMar 2,322 2,552 1,292 1,380 Finance lease liability; lessor is a member of key management personnel 8,371 6,925 — — |
Financial Instruments And Finan
Financial Instruments And Financial Risk Management (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of Company's Financial Instruments | The following tables summarize the Company’s financial instruments as of December 31, 2020 and 2019: 2020 ($ in thousands) Amortized Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 136,339 $ — $ — $ — $ 136,339 Restricted cash 1 4,435 — — — 4,435 Accounts receivable, net 29,266 — — — 29,266 Loans receivable, short-term 921 — 2,237 (720 ) 2,438 Loans receivable, long-term 1,204 — — 20,020 21,224 Investments 2 3,192 — 1,049 119 4,360 Security deposits 3,558 — — — 3,558 Financial Liabilities: Accounts payable and other accrued expenses $ 86,326 $ — $ — $ — $ 86,326 Short-term borrowings 15,046 — — — 15,046 Current portion of lease liabilities 24,742 — — — 24,742 Deferred consideration, contingent consideration and other payables — 22 — 19,093 19,115 Derivative liabilities, long-term — — 30,129 — 30,129 Lease liabilities 145,320 — — — 145,320 Deferred consideration and contingent consideration — — — 7,247 7,247 Long-term notes payable and loans payable 169,475 — — — 169,475 1 Restricted cash balances include various escrow accounts related to investments, acquisitions, facility requirements and building improvements. 2 Investment balances in the amortized cost column represent equity method investments. 2019 ($ in thousands) Amortized Level 1 Level 2 Level 3 Total Financial Assets: Cash and cash equivalents $ 49,102 $ — $ — $ — $ 49,102 Restricted cash 1 5,050 — — — 5,050 Accounts receivable, net 16,455 — — — 16,455 Loans receivable, short-term 644 — — — 644 Loans receivable, long-term 390 — 18,243 — 18,633 Investments — — 1,210 68 1,278 Security deposits 1,084 — — — 1,084 Financial Liabilities: Accounts payable and other accrued expenses $ 62,834 $ — $ — $ — $ 62,834 Current portion of lease liabilities 12,019 — — — 12,019 Deferred consideration, contingent consideration and other payables 49,451 339 — 10,150 59,940 Derivative liabilities, short-term — — 178 — 178 Derivative liabilities, long-term — — 15,243 — 15,243 Lease liabilities 82,856 — — — 82,856 Deferred consideration and contingent consideration — — — 21,901 21,901 Long-term notes payable and loans payable 550 — — — 550 1 cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. |
Summary of Short Term Loan Receivable | The following is a summary of Loans receivable, short-term balances and IFRS 9 classifications (discussed further below) as of December 31, 2020 and 2019: ($ in thousands) IFRS 9 classification 2020 2019 Short-term loans receivable - Lighthouse FVTPL $ 1,517 $ — Interest receivable Amortized cost 921 644 Total Loans receivable, short-term $ 2,438 $ 644 |
Summary of Long Term Loan Receivable | ($ in thousands) IFRS 9 classification 2020 2019 Long-term loans receivable - Verdant FVTPL $ 20,020 $ 16,007 Long-term loans receivable - Lighthouse FVTPL — 2,236 Long-term loans receivable - Other Amortized cost 367 390 Interest receivable Amortized cost 837 — Total Loans receivable, long-term $ 21,224 $ 18,633 |
Disclosure of Fair Value of Liability Warrants using Black-Scholes Option-pricing Model as Follows | As of December 31, 2020 and 2019, the fair value of liability-classified warrants was determined using the Black-Scholes option-pricing model utilizing the following assumptions: 2020 2019 Risk-free annual interest rate 0.13% 1.58% - 1.61% Expected annual dividend yield 0% 0% Expected stock price volatility 83% 81% Expected life of stock warrants 1.75 - 1.83 years 0.4 - 1.4 years Forfeiture rate 0% 0% Share price at period end $9.86 $6.86 |
Summary of Accounts Receivables | The Company’s aging of Accounts receivables as of December 31, 2020 and 2019 was approximately as follows: ($ in thousands) 2020 2019 0 to 60 days $ 27,604 $ 10,276 61 to 120 days 1,134 5,551 120 days + 1,224 899 Total accounts receivable, gross $ 29,962 $ 16,726 |
Summary of Contractual Obligations | In addition to the commitments outlined in Note 7, the Company has the following contractual obligations as of December 31, 2020: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable & other accrued expenses $ 86,326 $ — $ — $ 86,326 Deferred consideration, contingent consideration and other payables 19,115 — — 19,115 Deferred consideration and contingent consideration — 7,247 — 7,247 Long-term notes payable and loans payable and Short-term borrowings 15,046 169,475 — 184,521 Total obligations as of December 31, 2020 $ 120,487 $ 176,722 $ — $ 297,209 In addition to the commitments outlined in Note 7, the Company has the following contractual obligations as of December 31, 2019: ($ in thousands) < 1 Year 1 to 3 Years 3 to 5 Years Total Accounts payable and other accrued expenses $ 62,834 $ — $ — $ 62,834 Deferred consideration, contingent consideration and other payables 59,940 — — 59,940 Deferred consideration and contingent consideration — 21,901 — 21,901 Other long-term liabilities — 550 — 550 Total obligations as of December 31, 2019 $ 122,774 $ 22,451 $ — $ 145,225 |
Earnings (Loss) Per Share (Tabl
Earnings (Loss) Per Share (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Earnings per share [abstract] | |
Summary of Reconciliation for Basic and Diluted Loss Per Share | The following is a reconciliation for the calculation of basic and diluted loss per share for the years ended December 31, 2020 and 2019: (in thousands, except per share data) 2020 2019 Basic and diluted loss per share Net loss attributable to Cresco Labs Inc. shareholders $ (81,925 ) $ (43,201 ) Weighted-average number of shares outstanding 210,466 118,318 Loss per share – basic and diluted $ (0.39 ) $ (0.37 ) |
Interest (Expense) Income, Net
Interest (Expense) Income, Net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of Interest Expenses [Abstract] | |
Summary of Interest expense, net | Interest expense, net consisted of the following for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Interest expense – leases $ (20,375 ) $ (7,078 ) Interest expense – notes and loans payable (14,353 ) — Accretion of debt discount and amortization of deferred financing fees (6,139 ) — Other interest expense (40 ) (2,380 ) Interest income 1,414 1,583 Total Interest expense, net $ (39,493 ) $ (7,875 ) |
Provision For Income Taxes An_2
Provision For Income Taxes And Deferred Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Text Block [Abstract] | |
Summary of provision for income taxes | Provision for income taxes consists of the following for the years ended December 31, 2020 and 2019: ($ in thousands) 2020 2019 Current Federal $ 35,784 $ 10,455 State 12,383 2,830 Total current $ 48,167 $ 13,285 Deferred Federal $ (2,566 ) $ 1,124 State (1,881 ) 52 Total deferred $ (4,447 ) $ 1,176 Total $ 43,720 $ 14,461 |
Summary of components of deferred tax assets and liabilities | As of December 31, 2020 and 2019, the components of deferred tax assets and liabilities were as follows: ($ in thousands) 2020 2019 Deferred tax assets Share-based compensation $ 2,080 $ 1,177 Net operating losses 12,440 1,285 Lease liabilities 20,146 13,202 Inventory — 188 Other 817 425 Total deferred tax assets $ 35,483 $ 16,277 Deferred tax liabilities Biological assets $ (7,396 ) $ (4,213 ) ROU assets (8,699 ) (6,488 ) Inventory (8,026 ) — Property, plant and equipment (8,407 ) (7,923 ) Intangible assets (48,517 ) (18,877 ) Other (137 ) (227 ) Total deferred tax liabilities $ (81,182 ) $ (37,728 ) Net deferred tax liabilities $ (45,699 ) $ (21,451 ) |
Summary of reconciliation between the effective tax rate | The reconciliation between the effective tax rate on income from continuing operations and the statutory tax rate is as follows: ($ in thousands) 2020 2019 Expected income tax (recovery) expense at statutory tax rate $ 4,833 $ (10,783 ) Tax rate differences 76 (5,383 ) Pass through and non-controlling (13,559 ) 186 State tax expense, net 11,148 1,726 Permanently non-deductible 29,635 16,382 Uncertain tax treatment 7,598 4,875 Share-based compensation 3,349 3,869 Change in tax status — 3,102 Return-to-provision (4,301 ) — Net changes in deferred tax assets not recognized 5,586 608 Other (645 ) (121 ) Income tax expense $ 43,720 $ 14,461 Effective tax rate 206.8 % (28.4 %) |
Summary of movement in net deferred tax liabilities | Movement in net deferred tax liabilities: ($ in thousands) 2020 2019 Balance at the beginning of the year $ (21,451 ) $ (4,459 ) Recognized in profit/loss 4,447 (1,176 ) Recognized in goodwill (30,199 ) (16,108 ) Recognized in equity 1,504 292 Balance at the end of the year $ (45,699 ) $ (21,451 ) |
Summary of deferred tax assets not recognized in deductible temporary differences | Deferred tax assets have not been recognized in respect of the following deductible temporary differences: ($ in thousands) 2020 2019 Unrecognized deductible temporary differences: Canadian non-capital $ 55,552 $ 1,677 Canadian capital losses carried forward — 809 U.S. non-capital 7,637 — California non-capital 25,864 — U.S. and California amortization of intangible assets 1,763 — Capital raise expenses 10,375 2,332 Other 6,548 63 Total $ 107,739 $ 4,881 |
Nature of Operations - Addition
Nature of Operations - Additional Information (Detail) | 12 Months Ended | |
Dec. 31, 2020 | Nov. 30, 2018 | |
General Information [Line Items] | ||
Date of incorporation | Jul. 6, 1990 | |
Reverse Take Over [Member] | ||
General Information [Line Items] | ||
Share consolidation ratio | 812.63 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Summary of Significant Investments in Subsidiaries (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of subsidiaries [line items] | |
Location | British Columbia, Canada |
Purpose | Parent Company |
Cresco U.S. Corp. [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Manager of Cresco Labs, LLC |
Percentage Held | 100.00% |
Cresco Labs, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Operating Entity |
Percentage Held | 49.98% |
Cresco Labs Notes Issuer, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
Gloucester Street Capital, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | New York |
Purpose | Holding Company |
Percentage Held | 100.00% |
Valley Agriceuticals, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | New York |
Purpose | Operating Entity |
Percentage Held | 100.00% |
MedMar Inc.[Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
MedMar Lakeview, LLC (Sunnyside - Lakeview and Sunnyside - River North) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Dispensary |
Percentage Held | 87.60% |
MedMar Rockford, LLC (Sunnyside - Rockford and Sunnyside - South Beloit) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Dispensary |
Percentage Held | 75.00% |
CannaRoyalty Corp. (Origin House) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Ontario, Canada |
Purpose | Holding Company |
Percentage Held | 100.00% |
Cali-AntiFragile Corp. [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Holding Company |
Percentage Held | 100.00% |
Alta Supply Inc. (Continuum) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Distribution |
Percentage Held | 100.00% |
Kaya Management Inc. [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Production |
Percentage Held | 100.00% |
RPE Inc. (Continuum) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Distribution |
Percentage Held | 100.00% |
FloraCal [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Cultivation |
Percentage Held | 100.00% |
Cub City, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Distribution |
Percentage Held | 100.00% |
CRHC Holdings Corp. [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Ontario, Canada |
Purpose | Holding Company |
Percentage Held | 100.00% |
2360149 Ontario Inc. (180 Smoke) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Ontario, Canada |
Purpose | Nicotine Vape Company |
Percentage Held | 100.00% |
Cresco Labs Michigan, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Michigan |
Purpose | Cultivation and Production Facility |
Percentage Held | 85.00% |
Cresco Labs Ohio, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Ohio |
Purpose | Cultivation, Production and Dispensary Facility |
Percentage Held | 98.77% |
Wellbeings, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Delaware |
Purpose | CBD Wellness Product Development |
Percentage Held | 100.00% |
Cresco Labs SLO, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Holding Company |
Percentage Held | 100.00% |
SLO Cultivation Inc. [Member] | |
Disclosure of subsidiaries [line items] | |
Location | California |
Purpose | Cultivation and Production Facility |
Percentage Held | 80.00% |
Cresco Labs Joliet, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Cultivation and Production Facility |
Percentage Held | 100.00% |
Cresco Labs Kankakee, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Cultivation and Production Facility |
Percentage Held | 100.00% |
Cresco Labs Logan, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Cultivation and Production Facility |
Percentage Held | 100.00% |
Cresco Labs PA, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Pennsylvania; Registered: Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
Cresco Yeltrah, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Pennsylvania |
Purpose | Cultivation, Production and Dispensary Facility |
Percentage Held | 100.00% |
Cresco Labs Arizona, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Arizona |
Purpose | Holding Company |
Percentage Held | 100.00% |
Arizona Facilities Supply, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Arizona/Maryland |
Purpose | Cultivation, Production and Dispensary Facility |
Percentage Held | 100.00% |
Cresco Labs Tinad, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
PDI Medical III, LLC (Sunnyside - Buffalo Grove and Sunnyside - Naperville) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Dispensary |
Percentage Held | 100.00% |
Cresco Labs Phoenix Farms, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
Phoenix Farms of Illinois, LLC (Sunnyside - Champaign and Sunnyside - Danville) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Dispensary |
Percentage Held | 100.00% |
JDC Elmwood, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
FloraMedex, LLC (Sunnyside - Elmwood Park and Sunnyside - Schaumburg) [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Dispensary |
Percentage Held | 100.00% |
Cresco Edibles, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Holding Company |
Percentage Held | 100.00% |
TSC Cresco, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Illinois |
Purpose | Licensing |
Percentage Held | 75.00% |
Cresco HHH, LLC [Member] | |
Disclosure of subsidiaries [line items] | |
Location | Massachusetts |
Purpose | Cultivation, Production and Dispensary Facility |
Percentage Held | 100.00% |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Summary of Significant Investments in Subsidiaries (Parenthetical) (Detail) - Cresco Labs Michigan, LLC [Member] | 12 Months Ended |
Dec. 31, 2020 | |
Disclosure of subsidiaries [line items] | |
Percentage of ownership interest in subisdiaries | 85.00% |
Within the Management of the Company [Member] | |
Disclosure of subsidiaries [line items] | |
Percentage of ownership interest in subisdiaries | 85.00% |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property Plant and Equipment (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Leasehold Improvements [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Amortized over the lesser of the life of the lease or estimated useful life of the improvement |
Leasehold Improvements [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 1 year |
Leasehold Improvements [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 15 years |
Machinery and Equipment [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Machinery and Equipment [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 5 years |
Machinery and Equipment [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 15 years |
Fixtures and Fittings [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Fixtures and Fittings [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 3 years |
Fixtures and Fittings [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 8 years |
Vehicles [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Estimated Useful Life | 5 years |
Website and Software [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Website and Software [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 3 years |
Website and Software [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 7 years |
Computer Equipment [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Computer Equipment [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 3 years |
Computer Equipment [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 7 years |
Buildings and Building Improvements [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Methodology | Over the estimated useful life of the asset |
Buildings and Building Improvements [member] | Bottom of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 5 years |
Buildings and Building Improvements [member] | Top of range [member] | |
Disclosure of detailed information about property, plant and equipment [line items] | |
Estimated Useful Life | 39 years |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Summary of Useful Lives of Finite Lived Intangible Assets Other Than Goodwill (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Market-Related Intangibles [member] | Bottom of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 12 months |
Market-Related Intangibles [member] | Top of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 18 months |
Customer Relationships [member] | Bottom of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 7 years |
Customer Relationships [member] | Top of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 19 years |
Non-Compete Agreements [member] | Bottom of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 4 years |
Non-Compete Agreements [member] | Top of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 5 years |
Internally Developed Software [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 10 years |
Trade Names [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 10 years |
Permit Application Fees [member] | Bottom of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 1 year |
Permit Application Fees [member] | Top of range [member] | |
Disclosure of detailed information about intangible assets [line items] | |
Estimated Useful Life | 2 years |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Summary of Measurement Category of Financial Assets and Financial Liabilities (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Accounts payable and accrued expenses and Other long-term liabilities [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | Amortized cost |
Measurement, Liabilities | Amortized cost |
Deferred consideration, contingent consideration and other payables [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | FVTPL |
Measurement, Liabilities | Fair value |
Derivative liabilities [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | FVTPL |
Measurement, Liabilities | Fair value |
Short-term borrowings [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | Amortized cost |
Measurement, Liabilities | Amortized cost |
Lease liabilities [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | Amortized cost |
Measurement, Liabilities | Amortized cost |
Long-term notes payable and loans payable [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Liabilities | Amortized cost |
Measurement, Liabilities | Amortized cost |
Cash and cash equivalents [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Assets | Amortized cost |
Measurement, Assets | Amortized cost |
Restricted cash [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Assets | Amortized cost |
Measurement, Assets | Amortized cost |
Accounts receivable [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Assets | Amortized cost |
Measurement, Assets | Amortized cost |
Loans receivable [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Assets | Amortized cost or FVTPL |
Measurement, Assets | Amortized cost or fair value |
Investments [member] | |
Description of Measurement Category of Financial Assets and Financial Liabilities [Line Items] | |
Classification, Assets | FVTPL |
Measurement, Assets | Fair value |
Summary of Significant Accoun_9
Summary of Significant Accounting Policies - Summary of Reconciliation of Lease Liabilities (Detail) - USD ($) $ in Thousands | Jan. 01, 2019 | Dec. 31, 2020 | Dec. 31, 2018 |
Significant Accounting Policies [Abstract] | |||
Lease obligations in accordance with IAS 17 at December 31, 2018 | $ 60,451 | ||
Leases not commenced at January 1, 2019 | $ (929) | ||
Exemption for short-term leases | (133) | ||
Lease extension options | 34,841 | ||
Other | 1,149 | ||
Obligations from lease arrangements (undiscounted) | 95,379 | ||
Effect of discounting | (57,672) | ||
Lease liability recognized as of January 1, 2019 | $ 37,707 | $ 170,062 |
Summary of Significant Accou_10
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | |
Significant Accounting Policies [Line Items] | |||
Restricted cash current | $ 4,400 | $ 5,100 | |
Impairment of intangible assets other than goodwill | 0 | 0 | |
Impairment of goodwill | 0 | 0 | |
Right-of-use assets | 92,169 | 46,696 | |
Lease liabilities | 170,062 | $ 37,707 | |
Accumulated deficit | (286,197) | (114,632) | |
Non-controlling interest | 150,312 | $ 135,541 | |
Market-Related Intangibles [member] | |||
Significant Accounting Policies [Line Items] | |||
Impairment of goodwill | 1,200 | ||
Reversal of impairment loss | $ 1,200 | ||
Upon adoption of IFRS 16 [member] | |||
Significant Accounting Policies [Line Items] | |||
Right-of-use assets | 32,500 | ||
Lease liabilities | 37,700 | ||
Accumulated deficit | 1,500 | ||
Deferred rent | 2,200 | ||
Non-controlling interest | $ 1,500 |
Accounts Receivable - Summary o
Accounts Receivable - Summary of Accounts Receivable (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Trade and other current receivables [abstract] | ||
Accounts receivable, gross | $ 29,962 | $ 16,726 |
Allowance for doubtful accounts | (696) | (271) |
Total Accounts receivable, net | $ 29,266 | $ 16,455 |
Biological assets - Summary of
Biological assets - Summary of Changes in the Carrying Value of Biological Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about biological assets [abstract] | ||
Biological assets | $ 31,791 | $ 17,673 |
Biological assets acquired (Note 13) | 2,002 | 1,436 |
Transferred to inventory upon harvest | (280,863) | (96,849) |
Changes in fair value of biological assets | 293,119 | 109,531 |
Biological assets | $ 46,049 | $ 31,791 |
Biological assets - Summary o_2
Biological assets - Summary of Sensitivity of the Inputs in Relation to Biological Assets (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Selling price per gram, less cost to sell [member] | Increase [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets | $ 2,292 | $ 6,360 |
Percentage of reasonably possible increase in unobservable input, assets | 5.00% | |
Selling price per gram, less cost to sell [member] | Decrease [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets | $ (2,292) | (6,360) |
Percentage of reasonably possible decrease in unobservable input, assets | 5.00% | |
Attrition rate [member] | Increase [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets | $ (2,425) | (1,602) |
Percentage of reasonably possible increase in unobservable input, assets | 5.00% | |
Attrition rate [member] | Decrease [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets | $ 1,729 | 1,298 |
Percentage of reasonably possible decrease in unobservable input, assets | 5.00% | |
Average yield per plant [member] | Increase [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets | $ 2,292 | 1,590 |
Percentage of reasonably possible increase in unobservable input, assets | 5.00% | |
Average yield per plant [member] | Decrease [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets | $ (2,292) | (1,590) |
Percentage of reasonably possible decrease in unobservable input, assets | 5.00% | |
Cumulative stage of completion [member] | Increase [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, assets | $ 5,330 | 3,177 |
Percentage of reasonably possible increase in unobservable input, assets | 5.00% | |
Cumulative stage of completion [member] | Decrease [member] | ||
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | ||
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, assets | $ (5,326) | $ (3,177) |
Percentage of reasonably possible decrease in unobservable input, assets | 5.00% |
Biological assets - Summary o_3
Biological assets - Summary of Sensitivity of the Inputs in Relation to Biological Assets (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Bottom of range [member] | |
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | |
Net selling price per unit | 1.25 |
Attrition rate | 7.00% |
Average yield per plant | 43 grams |
Cumulative stage of completion | 35.00% |
Top of range [member] | |
Disclosure of Sensitivity Analysis and Its Impact on the Fair Value of Biological Assets [Line Items] | |
Net selling price per unit | 6.23 |
Attrition rate | 15.00% |
Average yield per plant | 136 grams |
Cumulative stage of completion | 55.00% |
Biological assets - Additional
Biological assets - Additional Information (Detail) - Grams Grams in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Scenario Forecast [member] | ||
Disclosure of detailed information about biological assets [line items] | ||
Estimated output | 21.4 | 13.1 |
Inventory - Summary of Inventor
Inventory - Summary of Inventory (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of Detailed Information About Inventories [Line Items] | ||
Work-in-process | $ 24,906 | $ 14,100 |
Finished goods | 29,027 | 13,114 |
Total Inventory | 136,605 | 49,555 |
Cannabis [Member] | ||
Disclosure of Detailed Information About Inventories [Line Items] | ||
Raw materials | 67,176 | 16,521 |
Non Cannabis [Member] | ||
Disclosure of Detailed Information About Inventories [Line Items] | ||
Raw materials | $ 15,496 | $ 5,820 |
Inventory - Additional Informat
Inventory - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure Of Detailed Information About Inventories [Line Items] | ||
Write downs of inventories | $ 5,900 | $ 8,400 |
Write downs reversals of inventories | 400 | |
Inventory reserves | 4,200 | 200 |
Cost of inventories recognized as operating costs | 485,400 | 174,000 |
Realized changes in fair value of inventory sold | 214,901 | 91,080 |
Cost of Sales [member] | ||
Disclosure Of Detailed Information About Inventories [Line Items] | ||
Inventory reserves | 4,000 | 0 |
Cost of inventories recognized as operating costs | $ 270,500 | $ 82,900 |
Property And Equipment - Summar
Property And Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | $ 155,839 | |
Depreciation | (16,300) | $ (5,100) |
Purchase related to sale-leaseback transactions | 78,272 | 91,673 |
Ending Balance | 195,231 | 155,839 |
Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 162,558 | 41,350 |
Additions | 70,694 | 105,428 |
Transfers | 0 | 0 |
Disposals | (381) | |
Purchase related to sale-leaseback transactions | 37,062 | |
Sales related to sale-leaseback transactions | (33,486) | (37,062) |
Additions from acquisition | 18,625 | |
Business acquisitions | 15,780 | |
Effect of foreign exchange and other adjustments | (230) | |
Ending Balance | 217,780 | 162,558 |
Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (6,719) | (1,629) |
Depreciation | (16,287) | (5,090) |
Sales related to sale-leaseback transactions | 457 | |
Ending Balance | (22,549) | (6,719) |
Land and Buildings [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 27,575 | |
Ending Balance | 7,960 | 27,575 |
Land and Buildings [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 28,007 | 11,125 |
Additions | 1,055 | 3,683 |
Transfers | 1,728 | 5,397 |
Disposals | 0 | |
Purchase related to sale-leaseback transactions | 37,062 | |
Sales related to sale-leaseback transactions | (22,083) | (37,062) |
Additions from acquisition | 0 | |
Business acquisitions | 7,802 | |
Effect of foreign exchange and other adjustments | 0 | |
Ending Balance | 8,707 | 28,007 |
Land and Buildings [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (432) | (50) |
Depreciation | (315) | (382) |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | (747) | (432) |
Machinery and Equipment [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 14,402 | |
Ending Balance | 19,966 | 14,402 |
Machinery and Equipment [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 15,650 | 4,449 |
Additions | 5,908 | 9,473 |
Transfers | 1,290 | 694 |
Disposals | (110) | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | 0 | 0 |
Additions from acquisition | 455 | |
Business acquisitions | 1,034 | |
Effect of foreign exchange and other adjustments | 6 | |
Ending Balance | 23,199 | 15,650 |
Machinery and Equipment [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (1,248) | (335) |
Depreciation | (1,985) | (913) |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | (3,233) | (1,248) |
Fixtures and Fittings [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 9,464 | |
Ending Balance | 14,423 | 9,464 |
Fixtures and Fittings [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 10,458 | 2,088 |
Additions | 4,804 | 7,635 |
Transfers | 2,191 | 0 |
Disposals | (33) | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | 0 | 0 |
Additions from acquisition | 473 | |
Business acquisitions | 735 | |
Effect of foreign exchange and other adjustments | (273) | |
Ending Balance | 17,620 | 10,458 |
Fixtures and Fittings [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (994) | (234) |
Depreciation | (2,203) | (760) |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | (3,197) | (994) |
Leasehold Improvements [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 59,823 | |
Ending Balance | 128,438 | 59,823 |
Leasehold Improvements [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 62,965 | 17,828 |
Additions | 10,415 | 36,793 |
Transfers | 56,401 | 4,837 |
Disposals | (214) | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | 0 | 0 |
Additions from acquisition | 11,615 | |
Business acquisitions | 3,507 | |
Effect of foreign exchange and other adjustments | 130 | |
Ending Balance | 141,312 | 62,965 |
Leasehold Improvements [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (3,142) | (633) |
Depreciation | (10,189) | (2,509) |
Sales related to sale-leaseback transactions | 457 | |
Ending Balance | (12,874) | (3,142) |
Website Computer Equipment and Software [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 1,972 | |
Ending Balance | 3,762 | 1,972 |
Website Computer Equipment and Software [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 2,715 | 1,096 |
Additions | 2,409 | 1,446 |
Transfers | 125 | 0 |
Disposals | (24) | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | 0 | 0 |
Additions from acquisition | 585 | |
Business acquisitions | 173 | |
Effect of foreign exchange and other adjustments | (43) | |
Ending Balance | 5,767 | 2,715 |
Website Computer Equipment and Software [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (743) | (327) |
Depreciation | (1,262) | (416) |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | (2,005) | (743) |
Vehicles [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 555 | |
Ending Balance | 1,452 | 555 |
Vehicles [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 715 | 386 |
Additions | 878 | 295 |
Transfers | 21 | 0 |
Disposals | 0 | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | 0 | 0 |
Additions from acquisition | 331 | |
Business acquisitions | 34 | |
Effect of foreign exchange and other adjustments | 0 | |
Ending Balance | 1,945 | 715 |
Vehicles [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | (160) | (50) |
Depreciation | (333) | (110) |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | (493) | (160) |
Construction In Progress [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 42,048 | |
Ending Balance | 19,230 | 42,048 |
Construction In Progress [member] | Gross carrying amount [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 42,048 | 4,378 |
Additions | 45,225 | 46,103 |
Transfers | (61,756) | (10,928) |
Disposals | 0 | |
Purchase related to sale-leaseback transactions | 0 | |
Sales related to sale-leaseback transactions | (11,403) | 0 |
Additions from acquisition | 5,166 | |
Business acquisitions | 2,495 | |
Effect of foreign exchange and other adjustments | (50) | |
Ending Balance | 19,230 | 42,048 |
Construction In Progress [member] | Accumulated depreciation and amortisation [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Beginning balance | 0 | 0 |
Depreciation | 0 | 0 |
Sales related to sale-leaseback transactions | 0 | |
Ending Balance | $ 0 | $ 0 |
Property And Equipment - Additi
Property And Equipment - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation, property, plant and equipment | $ 16.3 | $ 5.1 |
Closing inventories [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation, property, plant and equipment | 0.7 | 0.4 |
Selling, general and administrative expense [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation, property, plant and equipment | 4.1 | 1.2 |
Selling, general and administrative expense [member] | Closing inventories [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation, property, plant and equipment | 11.9 | 3.7 |
Selling, general and administrative expense [member] | Closing inventories [member] | Previously stated [member] | ||
Disclosure of detailed information about property, plant and equipment [line items] | ||
Depreciation, property, plant and equipment | $ 0.5 | $ 0.1 |
Leases - Summary of Right of us
Leases - Summary of Right of use Assets (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of quantitative information about right-of-use assets [line items] | ||
Total ROU assets | $ 92,169 | $ 46,696 |
Real estate [member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Total ROU assets | 92,159 | 46,696 |
Vehicles [member] | ||
Disclosure of quantitative information about right-of-use assets [line items] | ||
Total ROU assets | $ 10 | $ 0 |
Leases - Summary of Maturities
Leases - Summary of Maturities of Lease Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | $ 527,870 | ||
Less: imputed interest | (310,142) | ||
Less: tenant improvement allowance | (47,666) | ||
Present value of lease liabilities | 170,062 | $ 37,707 | |
Less: current lease liabilities | (24,742) | $ (12,019) | |
Present value of long-term lease liabilities | 145,320 | $ 82,856 | |
2021 | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | 33,207 | ||
2022 | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | 33,560 | ||
2023 | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | 34,265 | ||
2024 | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | 35,528 | ||
2025 | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | 36,324 | ||
Thereafter | |||
Disclosure Of Maturity Analysis Of Operating Lease Payments Due [Line Items] | |||
Total lease payments | $ 354,986 |
Leases - Summary of Contractual
Leases - Summary of Contractual Receipts for Lease Contract Due (Detail) $ in Thousands | Dec. 31, 2020USD ($) |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | $ 5,913 |
2021 | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | 642 |
2022 | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | 591 |
2023 | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | 609 |
2024 | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | 642 |
2025 | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | 646 |
Thereafter | |
Disclosure of maturity analysis of operating lease payments [line items] | |
Total lease payments | $ 2,783 |
Leases - Additional Information
Leases - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of Leases [Line Items] | ||
Additions to right of use assets | $ 36,600 | |
Decrease in right of use assets due to termination | 100 | |
Lease-related interest expense | 20,375 | $ 7,078 |
Depreciation capitalised related to leases | 8,700 | 4,100 |
Depreciation related to leases | $ 200 | 100 |
Operating lease term | 10-year | |
Operating lease term, Maturity date | December 2029 | |
Finance lease term, Maturity date | February 2021 | |
Outstanding sublease receivables | $ 0 | |
Sale and leaseback agreements net book value | 33,000 | 37,100 |
Gain loss on sale of assets | 500 | 6,400 |
Proceeds from sale and lease back transactions | 29,900 | 36,400 |
Increase decrease in right of use assets due to sale and lease back transactions | 25,200 | 100 |
Increase decrease in operating lease liabilities | 24,500 | 36,600 |
Operating lease liability tenant additional improvement allowance | 52,900 | 47,700 |
Loss on lease termination | 7,100 | |
Income from reimbursements under tenant improvement allowances | 27,300 | |
Hope Heal Health Loan [member] | ||
Disclosure of Leases [Line Items] | ||
Settlement of security deposits | 600 | |
Selling, general and administrative expense [member] | ||
Disclosure of Leases [Line Items] | ||
Depreciation capitalised related to leases | 4,700 | 1,600 |
Short term lease rent expenses | 1,100 | 300 |
Cost of Sales [member] | ||
Disclosure of Leases [Line Items] | ||
Depreciation related to leases | 3,900 | 2,600 |
Cost of Sales [member] | Previously stated [member] | ||
Disclosure of Leases [Line Items] | ||
Depreciation related to leases | 100 | $ 300 |
Other expense income net [member] | ||
Disclosure of Leases [Line Items] | ||
Rental income | 700 | |
Loss on lease termination | 700 | |
Canna Royalty Corp [Member] | ||
Disclosure of Leases [Line Items] | ||
Additions to right of use assets | $ 18,000 | |
Bottom of range [member] | ||
Disclosure of Leases [Line Items] | ||
Lease term | one year | |
Lease renewal term | one year | |
Lease exercise renewal options term | one year | |
Top of range [member] | ||
Disclosure of Leases [Line Items] | ||
Lease term | 20 years | |
Lease renewal term | 35 years | |
Lease exercise renewal options term | 10 years |
Investments - Summary of Inves
Investments - Summary of Investments at Fair Value (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure Of Investments Measured At Fair Value [Line Items] | ||
Total Investments | $ 1,168 | $ 1,278 |
420 Capital [member] | ||
Disclosure Of Investments Measured At Fair Value [Line Items] | ||
Total Investments | 68 | 68 |
Lighthouse [member] | ||
Disclosure Of Investments Measured At Fair Value [Line Items] | ||
Total Investments | 1,049 | 1,209 |
Fleurish [member] | ||
Disclosure Of Investments Measured At Fair Value [Line Items] | ||
Total Investments | 51 | 0 |
MassRoots, Inc. [member] | ||
Disclosure Of Investments Measured At Fair Value [Line Items] | ||
Total Investments | $ 0 | $ 1 |
Investments - Summary of Invest
Investments - Summary of Investment in Associates Accounted for as an Equity Method Investment (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of associates [line items] | ||
Total Investment | $ 3,192 | $ 0 |
Trichome [member] | ||
Disclosure of associates [line items] | ||
Total Investment | $ 3,192 | $ 0 |
Investments - Additional Inform
Investments - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Jan. 08, 2020 | Aug. 12, 2019 | |
Trichome Financial Corp [member] | ||||
Disclosure Of Significant Investments [Line Items] | ||||
Investments at fair value and equity | $ 4.3 | |||
Percentage of ownership stake | 23.00% | |||
Loss on investment | $ 1.2 | $ 0.6 | ||
Distributions received from associate | 0 | $ 1.6 | ||
CHP Fresco [member] | ||||
Disclosure Of Significant Investments [Line Items] | ||||
Percentage of ownership stake | 13.00% | |||
Proceeds from dissolution of associate | $ 1.5 | |||
Gain on dissolution of associate | 1.3 | |||
Market risk [member] | ||||
Disclosure Of Significant Investments [Line Items] | ||||
Mark to market loss of investments held | 0.2 | $ 2.8 | ||
Lighthouse Strategies LLC [member] | ||||
Disclosure Of Significant Investments [Line Items] | ||||
Outstanding loan receivable | $ 3.3 | |||
Percentage of ownership interest | 1.00% | |||
Investment Accounted Using Equity Method | $ 1.9 | |||
Fleurish Cannabis Inc [member] | ||||
Disclosure Of Significant Investments [Line Items] | ||||
Percentage of ownership interest | 1.30% | |||
Investments at fair value and equity | $ 0.1 |
Intangible Assets and Goodwil_2
Intangible Assets and Goodwill - Detailed Information of Intangible assets and Goodwill (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | $ 647,379 | $ 231,925 |
Customer Relationships [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 65,400 | 6,071 |
Trade Names [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 35,730 | 0 |
Permit Application Costs [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 1,610 | 3,577 |
Licenses [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 89,347 | 83,447 |
Other Intangibles [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 3,431 | 1,111 |
Goodwill [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Intangible assets and goodwill net | 451,861 | 137,719 |
Gross carrying amount [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 237,070 | 78,844 |
Additions | 4,608 | 4,466 |
Additions from acquisitions | 423,317 | 153,760 |
Foreign exchange | 4 | |
Measurement period adjustments | 2,775 | |
Ending balance | 667,774 | 237,070 |
Gross carrying amount [member] | Customer Relationships [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 6,929 | 5,429 |
Additions | 0 | 0 |
Additions from acquisitions | 52,200 | 1,500 |
Foreign exchange | 0 | |
Measurement period adjustments | 11,400 | |
Ending balance | 70,529 | 6,929 |
Gross carrying amount [member] | Trade Names [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 0 | 0 |
Additions | 0 | 0 |
Additions from acquisitions | 41,800 | 0 |
Foreign exchange | 0 | |
Measurement period adjustments | (2,100) | |
Ending balance | 39,700 | 0 |
Gross carrying amount [member] | Permit Application Costs [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 6,842 | 2,389 |
Additions | 1,886 | 4,453 |
Additions from acquisitions | 0 | 0 |
Foreign exchange | 0 | |
Measurement period adjustments | 0 | |
Ending balance | 8,728 | 6,842 |
Gross carrying amount [member] | Licenses [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 83,447 | 18,047 |
Additions | 0 | 0 |
Additions from acquisitions | 5,900 | 65,400 |
Foreign exchange | 0 | |
Measurement period adjustments | 0 | |
Ending balance | 89,347 | 83,447 |
Gross carrying amount [member] | Other Intangibles [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 2,133 | 1,833 |
Additions | 2,722 | 0 |
Additions from acquisitions | 2,865 | 300 |
Foreign exchange | 0 | |
Measurement period adjustments | (111) | |
Ending balance | 7,609 | 2,133 |
Gross carrying amount [member] | Goodwill [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 137,719 | 51,146 |
Additions | 0 | 13 |
Additions from acquisitions | 320,552 | 86,560 |
Foreign exchange | 4 | |
Measurement period adjustments | (6,414) | |
Ending balance | 451,861 | 137,719 |
Accumulated depreciation and amortisation [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | (5,145) | (2,234) |
Amortization | (15,250) | (2,911) |
Ending balance | (20,395) | (5,145) |
Accumulated depreciation and amortisation [member] | Customer Relationships [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | (858) | (130) |
Amortization | (4,271) | (728) |
Ending balance | (5,129) | (858) |
Accumulated depreciation and amortisation [member] | Trade Names [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 0 | 0 |
Amortization | (3,970) | 0 |
Ending balance | (3,970) | 0 |
Accumulated depreciation and amortisation [member] | Permit Application Costs [Member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | (3,265) | (1,866) |
Amortization | (3,853) | (1,399) |
Ending balance | (7,118) | (3,265) |
Accumulated depreciation and amortisation [member] | Licenses [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 0 | 0 |
Amortization | 0 | 0 |
Ending balance | 0 | 0 |
Accumulated depreciation and amortisation [member] | Other Intangibles [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | (1,022) | (238) |
Amortization | (3,156) | (784) |
Ending balance | (4,178) | (1,022) |
Accumulated depreciation and amortisation [member] | Goodwill [member] | ||
Disclosure of reconciliation of changes in intangible assets and goodwill [line items] | ||
Openning balance | 0 | 0 |
Amortization | 0 | 0 |
Ending balance | $ 0 | $ 0 |
Intangible Assets and Goodwil_3
Intangible Assets and Goodwill - Additional Information (Detail) - USD ($) $ in Thousands | Nov. 18, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Statements [Line Items] | |||
Amortisation expense | $ 15,300 | $ 2,900 | |
Inventory Capitalized Costs | 300 | 300 | |
Inventory Capitalized Costs prior year | 300 | 100 | |
Impairment charge | $ 0 | 0 | |
Growth rate used to extrapolate cash flow projections | 3.00% | ||
Bottom of range [member] | |||
Statements [Line Items] | |||
Discounted future cash flow projection period | 2021 years | ||
Discount rate applied to cash flow projections | 13.00% | ||
Top of range [member] | |||
Statements [Line Items] | |||
Discounted future cash flow projection period | 2025 years | ||
Discount rate applied to cash flow projections | 14.50% | ||
Kings Garden [Member] | |||
Statements [Line Items] | |||
Intangible assets other than goodwill, revalued assets | $ 2,500 | ||
Stock Issued During Period Value Issued For Services | $ 200 | ||
Origin House [Member] | |||
Statements [Line Items] | |||
Acquisitions through business combinations of License | $ 2,400 | ||
Market Related Intangibles [Member] | |||
Statements [Line Items] | |||
Impairment charge | 1,200 | ||
Reversal of impairment loss | 1,200 | ||
Gross carrying amount [member] | |||
Statements [Line Items] | |||
Acquisitions through business combinations of License | 423,317 | 153,760 | |
Gross carrying amount [member] | Licences [member] | |||
Statements [Line Items] | |||
Acquisitions through business combinations of License | 5,900 | ||
Selling general and administrative expenses [Member] | |||
Statements [Line Items] | |||
Amortisation expense | 12,600 | 1,400 | |
Cost Of Sales [Member] | |||
Statements [Line Items] | |||
Amortisation expense | $ 2,800 | $ 1,400 |
Accounts Payable And Other Ac_3
Accounts Payable And Other Accrued Expenses - Summary of accounts payable and other accrued expenses (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Text Block [Abstract] | ||
Accounts payable | $ 26,170 | $ 32,463 |
Accrued expenses | 34,843 | 24,133 |
Payroll liabilities | 14,858 | 5,195 |
Excise taxes payable | 8,675 | 540 |
Contract liability | 1,182 | 0 |
Tax penalty | 578 | 455 |
Property taxes payable | 20 | 48 |
Total Accounts payable and other accrued expenses | $ 86,326 | $ 62,834 |
Share Capital - Additional Info
Share Capital - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Nov. 30, 2020 | Aug. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | Apr. 30, 2020 | Mar. 31, 2020 | Oct. 24, 2019 | Sep. 30, 2019 | Feb. 28, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Share Capital [Line Items] | ||||||||||||
Stock Conversion Ratio | 1 PVS for 200 SVS | |||||||||||
Proceeds from issue of ordinary shares | $ 3,500 | |||||||||||
Number Of Shares Issued During The Period New Issues | 700,000 | |||||||||||
Weighted average share price | $ 4.70 | |||||||||||
Payments for share issue costs | $ 3,200 | $ 200 | ||||||||||
Number Of units Issued During The Period New Issues | 7,400,000 | |||||||||||
Unit Price | $ 7.55 | |||||||||||
Value Of units Issued During The Period New Issues | 55.5 | |||||||||||
Proceeds From Issuance of Equity | $ 900 | $ 52,300 | ||||||||||
Payments For Commission And Other Fees | 49,200 | |||||||||||
Payments for share issue costs | $ 3,200 | $ 200 | ||||||||||
Warrant Exercise Price | 600,000 | |||||||||||
Additional Warrant Exercise Price | 1,640,000 | |||||||||||
Number of warrants, Excercised | (270,635) | (169,545) | ||||||||||
Value Of Warrant Exercised During The Period | $ 2,500 | |||||||||||
Foreign Exchange Gain Loss On Sale Of Equity | $ 500 | |||||||||||
Number Of Warrants Outstanding | 6,183,149 | 6,453,784 | 397,079 | |||||||||
Dividendsgnised as distributions to non-controlling interests | $ 1,800 | |||||||||||
Number Of Redeemable Units Redeemed During The Period | 15.7 | 1,700,000 | ||||||||||
Percentage Of Decrease In Noncontrolling Interest | 0.70% | |||||||||||
Number of warrants, Issued | 6,226,250 | |||||||||||
Two Thousand Nineteen Unit Holders [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Dividends recognised as distributions to owners | $ 9,500 | |||||||||||
Two Thousand Twenty Unit Holders [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Dividendsgnised as distributions to non-controlling interests | $ 7,200 | |||||||||||
Two Thousand Eighteen Unit Holders [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Dividendsgnised as distributions to non-controlling interests | $ 3,600 | |||||||||||
Equityclassified warrants [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number of warrants, Excercised | 200,000 | |||||||||||
Value Of Warrant Exercised During The Period | $ 1,400 | |||||||||||
Foreign Exchange Gain Loss On Sale Of Equity | 13 | |||||||||||
Increase Decrease In Equity | $ 2,000 | |||||||||||
Number of warrants, Issued | 0 | 0 | ||||||||||
Broker warrants [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number of warrants, Excercised | 35,000,000 | |||||||||||
Value Of Warrant Exercised During The Period | $ 200 | |||||||||||
Foreign Exchange Gain Loss On Sale Of Equity | 35 | |||||||||||
Increase Decrease In Equity | $ 400 | |||||||||||
MedMar Inc Lakeview [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 3,000,000 | |||||||||||
Cresco Labs Inc [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Percentage Of Decrease In Noncontrolling Interest | 6.10% | |||||||||||
PDI Medical III LLC [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Perecentage of ownership interests held by non-controlling interests | 0.00% | 2.00% | 1.00% | |||||||||
PDI Medical III LLC [Member] | Bottom of range [member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Perecentage of ownership interests held by non-controlling interests | 10.00% | |||||||||||
PDI Medical III LLC [Member] | Top of range [member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Perecentage of ownership interests held by non-controlling interests | 11.00% | |||||||||||
Phoenix Farms of Illinois LLC [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Perecentage of ownership interests held by non-controlling interests | 10.00% | |||||||||||
Consideration paid (received) | $ 600 | $ 200 | ||||||||||
Phoenix Farms of Illinois LLC [Member] | Retained earnings [member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Increase Decrease In Equity | 200 | |||||||||||
Phoenix Farms of Illinois LLC [Member] | Non- controlling interests [member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Increase Decrease In Equity | $ 34 | |||||||||||
Special Subordinate Voting Shares [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Description Of Voting Rights | 0.00001 | |||||||||||
Conversion Of Stock, Shares Converted | 1,000 | |||||||||||
Conversion Of Stock, Amount Converted | $ 3 | |||||||||||
Proportionate Voting Shares [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Description Of Voting Rights Conversion | 200 | |||||||||||
Conversion Of Stock, Shares Converted | 0.1 | 0.2 | ||||||||||
Proportionate Voting Shares [Member] | Gloucester Street Capital, LLC [Member] | Deferred Consieration [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 300,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 1,200 | |||||||||||
Proportionate Voting Shares [Member] | Cresco Labs Inc [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 8,700,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 48,900 | |||||||||||
Super Voting Shares [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Description Of Voting Rights | 2,000 | |||||||||||
Subordinate Voting Shares [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Description Of Voting Rights | one | |||||||||||
Conversion Of Stock, Shares Issued On Conversion | 28.9 | 37.1 | ||||||||||
Proceeds from issue of ordinary shares | $ 200 | |||||||||||
Number Of Shares Issued During The Period New Issues | 300,000 | 1,600,000 | ||||||||||
Number Of Shares Valued During The Period New Issues | 1,000,000 | |||||||||||
Number Of Shares Issued During The Period Acquisitions | 66,500,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 396,600 | |||||||||||
Number Of units Issued During The Period New Issues | 44,000 | |||||||||||
Value Of units Issued During The Period New Issues | 7.2 | |||||||||||
Subordinate Voting Shares [Member] | TSC Cresco, LLC [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period For Renewal Of Distribution Agreement | 200,000 | |||||||||||
Value Of Shares Issued During The Period For Renewal Of Distribution Agreement | $ 2,500 | |||||||||||
Subordinate Voting Shares [Member] | MedMar Inc Lakeview [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 19,000 | 100,000 | 100,000 | |||||||||
Value Of Shares Issued During The Period Acquisitions | $ 100 | $ 400 | $ 1,100 | |||||||||
Subordinate Voting Shares [Member] | Gloucester Street Capital, LLC [Member] | Contingent consideration [member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 500,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 1,500 | |||||||||||
Subordinate Voting Shares [Member] | Tryke Companies LLC and certain subsidiaries and affiliates [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 300,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 1,300 | |||||||||||
Subordinate Voting Shares [Member] | Cub City, LLC [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 800,000 | |||||||||||
Value Of Shares Issued During The Period Acquisitions | $ 2,200 | |||||||||||
Subordinate Voting Shares [Member] | Origin House [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Number Of Shares Issued During The Period Acquisitions | 800,000 | |||||||||||
Number Of Shares Canceled During The Period New Issues | 200,000 | |||||||||||
Value Of Shares canceled During The Period New Issues | $ 900 | |||||||||||
Subordinate Voting Shares [Member] | ATM Offering [Member] | ||||||||||||
Share Capital [Line Items] | ||||||||||||
Proceeds from issue of ordinary shares | $ 55,000 |
Share Capital - Summary of issu
Share Capital - Summary of issued and outstanding shares (Detail) - shares shares in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Redeemable Units [Member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 142,172 | 143,844 |
Ending balance | 126,338 | 142,172 |
Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 73,600 | 26,711 |
Ending balance | 194,086 | 73,600 |
Super Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 500 | 500 |
Ending balance | 500 | 500 |
Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 57,937 | 82,803 |
Ending balance | 29,311 | 57,937 |
Special Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Ending balance | 1 | |
Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Beginning balance | 3,020 | |
Ending balance | 145 | |
Stock Option Exercise [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 575 | |
Stock Option Exercise [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 342 | |
Warrant Exercise [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 170 | |
Issuance Of MedMar Shares [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 3,020 | |
Issuance Of MedMar Shares [Member] | Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | (3,020) | |
Issuance Of Valley Ag Shares [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 8,660 | |
PVS Converted To SVS And Adjustments [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 37,122 | |
PVS Converted To SVS And Adjustments [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | (36,888) | |
Cresco LLC Redemption [Member] | Redeemable Units [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | (15,834) | (1,672) |
Cresco LLC Redemption [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 15,681 | 1,672 |
Share Issuance From Equity Raise [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 7,350 | |
Options And Warrants Exercise [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 1,688 | |
Options And Warrants Exercise [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 12 | |
Options And Warrants Exercise [Member] | Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 23 | |
RSU Issued [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 2,034 | |
RSU Issued [Member] | Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 28 | |
Issuance Of Shares Related To Acquisitions [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 70,084 | |
Issuance Of Shares Related To Acquisitions [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 233 | |
Issuance Of Shares Related To Acquisitions [Member] | Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | (155) | |
Issuance Of Shares Related To Distribution Agreements [Member] | Shares To Be Issued Or Canceled [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 249 | |
PVS Converted To SVS [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 28,871 | |
PVS Converted To SVS [Member] | Proportionate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | (28,871) | |
Issuances Related To Employee Taxes On Certain Share Based Payment Arrangements [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 1,336 | |
Share Issuances [Member] | Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 792 | |
Share Issuances [Member] | Special Subordinate Voting Shares [Member] | ||
Disclosure of classes of share capital [line items] | ||
Increase (decrease) in number of shares outstanding | 1 |
Share Capital - Summary of is_2
Share Capital - Summary of issued and outstanding shares (Parenthetical) (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
Proportionate Voting Shares [Member] | |
Disclosure of classes of share capital [line items] | |
Description of stock conversion ratio | 1-to-200 |
Special Subordinate Voting Shares [Member] | |
Disclosure of classes of share capital [line items] | |
Description of stock conversion ratio | 1-to-0.00001 |
Share Capital - Summary of warr
Share Capital - Summary of warrants outstanding (Detail) - $ / shares | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of Detailed Information About Warrants Outstanding [Line Items] | ||
Number of warrants, Beginning balance | 6,453,784 | 397,079 |
Number of warrants, Issued | 6,226,250 | |
Number of warrants, Excercised | (270,635) | (169,545) |
Number of warrants, Ending balance | 6,183,149 | 6,453,784 |
Weighted- average exercise price, Beginning balance | $ 7.73 | $ 5.35 |
Weighted- average exercise price, Issued | 7.78 | |
Weighted- average exercise price, Exercised | 6.05 | 6.16 |
Weighted- average exercise price, Ending balance | $ 7.80 | $ 7.73 |
Share Capital - Summary of chan
Share Capital - Summary of changes in ownership and non-controlling interests (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | $ 971,370 | $ 457,216 |
Current assets | 361,754 | 159,338 |
Non-current liabilities | (413,726) | (143,762) |
Current liabilities | (194,640) | (150,169) |
Net assets | 724,758 | 322,623 |
Revenue | 476,251 | 128,534 |
Gross profit | 283,940 | 64,081 |
Total comprehensive income (loss) | (37,183) | (65,302) |
Comprehensive income (loss) allocated to NCI | 45,684 | (22,101) |
Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | 150,311 | 135,541 |
Total comprehensive income (loss) | (36,562) | (65,302) |
Comprehensive income (loss) allocated to NCI | 45,363 | (22,101) |
Reportable Legal Entity [Member] | TSC Cresco LLC [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 4,064 | 3,185 |
Current assets | 31,489 | 14,081 |
Current liabilities | (24,209) | (13,442) |
Net assets | 11,344 | 3,824 |
Revenue | 16,874 | 6,417 |
Gross profit | 9,882 | 5,037 |
Total comprehensive income (loss) | 8,440 | 5,747 |
Comprehensive income (loss) allocated to NCI | $ 2,110 | $ 1,437 |
NCI percentage | 25.00% | 25.00% |
Reportable Legal Entity [Member] | TSC Cresco LLC [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ 3,197 | $ 1,567 |
Reportable Legal Entity [Member] | MedMar Inc Lakeview [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 32,680 | 16,667 |
Current assets | 26,199 | 750 |
Non-current liabilities | (11,942) | (1,634) |
Current liabilities | (31,706) | (1,479) |
Net assets | 15,231 | 14,304 |
Revenue | 31,320 | 4,088 |
Gross profit | 16,404 | 1,999 |
Total comprehensive income (loss) | 3,559 | (980) |
Comprehensive income (loss) allocated to NCI | $ 441 | $ (121) |
NCI percentage | 12.40% | 12.40% |
Reportable Legal Entity [Member] | MedMar Inc Lakeview [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ 3,264 | $ 2,907 |
Reportable Legal Entity [Member] | MedMar Inc Rockford [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 20,634 | 21,419 |
Current assets | 37,996 | 1,644 |
Non-current liabilities | (2,279) | (1,993) |
Current liabilities | (26,686) | (2,172) |
Net assets | 29,665 | 18,898 |
Revenue | 38,417 | 5,310 |
Gross profit | 20,136 | 2,565 |
Total comprehensive income (loss) | 10,738 | (555) |
Comprehensive income (loss) allocated to NCI | $ 2,684 | $ (139) |
NCI percentage | 25.00% | 25.00% |
Reportable Legal Entity [Member] | MedMar Inc Rockford [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ 4,468 | $ 2,081 |
Reportable Legal Entity [Member] | Cresco Labs Ohio LLC [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 11,392 | 12,575 |
Current assets | 41,258 | 30,949 |
Non-current liabilities | (7,113) | (95) |
Current liabilities | (47,512) | (37,660) |
Net assets | (1,975) | 5,769 |
Revenue | 14,646 | 7,759 |
Gross profit | 3,332 | 2,210 |
Total comprehensive income (loss) | (7,996) | (6,259) |
Comprehensive income (loss) allocated to NCI | $ (80) | $ (63) |
NCI percentage | 1.00% | 1.00% |
Reportable Legal Entity [Member] | Cresco Labs Ohio LLC [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ 70 | $ 150 |
Reportable Legal Entity [Member] | SLO Cultivation Inc [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 23,848 | 23,317 |
Current assets | 79,822 | 47,529 |
Non-current liabilities | (10,643) | (13,940) |
Current liabilities | (120,195) | (68,822) |
Net assets | (27,168) | (11,916) |
Revenue | 19,772 | 21,148 |
Gross profit | (4,901) | (505) |
Total comprehensive income (loss) | (12,214) | (15,295) |
Comprehensive income (loss) allocated to NCI | $ (2,443) | $ (3,059) |
NCI percentage | 20.00% | 20.00% |
Reportable Legal Entity [Member] | SLO Cultivation Inc [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ (5,383) | $ (2,940) |
Reportable Legal Entity [Member] | Other entities including Cresco Labs LLC [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Non-current assets | 878,752 | 380,053 |
Current assets | 298,846 | 116,472 |
Non-current liabilities | (381,749) | (126,100) |
Current liabilities | (107,753) | (78,522) |
Net assets | 688,096 | 291,903 |
Revenue | 386,257 | 99,290 |
Gross profit | 243,674 | 61,935 |
Total comprehensive income (loss) | (39,089) | (47,960) |
Comprehensive income (loss) allocated to NCI | $ 42,651 | $ (20,156) |
NCI percentage | 50.02% | 56.20% |
Reportable Legal Entity [Member] | Other entities including Cresco Labs LLC [Member] | Non-controlling interests [member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Net assets | $ 144,695 | $ 131,776 |
Consolidation Elimination [Member] | ||
Disclosure Of Non Controlling Interest And Intercompany Eliminations [Line Items] | ||
Current assets | (153,856) | (52,087) |
Current liabilities | 163,421 | 51,928 |
Net assets | 9,565 | (159) |
Revenue | (31,035) | (15,478) |
Gross profit | $ (4,587) | $ (9,160) |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of the Status of the Stock Options Outstanding (Detail) | 12 Months Ended | |
Dec. 31, 2020shares$ / shares | Dec. 31, 2019shares$ / shares | |
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | ||
Number of stock options outstanding, beginning balance | shares | 22,370,168 | 19,500,000 |
Number of stock options outstanding, granted | shares | 7,278,021 | 4,474,000 |
Number of stock options outstanding, exercised | shares | (1,945,401) | (934,682) |
Number of stock options outstanding, origin house replacement awards | shares | 629,275 | |
Number of stock options outstanding, forfeited | shares | (5,845,350) | (669,150) |
Number of stock options outstanding, ending balance | shares | 22,486,713 | 22,370,168 |
Number of stock options outstanding, exercisable | shares | 9,550,535 | |
Weighted average exercise price, beginning balance | $ / shares | $ 3.19 | $ 2.11 |
Weighted average exercise price, granted | $ / shares | 5.04 | 7.48 |
Weighted average exercise price, exercised | $ / shares | 2.12 | 1.37 |
Weighted average exercise price, origin house replacement awards | $ / shares | 4.24 | |
Weighted average exercise price, forfeited | $ / shares | 2.77 | 2.88 |
Weighted average exercise price, ending balance | $ / shares | 3.96 | $ 3.19 |
Weighted average exercise price, exercisable | $ / shares | $ 3.25 |
Share Based Compensation - Summ
Share Based Compensation - Summary of Stock Options Outstanding (Detail) | Dec. 31, 2020shares$ / shares | Dec. 31, 2019shares$ / shares | Dec. 31, 2018shares$ / shares |
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 22,486,713 | 22,370,168 | 19,500,000 |
Exercise price | $ / shares | $ 3.96 | $ 3.19 | $ 2.11 |
Stock options exercisable | 9,550,535 | ||
October 2022 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 17,578 | ||
Exercise price | $ / shares | $ 3.13 | ||
Stock options exercisable | 17,578 | ||
April 2025 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 1,758 | ||
Exercise price | $ / shares | $ 4.49 | ||
Stock options exercisable | 879 | ||
May 2025 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 3,516 | ||
Exercise price | $ / shares | $ 6.01 | ||
Stock options exercisable | 2,636 | ||
June 2025 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 205,273 | ||
Stock options exercisable | 203,954 | ||
June 2025 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 0.50 | ||
June 2025 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 5.80 | ||
July 2025 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 3,515 | ||
Exercise price | $ / shares | $ 5.43 | ||
Stock options exercisable | 2,637 | ||
September 2025 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 250,000 | ||
Exercise price | $ / shares | $ 1 | ||
January - February 2026 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 75,000 | ||
Exercise price | $ / shares | $ 1 | ||
Stock options exercisable | 75,000 | ||
May - June 2026 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 600,000 | ||
Exercise price | $ / shares | $ 1 | ||
Stock options exercisable | 600,000 | ||
November - December 2026 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 17,500 | ||
Exercise price | $ / shares | $ 1 | ||
Stock options exercisable | 17,500 | ||
January 2027 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 5,000 | ||
Exercise price | $ / shares | $ 1 | ||
Stock options exercisable | 3,750 | ||
October 2027 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 200,000 | ||
Exercise price | $ / shares | $ 1 | ||
Stock options exercisable | 200,000 | ||
November 2027 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 250,000 | ||
Stock options exercisable | 162,500 | ||
November 2027 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 1 | ||
November 2027 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 1.14 | ||
December 2027 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 328,120 | ||
Stock options exercisable | 265,620 | ||
December 2027 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 1.14 | ||
December 2027 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 4.17 | ||
March 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 254,028 | ||
Exercise price | $ / shares | $ 1.14 | ||
Stock options exercisable | 121,250 | ||
May - June 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 610,000 | ||
Exercise price | $ / shares | $ 2.25 | ||
Stock options exercisable | 235,000 | ||
July 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 235,000 | ||
Stock options exercisable | 125,139 | ||
July 2028 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 2.25 | ||
July 2028 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 3.75 | ||
August 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 403,120 | ||
Stock options exercisable | 240,620 | ||
August 2028 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 3.75 | ||
August 2028 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 6.31 | ||
September 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 7,014,374 | ||
Stock options exercisable | 3,818,541 | ||
September 2028 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 1.13 | ||
September 2028 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 3.75 | ||
October - November 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 1,788,750 | ||
Exercise price | $ / shares | $ 3.75 | ||
Stock options exercisable | 868,750 | ||
December 2028 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 220,000 | ||
Exercise price | $ / shares | $ 6.50 | ||
Stock options exercisable | 110,000 | ||
January 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 149,876 | ||
Exercise price | $ / shares | $ 6.67 | ||
Stock options exercisable | 149,876 | ||
February 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 85,000 | ||
Exercise price | $ / shares | $ 6.50 | ||
Stock options exercisable | 21,250 | ||
March 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 272,000 | ||
Exercise price | $ / shares | $ 11.25 | ||
Stock options exercisable | 68,000 | ||
June 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 1,171,250 | ||
Exercise price | $ / shares | $ 10.28 | ||
Stock options exercisable | 297,500 | ||
September 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 1,186,250 | ||
Exercise price | $ / shares | $ 5.90 | ||
Stock options exercisable | 293,750 | ||
December 2029 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 582,000 | ||
Exercise price | $ / shares | $ 6.86 | ||
Stock options exercisable | 145,500 | ||
March 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 597,000 | ||
Exercise price | $ / shares | $ 2.99 | ||
Stock options exercisable | 0 | ||
May 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 3,812,023 | ||
Exercise price | $ / shares | $ 4.56 | ||
Stock options exercisable | 1,312,023 | ||
June 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 885,000 | ||
Exercise price | $ / shares | $ 4.11 | ||
Stock options exercisable | 0 | ||
July 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 19,544 | ||
Exercise price | $ / shares | $ 5.39 | ||
Stock options exercisable | 19,544 | ||
September 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 555,000 | ||
Exercise price | $ / shares | $ 6 | ||
Stock options exercisable | 0 | ||
December 2030 | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Stock options outstanding | 689,238 | ||
Stock options exercisable | 171,738 | ||
December 2030 | Minimum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 9.86 | ||
December 2030 | Maximum [member] | |||
Disclosure Of Number And Weighted Average Exercise Prices Of Share Options [Line Items] | |||
Exercise price | $ / shares | $ 10.19 |
Share Based Compensation - Su_2
Share Based Compensation - Summary Of Fair Value Of Stock Options Granted Under the Plan (Detail) | 12 Months Ended | |
Dec. 31, 2020yr$ / shares | Dec. 31, 2019yr$ / shares | |
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items] | ||
Risk-free annual interest rate | 0.13% | |
Expected life of stock options | yr | 4 | |
Bottom of range [member] | ||
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items] | ||
Risk-free annual interest rate | 0.54% | 1.97% |
Expected stock price volatility | 65.00% | 77.00% |
Expected life of stock options | yr | 5 | 5.5 |
Forfeiture rate | 5.00% | 0.00% |
Fair value at grant date | $ 1.84 | $ 3.88 |
Stock price at grant date | 2.99 | 5.90 |
Exercise price range | $ 2.99 | $ 5.90 |
Top of range [member] | ||
Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Period [Line Items] | ||
Risk-free annual interest rate | 1.79% | 2.49% |
Expected stock price volatility | 81.00% | 88.00% |
Expected life of stock options | yr | 7 | 7 |
Forfeiture rate | 15.00% | 3.00% |
Fair value at grant date | $ 6.48 | $ 8.26 |
Stock price at grant date | 10.19 | 11.25 |
Exercise price range | $ 10.19 | $ 11.25 |
Share Based Compensation - Addi
Share Based Compensation - Additional information (Detail) | Dec. 31, 2020USD ($)shares | Dec. 31, 2020USD ($)sharesyr$ / shares | Dec. 31, 2019USD ($)sharesyr$ / shares | Dec. 31, 2018shares |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average stock price of options Excercised | $ / shares | $ 2.12 | $ 1.37 | ||
Weighted-average fair value of stock options granted | $ / shares | 3.05 | 5.52 | ||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 5.04 | $ 7.48 | ||
Weighted average remaining contractual life of outstanding share options | 8 years 1 month 6 days | |||
Number of share options granted in share-based payment arrangement | shares | 7,278,021 | 4,474,000 | ||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 5.04 | $ 7.48 | ||
Number of share options outstanding in share-based payment arrangement | shares | 22,486,713 | 22,486,713 | 22,370,168 | 19,500,000 |
Liabilities from share-based payment transactions | $ 22,000 | $ 22,000 | $ 300,000 | |
Post acquisition compensation expense | 51,000 | |||
Expense from share-based payment transactions with employees | 16,659,000 | 14,046,000 | ||
Unrecognized compensation expense of option awards | $ 16,800,000 | |||
Option life, share options granted | yr | 4 | |||
Unrecognized compensation for replacement options | $ 6,000 | |||
compensation expense capitalized to inventory | 900,000 | 39,000 | ||
Selling general and administrative expenses [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Expense from share-based payment transactions with employees | 15,300,000 | 13,800,000 | ||
Cost Of Sales [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Expense from share-based payment transactions with employees | 1,800,000 | 800,000 | ||
Deferred Share Awards [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Expense from share-based payment transactions with employees | $ 15,800,000 | $ 14,500,000 | ||
Restricted Stock Units [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Number of other equity instruments granted in share-based payment arrangement | shares | 661,190 | 404,215 | ||
Expense from share-based payment transactions with employees | $ 1,500,000 | $ 1,200,000 | ||
Unrecognized compensation expense of option awards | $ 3,200,000 | |||
Option life, share options granted | yr | 3 | |||
Share-based Payment Arrangement, Amount Capitalized | $ 900,000 | 900,000 | ||
Restricted Stock Units [Member] | Selling general and administrative expenses [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Expense from share-based payment transactions with employees | $ 1,000,000 | $ 300,000 | ||
Bottom of range [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 0 years | |||
Option life, share options granted | yr | 5 | 5.5 | ||
Top of range [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 0 years | |||
Option life, share options granted | yr | 7 | 7 | ||
Weighted average [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average stock price of options Excercised | $ / shares | $ 5.96 | $ 7.12 | ||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | 5.13 | |||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 5.13 | |||
Number of share options outstanding in share-based payment arrangement | shares | 300,000 | 300,000 | ||
Origin House acquisition [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Number of share options granted in share-based payment arrangement | shares | 600,000 | |||
Origin House acquisition [Member] | Deferred Share Awards [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 5.96 | |||
Number of share options granted in share-based payment arrangement | shares | 1,600,000 | |||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 5.96 | |||
Share Repurchases, shares into share capital Settlement | $ 100,000 | $ 1,500,000 | ||
Origin House acquisition [Member] | Restricted Stock Units [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Number of other equity instruments granted in share-based payment arrangement | shares | 3,400,000 | |||
Weighted average fair value at measurement date, other equity instruments granted | $ 5.96 | $ 5.96 | ||
Post acquisition compensation expense | $ 0 | |||
Origin House acquisition [Member] | Weighted average [member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 4.24 | |||
Weighted average exercise price of share options granted in share-based payment arrangement | $ / shares | $ 4.24 | |||
Canadian dollars [Member] | ||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||
Number of Shares Available for Grant | 1 |
Share Based Compensation - Su_3
Share Based Compensation - Summary of Outstanding RSUs (Detail) - Restricted Stock Units [Member] | 12 Months Ended | |
Dec. 31, 2020shares$ / shares | Dec. 31, 2019shares$ / shares | |
Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items] | ||
Number of RSUs outstanding, Beginning balance | shares | 404,215 | 0 |
Number of RSUs outstanding, Granted | shares | 661,190 | 404,215 |
Number of RSUs outstanding, Origin House replacement awards | shares | 3,430,456 | |
Number of RSUs outstanding, Vested and settled | shares | (3,435,527) | |
Number of RSUs outstanding, Forfeited | shares | (66,005) | |
Number of RSUs outstanding, Ending balance | shares | 994,329 | 404,215 |
Number of RSUs outstanding, Liability classified | shares | 2,210 | |
Weighted average fair value, Beginning balance | $ / shares | $ 8.58 | $ 0 |
Weighted average fair value, Granted | $ / shares | 6 | 8.58 |
Weighted average fair value, Origin House replacement awards | $ / shares | 5.96 | |
Weighted average fair value, Vested and settled | $ / shares | 5.23 | |
Weighted average fair value, Forfeited | $ / shares | 8.91 | |
Weighted average fair value, Ending balance | $ / shares | 6.54 | $ 8.58 |
Weighted average fair value, Liability classified | $ / shares | $ 9.86 |
Acquisitions - Summary of signi
Acquisitions - Summary of significant business combinations (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Jan. 08, 2020 | Dec. 31, 2019 | Oct. 08, 2019 | Oct. 01, 2019 |
Total consideration | |||||
Cash | $ 18,774 | ||||
Deferred cash consideration | 52,596 | ||||
Common shares issued | 48,881 | ||||
Derivative liability consideration | 5,437 | ||||
Contingent consideration | 20,346 | ||||
Loan settlement | 14,953 | ||||
Total consideration | 160,987 | ||||
Net identifiable assets (liabilities) acquired | |||||
Cash | 1,512 | ||||
Accounts receivable | 451 | ||||
Inventory | 5,503 | ||||
Biological assets | 1,436 | ||||
Other current assets | 576 | ||||
Property and equipment | 15,780 | ||||
Right-of-use assets | 6,836 | ||||
Other non-current assets | 82 | ||||
Customer relationships | 1,500 | ||||
Non-compete agreement | 300 | ||||
Licenses | 65,400 | ||||
Total identifiable assets acquired | 99,376 | ||||
Short-term liabilities | (1,311) | ||||
Lease liabilities | (6,980) | ||||
Long-term liability | (550) | ||||
Deferred tax liabilities | (16,108) | ||||
Net identifiable assets acquired | 74,427 | ||||
Purchase price allocation | |||||
Net identifiable assets acquired | 74,427 | ||||
Goodwill | 86,560 | ||||
Total consideration | 160,987 | ||||
Net cash outflows | |||||
Cash consideration paid | (18,854) | ||||
Cash acquired | 1,512 | ||||
Total | (17,342) | ||||
Origin House [Member] | |||||
Total consideration | |||||
Common shares issued | $ 396,575 | $ 396,600 | |||
Replacement awards | 31,671 | 31,700 | |||
Contingent consideration | 3,800 | ||||
Total consideration | 428,246 | 428,200 | |||
Net identifiable assets (liabilities) acquired | |||||
Cash | 32,984 | ||||
Accounts receivable | 7,565 | ||||
Inventory | 14,658 | ||||
Biological assets | 2,002 | ||||
Other current assets | 2,197 | ||||
Property and equipment | 18,625 | ||||
Right-of-use assets | 17,984 | ||||
Loans receivable, long-term | 331 | ||||
Investment in associate | 4,302 | ||||
Investments | 139 | ||||
Customer relationships | 63,600 | ||||
Trade names | 39,700 | ||||
Licenses | 5,900 | ||||
Market related intangibles | 2,374 | ||||
Internally developed software | 380 | ||||
Total identifiable assets acquired | 212,741 | ||||
Short-term liabilities | (24,349) | ||||
Lease liabilities | (18,002) | ||||
Deferred and contingent consideration | (3,807) | ||||
Notes payable | (22,045) | ||||
Deferred tax liabilities | (30,200) | ||||
Net identifiable assets acquired | 114,338 | ||||
Purchase price allocation | |||||
Net identifiable assets acquired | 114,338 | ||||
Goodwill | 313,908 | ||||
Total consideration | 428,246 | $ 428,200 | |||
Net cash outflows | |||||
Cash acquired | $ 32,984 | ||||
Valley Agriceuticals, LLC [Member] | |||||
Total consideration | |||||
Cash | 18,774 | $ 18,800 | |||
Deferred cash consideration | 25,990 | ||||
Common shares issued | 48,881 | 49,000 | |||
Derivative liability consideration | 5,437 | ||||
Contingent consideration | 20,346 | 20,300 | |||
Loan settlement | 10,146 | 10,100 | |||
Total consideration | 129,574 | 129,600 | |||
Net identifiable assets (liabilities) acquired | |||||
Cash | 1,199 | ||||
Accounts receivable | 145 | ||||
Inventory | 800 | ||||
Other current assets | 558 | ||||
Property and equipment | 7,256 | ||||
Right-of-use assets | 6,836 | ||||
Other non-current assets | 81 | ||||
Customer relationships | 1,200 | ||||
Licenses | 53,400 | ||||
Total identifiable assets acquired | 71,475 | ||||
Short-term liabilities | (690) | ||||
Lease liabilities | (6,980) | ||||
Deferred tax liabilities | (16,108) | ||||
Net identifiable assets acquired | 47,697 | ||||
Purchase price allocation | |||||
Net identifiable assets acquired | 47,697 | ||||
Goodwill | 81,877 | ||||
Total consideration | 129,574 | $ 129,600 | |||
Net cash outflows | |||||
Cash consideration paid | (18,774) | ||||
Cash acquired | 1,199 | ||||
Total | (17,575) | ||||
Hope Heal Health Inc [Member] | |||||
Total consideration | |||||
Deferred cash consideration | 26,606 | ||||
Loan settlement | 4,807 | $ 4,800 | |||
Total consideration | 31,413 | ||||
Net identifiable assets (liabilities) acquired | |||||
Cash | 313 | ||||
Accounts receivable | 306 | ||||
Inventory | 4,703 | ||||
Biological assets | 1,436 | ||||
Other current assets | 18 | ||||
Property and equipment | 8,524 | ||||
Other non-current assets | 1 | ||||
Customer relationships | 300 | ||||
Non-compete agreement | 300 | ||||
Licenses | 12,000 | ||||
Total identifiable assets acquired | 27,901 | ||||
Short-term liabilities | (621) | ||||
Long-term liability | (550) | ||||
Net identifiable assets acquired | 26,730 | ||||
Purchase price allocation | |||||
Net identifiable assets acquired | 26,730 | ||||
Goodwill | 4,683 | ||||
Total consideration | 31,413 | ||||
Net cash outflows | |||||
Cash consideration paid | (80) | ||||
Cash acquired | 313 | ||||
Total | $ 233 |
Acquisitions - Summary of defer
Acquisitions - Summary of deferred consideration and other payables balance (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of Detailed Information of Deferred Consideration Contingent Consideration and Other Payables [Line Items] | ||
Interest payable - short term | $ 1,464 | |
Liability-classified equity awards | $ 22 | 339 |
Total Deferred consideration, contingent consideration and other payables | 19,115 | 59,940 |
Med Mar Inc [Member] | ||
Disclosure of Detailed Information of Deferred Consideration Contingent Consideration and Other Payables [Line Items] | ||
MedMar contingent consideration liability for tax payments | 2,000 | |
Contingent consideration | 1,927 | |
Hope Heal Health Inc [Member] | ||
Disclosure of Detailed Information of Deferred Consideration Contingent Consideration and Other Payables [Line Items] | ||
Contingent consideration | $ 19,093 | |
HHH deferred consideration | 27,237 | |
Valley Ag deferred consideration | 18,750 | |
Valley Ag operating cash flows consideration | 7,423 | |
Valley Ag make-whole liability | $ 800 |
Acquisitions - Summary of long-
Acquisitions - Summary of long-term conatingent consideration (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of Detailed Information of Long Term Contingent Consideration [Abstract] | ||
Valley Ag contingent consideration | $ 21,901 | |
Valley Ag operating cash flows consideration | $ 7,247 | |
Total Long-term deferred and contingent consideration | $ 7,247 | $ 21,901 |
Acquisitions - Additional Infor
Acquisitions - Additional Information (Detail) $ in Thousands, shares in Millions | Oct. 05, 2020USD ($) | May 31, 2020shares | Mar. 31, 2019USD ($) | Dec. 31, 2020USD ($)shares | Dec. 31, 2019USD ($) | Jan. 08, 2020USD ($)shares | Oct. 08, 2019USD ($)shares | Oct. 01, 2019USD ($) |
Increase of goodwill recognised from business acquisition | ||||||||
Increase of identifiable intangible assets recognised from business acquisition | $ 9,200 | |||||||
Increase of deferred tax liabilities recognised from business acquisition | 2,800 | |||||||
Goodwill recognized | $ 86,560 | |||||||
Total consideration | 160,987 | |||||||
Value of equity issued | 48,881 | |||||||
Goodwill expected to deductible for tax purposes | 0 | |||||||
Increase of goodwill recognised from business acquisition | 13 | |||||||
Contingent consideration | 20,346 | |||||||
Cash | 18,774 | |||||||
Loan receivable settlement | 14,953 | |||||||
Interest expense | 39,493 | 7,875 | ||||||
Current Deferred Consideration Contingent Consideration and Other Payables | 19,115 | 59,940 | ||||||
Market risk [member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Mark to market loss of investments held | $ 200 | 2,800 | ||||||
Subordinate Voting Shares [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of shares issued during the period acquisitions | shares | 66.5 | |||||||
Wellbeings, LLC [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Goodwill recognized | $ 200 | |||||||
Net liabiilities recognized | 200 | |||||||
Loss on previous investment | 500 | |||||||
Gain on reversel of expected credit loss | $ 300 | |||||||
Origin House [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Goodwill recognized | $ 313,908 | |||||||
Total consideration | 428,246 | $ 428,200 | ||||||
Value of equity issued | 396,575 | 396,600 | ||||||
Value of Replacement Awards Of Acquirer | 31,671 | $ 31,700 | ||||||
Increase Decrease In Contingent Consideration Liability | 100 | |||||||
Pro forma Revenue | 476,900 | |||||||
Pro forma Net loss | 37,000 | |||||||
Contributed revenue | 88,700 | |||||||
Contributed Net loss | 30,700 | |||||||
Percnetage of Voting rights | 100.00% | |||||||
Contingent consideration | 3,800 | |||||||
Origin House [Member] | FloraCal [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Deferred cash consideration | 1,500 | |||||||
Number of shares issued during the period acquisitions | shares | 0.3 | |||||||
Value of shares issued during the period new issues | 1,000 | |||||||
Origin House [Member] | Selling general and administrative expenses [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Transaction costs | $ 5,500 | |||||||
Origin House [Member] | Replacement Awards [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 5.7 | |||||||
Origin House [Member] | Replacement RSU [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 3.4 | |||||||
Origin House [Member] | Deferred Share Awards [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 1.6 | |||||||
Origin House [Member] | Replacement Options [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 0.6 | |||||||
Post acquisition Compensation Expense | $ 51,000 | |||||||
Origin House [Member] | Subordinate Voting Shares [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 66.5 | |||||||
Number of shares issued during the period acquisitions | shares | 0.8 | |||||||
Value of shares issued during the period new issues | $ 2,200 | |||||||
Valley Agriceuticals, LLC [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Goodwill recognized | 81,877 | |||||||
Total consideration | 129,574 | $ 129,600 | ||||||
Value of equity issued | 48,881 | $ 49,000 | ||||||
Pro forma Revenue | 129,800 | |||||||
Pro forma Net loss | 68,900 | |||||||
Contributed revenue | 800 | |||||||
Contributed Net loss | 500 | |||||||
Percnetage of Voting rights | 100.00% | |||||||
Contingent consideration | 20,346 | $ 20,300 | ||||||
Cash | 18,774 | 18,800 | ||||||
Deferred cash consideration | 26,000 | |||||||
Loan receivable settlement | 10,146 | $ 10,100 | ||||||
Mark to market fair value gain | 2,800 | |||||||
Current Deferred Consideration Contingent Consideration and Other Payables | 19,100 | |||||||
Fair value of real estate property as collateral for certain deferred payment obligations | 10,000 | |||||||
Increase decrease in cash flow due to incremental borrowing rate | 200 | |||||||
Non Current Operating Cash Flows Consideration Fair ValueThrough Profit Or Loss | 7,200 | |||||||
Valley Agriceuticals, LLC [Member] | New York [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Ratio of vertically integrated cannabis business licenses Granted held | 0.10% | |||||||
Valley Agriceuticals, LLC [Member] | Selling general and administrative expenses [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Transaction costs | 2,000 | |||||||
Valley Agriceuticals, LLC [Member] | Subordinate Voting Shares [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Deferred cash consideration | 18,800 | |||||||
Present Value of cash Consideration | $ 300 | |||||||
Number of shares issued during the period acquisitions | shares | 0.5 | |||||||
Value of shares issued during the period new issues | $ 1,300 | |||||||
Adjustment For Make Whole Liability | 1,500 | |||||||
Make whole adjustment liability | 0 | |||||||
Valley Agriceuticals, LLC [Member] | Proportionate Voting Shares [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 8.7 | |||||||
Value of equity issued | $ 5,400 | |||||||
Valley Agriceuticals, LLC [Member] | Proportionate Voting Shares [Member] | Share purchase warrants [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of instruments or interests issued | shares | 2 | |||||||
Maximum payment of contingent consideration | shares | 4.8 | |||||||
Hope Heal Health Inc [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Goodwill recognized | 4,683 | |||||||
Total consideration | 31,413 | |||||||
Pro forma Revenue | 129,600 | |||||||
Pro forma Net loss | 68,300 | |||||||
Contributed revenue | 2,000 | |||||||
Contributed Net loss | 3,000 | |||||||
Transaction costs | 600 | |||||||
Deferred cash consideration | 27,500 | $ 31,400 | ||||||
Loan receivable settlement | $ 4,807 | 4,800 | ||||||
Present Value of cash Consideration | $ 26,600 | |||||||
Interest expense | 300 | |||||||
MedMar Inc.[Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Deferred cash consideration | 1,500 | |||||||
MedMar contingent consideration liability for tax payments | 2,000 | |||||||
MedMar Inc.[Member] | Market risk [member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Mark to market loss of investments held | $ 73 | |||||||
MedMar Inc.[Member] | Subordinate Voting Shares [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Number of shares issued during the period acquisitions | shares | 0.1 | |||||||
Value of shares issued during the period new issues | $ 500 | |||||||
MedMar Inc.[Member] | Subordinate Voting Shares [Member] | Counterpartys Expected Tax Liability [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Deferred cash consideration | $ 900 | |||||||
Number of shares issued during the period acquisitions | shares | 0.1 | |||||||
Value of shares issued during the period new issues | $ 1,100 | |||||||
CubCity [Member] | ||||||||
Increase of goodwill recognised from business acquisition | ||||||||
Contingent consideration | $ 3,700 |
Long-term Notes and Loans Pay_3
Long-term Notes and Loans Payable - Summary of Loans Payable Balances as Follows (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of detailed information about borrowings [abstract] | ||
Term Loan | $ 180,863 | |
Interest payable | 3,658 | |
HHH Loan | $ 550 | |
Total borrowings and interest payable | 184,521 | 550 |
Less Short-term borrowings and interest payable | (15,046) | |
Total Long-term notes and loans payable | $ 169,475 | $ 550 |
Long-term Notes and Loans Pay_4
Long-term Notes and Loans Payable - Additional Information (Detail) - USD ($) $ in Thousands | Dec. 11, 2020 | Sep. 29, 2020 | Jun. 30, 2020 | Feb. 02, 2020 | Jan. 08, 2020 | Oct. 01, 2019 | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowing costs incurred | $ 200,000 | |||||||
Loans received | $ 180,863 | |||||||
Borrowings interest rate | 10.00% | |||||||
Gain (loss) on extinguishment of debt | $ 5,409 | |||||||
Deferred financing fees | 7,605 | $ 3,196 | ||||||
Interest expense, net | 39,493 | $ 7,875 | ||||||
Amortization of debt issuance costs | 3,600 | |||||||
Term Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Interest expense, net | $ 16,000 | |||||||
Tranche A lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings maturity | July 2021 | |||||||
Borrowings interest rate | 12.70% | |||||||
Interest rate effective percentage | 17.00% | |||||||
Borrowing costs capitalised | $ 5,500 | |||||||
Tranche B lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings maturity | January 2022 | |||||||
Borrowings interest rate | 13.20% | |||||||
Interest rate effective percentage | 16.10% | |||||||
Borrowing costs capitalised | $ 400 | |||||||
Non Extending lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | 11,700 | |||||||
Borrowings maturity | July 2021 | |||||||
Borrowings interest rate | 12.70% | |||||||
Interest rate effective percentage | 18.10% | |||||||
Borrowing costs capitalised | $ 100 | |||||||
Extending lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | 97,300 | |||||||
Borrowings maturity | January 2023 | |||||||
Borrowings interest rate | 12.00% | |||||||
Interest rate effective percentage | 17.60% | |||||||
Borrowing costs capitalised | $ 11,800 | |||||||
Increasing lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | 91,000 | |||||||
OCN Term Loan Lender [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Gain (loss) on extinguishment of debt | 4,300 | |||||||
Repayments of current borrowings | 5,400 | |||||||
Term Loan lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Repayments of current borrowings | 1,000 | |||||||
Extending and Increasing lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Repayments of current borrowings | 8,600 | |||||||
Deferred financing fees | 11,900 | |||||||
OCN Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Gain (loss) on extinguishment of debt | $ 40 | $ 1,100 | ||||||
Interest expense, net | 4,500 | |||||||
Amortization of debt issuance costs | $ 2,500 | |||||||
Borrowings terms extension fees | $ 100 | $ 600 | ||||||
OCN Loan [Member] | Origin House [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | $ 22,000 | |||||||
Borrowings maturity | June 2020 | |||||||
Borrowings interest rate | 10.00% | |||||||
Interest rate effective percentage | 23.80% | |||||||
Other Loan [Member] | HHH [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | $ 600 | |||||||
Borrowings maturity | June 2021 | |||||||
Repayments of current borrowings | $ 600 | |||||||
Loan commitments [member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | $ 200,000 | |||||||
Loans received | $ 100,000 | |||||||
Loan commitments [member] | Tranche A lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Loans received | 92,400 | |||||||
Loan commitments [member] | Tranche B lenders [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Loans received | 7,600 | |||||||
Bottom of range [member] | Term Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings | 100,000 | |||||||
Bottom of range [member] | OCN Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings maturity | 18.8 | June 30, 2020 | ||||||
Top of range [member] | Term Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowing costs incurred | $ 200,000 | |||||||
Top of range [member] | OCN Loan [Member] | ||||||||
Disclosure of detailed information about borrowings [line items] | ||||||||
Borrowings maturity | June 30, 2021 | |||||||
Borrowings interest rate | 27.10% |
Revenue and Loyalty Programs -
Revenue and Loyalty Programs - Summary of Disaggregated Revenue by Source (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total Revenue | $ 476,251 | $ 128,534 |
Wholesale | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total Revenue | 274,000 | 79,927 |
Dispensary | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total Revenue | $ 202,251 | $ 48,607 |
Revenue and Loyalty Programs _2
Revenue and Loyalty Programs - Additional Information (Detail) $ in Thousands | Mar. 12, 2019USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenue | $ 476,251 | $ 128,534 | |
Loyalty points outstanding | 52,500,000 | ||
Loyalty points outstanding value | $ 800 | ||
Loyalty point expected redemption period | 1 year | ||
Bottom of range [member] | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenue reduction per loyalty point | 0.025 | ||
Top of range [member] | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenue reduction per loyalty point | 0.10 | ||
Increase (decrease) due to application of IFRS 15 [member] | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Revenue | $ 2,100 |
Selling, General and Administ_3
Selling, General and Administrative Expenses - Summary of Selling General and Administrative Expense (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Text Block [Abstract] | ||
Salaries and related | $ 81,067 | $ 28,519 |
Consulting and professional fees | 24,576 | 18,091 |
Advertising and marketing | 19,030 | 12,630 |
Office | 17,696 | 4,884 |
Share based compensation | 16,659 | 14,046 |
Provision expense | 13,600 | |
Excise taxes | 13,167 | 4,341 |
Technology | 7,604 | 1,989 |
Insurance | 4,358 | 1,911 |
Travel and entertainment | 3,074 | 4,154 |
Rent expense | 1,478 | 286 |
Business expansion costs | 1,586 | 1,524 |
Other | 2,843 | 1,743 |
Total Selling, general and administrative expense | $ 206,738 | $ 94,118 |
Other (Expense) Income, net - S
Other (Expense) Income, net - Summary of Other (expense) income (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of Other expense income [Abstract] | ||
(Loss) gain on derivative instruments | $ (13,319) | $ (3,236) |
Gain on conversion of loan to investment | 703 | |
Gain (loss) on changes in fair value of deferred and contingent consideration | 2,126 | (3,186) |
Gain on debt modification | 5,409 | |
Gain on changes in fair value of loans receivable | 921 | 1,515 |
Impairment on loan receivable | (902) | (3,037) |
Loss on sale leaseback transactions | (670) | |
Sale and leaseback settlement costs | (479) | |
Dividend income | 97 | |
Unrealized loss on investments held at fair value | (160) | (2,827) |
(Loss) gain on foreign currency | (2,394) | 421 |
Other (loss) income on investments | (1,000) | |
Gain on dissolution of previously held equity investment | 1,309 | |
Other income | 1,789 | 264 |
Total Other (expense) income, net | $ (8,009) | $ (8,647) |
Related Party Transactions - Su
Related Party Transactions - Summary Of Key Management Personnel Compensation (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of transactions between related parties [line items] | ||
Management compensation | $ 6,234 | $ 3,139 |
Share-based compensation expense | 10,992 | 5,972 |
Total | $ 17,226 | $ 9,111 |
Related Party Transactions - _2
Related Party Transactions - Summary of Expense Resulting From The Related Party Transactions (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of transactions between related parties [line items] | ||
Interest expense | $ 20,375 | $ 7,078 |
Key management personnel of entity or parent [member] | ||
Disclosure of transactions between related parties [line items] | ||
Depreciation expense | 551 | 0 |
Interest expense | 564 | 0 |
SLO Cultivation Inc [Member] | Subsidiaries [member] | ||
Disclosure of transactions between related parties [line items] | ||
Depreciation expense | 295 | 382 |
Interest expense | 1,494 | 1,650 |
MedMar Inc [Member] | Subsidiaries [member] | ||
Disclosure of transactions between related parties [line items] | ||
Depreciation expense | 209 | 155 |
Interest expense | $ 281 | $ 177 |
Related Party Transactions - _3
Related Party Transactions - Summary of ROU Assets And Lease Liabilities Attributable To Related Party Transactions (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Disclosure of transactions between related parties [line items] | |||
Right-of-use assets | $ 92,169 | $ 46,696 | |
Lease liabilities | 170,062 | $ 37,707 | |
Key management personnel of entity or parent [member] | |||
Disclosure of transactions between related parties [line items] | |||
Right-of-use assets | 8,371 | 0 | |
Lease liabilities | 6,925 | 0 | |
SLO Cultivation Inc [Member] | Subsidiaries [member] | |||
Disclosure of transactions between related parties [line items] | |||
Right-of-use assets | 5,219 | 9,930 | |
Lease liabilities | 8,551 | 11,727 | |
Med Mar Inc [Member] | Subsidiaries [member] | |||
Disclosure of transactions between related parties [line items] | |||
Right-of-use assets | 2,322 | 1,292 | |
Lease liabilities | $ 2,552 | $ 1,380 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) | 12 Months Ended | |
Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Disclosure of transactions between related parties [line items] | ||
Non-controlling interests | $ 150,312,000 | $ 135,541,000 |
Interest expense | 39,493,000 | 7,875,000 |
Borrowings with Related Parties [Member] | ||
Disclosure of transactions between related parties [line items] | ||
Borrowings | 18,300,000 | |
Interest expense | 1,800,000 | 0 |
Interest payable | 100,000 | 0 |
Key management personnel of entity or parent [member] | ||
Disclosure of transactions between related parties [line items] | ||
Receivables due from related parties | 200,000 | 700,000 |
Amounts payable related party transactions | $ 2,300,000 | $ 100,000 |
Number of redeemable units held by related party | 109,400,000 | |
Non-controlling interests | $ 125,600,000 | |
Percentage of tax distribution payments to related party | 83.30% | 71.90% |
Proceeds from net funding of sale and leaseback transactions | $ 8,600,000 | |
Reimbursements of tenant improvement allowance | 800,000 | |
Expected reimbursements of tenant improvement allowance | $ 2,200,000 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Commitments And Contingencies [Line Items] | ||
Loss Contingency, Damages Awarded, Value | $ 1.3 | |
Contingent Liabilities | 13.6 | |
Contractual commitments for construction project | 31.6 | |
Entering into significant commitments or contingent liabilities [member] | ||
Commitments And Contingencies [Line Items] | ||
Payments For Legal Settlements | $ 1.3 | |
Origin House [Member] | ||
Commitments And Contingencies [Line Items] | ||
Contingent consideration liability | $ 0.1 |
Financial Instruments And Fin_2
Financial Instruments And Financial Risk Management - Additional Information (Detail) shares in Thousands, $ in Thousands, $ in Millions | Dec. 11, 2020USD ($) | Aug. 12, 2019 | Apr. 30, 2020USD ($) | Dec. 31, 2020USD ($)shares | Dec. 31, 2020CAD ($)shares | Dec. 31, 2019USD ($) |
Disclosure of detailed information about financial instruments [line items] | ||||||
Loans and receivables | $ 2,438 | $ 644 | ||||
Borrowings, interest rate | 10.00% | |||||
Non-current interest receivable | $ 837 | 0 | ||||
Non-current loans and receivables | 21,224 | 18,633 | ||||
Derivative financial liabilities | $ 200 | |||||
Significant unobservable input, assets | 9 | |||||
Purchase of interests in associates | $ 200 | |||||
Increase Decrease in share price | $ 25 | |||||
Increase through other contributions by owners, equity | $ 100 | |||||
Unrealized foreign exchange loss | (2,394) | 421 | ||||
Expenses for bad and doubtful debt | 400 | 300 | ||||
Bad debts write-offs | 400 | 200 | ||||
Borrowing costs incurred | $ 200,000 | |||||
Foreign exchange loss | (2,394) | 421 | ||||
Foreign exchange gain | (2,394) | 421 | ||||
Interest expense | 200 | |||||
Liquidity risk [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Increase through other contributions by owners, equity | $ 55 | |||||
Working Capital | 167,100 | |||||
Borrowing costs incurred | 200,000 | |||||
Tenant Improvements | 47,700 | |||||
Currency risk [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Unrealized foreign exchange loss | 2,400 | 400 | ||||
Foreign exchange loss | 2,400 | 400 | ||||
Foreign exchange gain | $ 2,400 | $ 400 | ||||
Average rate of hedging instrument | 0.00% | 0.00% | ||||
Equity price risk [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Percentage of Equity stock price | 10.00% | |||||
Increase in fair value of Equity market price | $ 6,700 | |||||
Decrease in fair value of Equity market price | 6,500 | |||||
Share purchase warrants [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Increase Decrease in share price | 13,300 | $ 200 | ||||
Unrealized foreign exchange loss | 1,800 | 12 | ||||
Foreign exchange loss | 1,800 | 12 | ||||
Foreign exchange gain | $ 1,800 | 12 | ||||
Randsburg Warrants [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Stock Issued During Period, shares, Stock Options Exercised | shares | 18 | 18 | ||||
Stock Issued During Period, Value, Stock Options Exercised | $ 100 | |||||
Unrealized Gain (Loss) on Derivatives | 47 | |||||
Increase through other contributions by owners, equity | 400 | |||||
Warrants Outstanding | 0 | |||||
Wellbeings [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Non-current loans and receivables | 500 | |||||
Expected Credit Loss on Loan receivable | $ 300 | |||||
Bottom of range [member] | Interest rate risk [member] | Floating interest rate [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Borrowings, interest rate | 17.60% | |||||
Bottom of range [member] | Interest rate risk [member] | Fixed interest rate [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Borrowings, interest rate | 12.00% | |||||
Top of range [member] | Interest rate risk [member] | Floating interest rate [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Borrowings, interest rate | 18.10% | |||||
Top of range [member] | Interest rate risk [member] | Fixed interest rate [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Borrowings, interest rate | 12.70% | |||||
Lighthouse [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Proportion of ownership interest in subsidiary | 1.00% | |||||
Borrowings, maturity | 18 months | |||||
Loans and receivables | $ 1,500 | 2,200 | ||||
Impairment losses | $ 700 | 0 | ||||
Verdant Creations LLC [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Borrowings, interest rate | 5.25% | |||||
Percentage of risk-free rate | 0.10% | |||||
Fair value gain loss on Financial asset | $ 900 | 2,000 | ||||
Non-current financial assets at fair value through profit or loss | 20,000 | 16,000 | ||||
Non-current interest receivable | 800 | 0 | ||||
Current interest receivable | 500 | 0 | ||||
Gross loan commitments | 16,900 | |||||
Loan Amount Withdrawn | $ 17,100 | |||||
Verdant Creations LLC [Member] | Bottom of range [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Percentage of market rates | 1.70% | |||||
Verdant Creations LLC [Member] | Top of range [member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Percentage of market rates | 17.40% | |||||
Origin House [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Impairment losses | $ 200 | 0 | ||||
Current financial assets at fair value through profit or loss | $ 400 | $ 300 | ||||
Valley Ag [Member] | Share purchase warrants [Member] | ||||||
Disclosure of detailed information about financial instruments [line items] | ||||||
Number of shares outstanding | shares | 6,200 | |||||
Stock Issued During Period, shares, Stock Options Exercised | shares | 43 | 43 | ||||
Stock Issued During Period, Value, Stock Options Exercised | $ 200 |
Financial Instruments And Fin_3
Financial Instruments And Financial Risk Management - Summary of Company's financial instruments (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | |||
Accounts Payable And Other Accrued Expenses [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | $ 86,326 | $ 62,834 | |||
Financial liabilities, at fair value | 86,326 | 62,834 | |||
Short-term borrowings [member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | 15,046 | ||||
Financial liabilities, at fair value | 15,046 | ||||
Current Portion Of Lease Liabilities [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | 24,742 | 12,019 | |||
Financial liabilities, at fair value | 24,742 | 12,019 | |||
Deferred Consideration Contingent Consideration And Other Payables [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | 0 | 49,451 | |||
Financial liabilities, at fair value | 19,115 | 59,940 | |||
Derivative Liabilities Short Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 178 | ||||
Derivative Liabilities Long Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 30,129 | 15,243 | |||
Lease liabilities [member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | 145,320 | 82,856 | |||
Financial liabilities, at fair value | 145,320 | 82,856 | |||
Deferred Consideration And Contingent Consideration [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 7,247 | 21,901 | |||
LongTerm Notes Payable And Loans Payable [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities at amortised cost | 169,475 | 550 | |||
Financial liabilities, at fair value | 169,475 | 550 | |||
Cash And Cash Equivalents [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 136,339 | 49,102 | |||
Financial assets, at fair value | 136,339 | 49,102 | |||
Restricted Cash [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 4,435 | [1] | 5,050 | [2] | |
Financial assets, at fair value | 4,435 | [1] | 5,050 | [2] | |
Accounts Receivable Net [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 29,266 | 16,455 | |||
Financial assets, at fair value | 29,266 | 16,455 | |||
Loans Receivable ShortTerm [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 921 | 644 | |||
Financial assets, at fair value | 2,438 | 644 | |||
Loans Receivable Long Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 1,204 | 390 | |||
Financial assets, at fair value | 21,224 | 18,633 | |||
Investments [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | [3] | 3,192 | |||
Financial assets, at fair value | 4,360 | [3] | 1,278 | ||
Security Deposits [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets at amortised cost | 3,558 | 1,084 | |||
Financial assets, at fair value | 3,558 | 1,084 | |||
Level 1 | Deferred Consideration Contingent Consideration And Other Payables [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 22 | 339 | |||
Level 2 | Derivative Liabilities Short Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 178 | ||||
Level 2 | Derivative Liabilities Long Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 30,129 | 15,243 | |||
Level 2 | Loans Receivable ShortTerm [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | 2,237 | ||||
Level 2 | Loans Receivable Long Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | 18,243 | ||||
Level 2 | Investments [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | 1,049 | 1,210 | |||
Level 3 | Deferred Consideration Contingent Consideration And Other Payables [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 19,093 | 10,150 | |||
Level 3 | Deferred Consideration And Contingent Consideration [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial liabilities, at fair value | 7,247 | 21,901 | |||
Level 3 | Loans Receivable ShortTerm [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | (720) | ||||
Level 3 | Loans Receivable Long Term [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | 20,020 | ||||
Level 3 | Investments [Member] | |||||
Disclosure of detailed information about financial instruments [line items] | |||||
Financial assets, at fair value | $ 119 | [3] | $ 68 | ||
[1] | Restricted cash balances include various escrow accounts related to investments, acquisitions, facility requirements and building improvements. | ||||
[2] | Restricted cash balances include various escrow accounts related to investments, acquisitions and facility licensing requirements. | ||||
[3] | Investment balances in the amortized cost column represent equity method investments. |
Financial Instruments And Fin_4
Financial Instruments And Financial Risk Management - Summary of Short term Loan Receivable (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure Of Short Term Loan Receivable [Line Items] | ||
Interest receivable | $ 921 | $ 644 |
Total Loans receivable, short-term | 2,438 | $ 644 |
Lighthouse [Member] | ||
Disclosure Of Short Term Loan Receivable [Line Items] | ||
Short-term loans receivable - Lighthouse | $ 1,517 |
Financial Instruments And Fin_5
Financial Instruments And Financial Risk Management - Summary of Long Term Loan Receivable (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure Of Long Term Loan Receivable [Line Items] | ||
Interest receivable | $ 837 | $ 0 |
Total Loans receivable, long-term | 21,224 | 18,633 |
Verdant Creations LLC [Member] | ||
Disclosure Of Long Term Loan Receivable [Line Items] | ||
Long-term loans receivable | 20,020 | 16,007 |
Lighthouse [Member] | ||
Disclosure Of Long Term Loan Receivable [Line Items] | ||
Long-term loans receivable | 0 | 2,236 |
Other Loan [Member] | ||
Disclosure Of Long Term Loan Receivable [Line Items] | ||
Long-term loans receivable - Other | $ 367 | $ 390 |
Financial Instruments And Fin_6
Financial Instruments And Financial Risk Management - Disclosure of Fair Value of Liability Warrants Using Black-Scholes Option-Pricing Model (Detail) | 12 Months Ended | |
Dec. 31, 2020yr$ / shares | Dec. 31, 2019yr$ / shares | |
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Risk-free annual interest rate | 0.13% | |
Expected life of stock warrants | 4 | |
Bottom of range [member] | ||
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Risk-free annual interest rate | 0.54% | 1.97% |
Expected annual dividend yield | 5.00% | 0.00% |
Expected stock price volatility | 65.00% | 77.00% |
Expected life of stock warrants | 5 | 5.5 |
Share price at period end | $ / shares | $ 2.99 | $ 5.90 |
Top of range [member] | ||
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Risk-free annual interest rate | 1.79% | 2.49% |
Expected annual dividend yield | 15.00% | 3.00% |
Expected stock price volatility | 81.00% | 88.00% |
Expected life of stock warrants | 7 | 7 |
Share price at period end | $ / shares | $ 10.19 | $ 11.25 |
Share purchase warrants [Member] | ||
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Expected annual dividend yield | 0.00% | 0.00% |
Expected stock price volatility | 83.00% | 81.00% |
Forfeiture rate | 0.00% | 0.00% |
Share price at period end | $ / shares | $ 9.86 | $ 6.86 |
Share purchase warrants [Member] | Bottom of range [member] | ||
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Risk-free annual interest rate | 1.58% | |
Expected life of stock warrants | 1.75 | 0.4 |
Share purchase warrants [Member] | Top of range [member] | ||
Disclosure Of Fair Value Of liability Using BlackScholes Option Pricing Model [Line Items] | ||
Risk-free annual interest rate | 1.61% | |
Expected life of stock warrants | 1.83 | 1.4 |
Financial Instruments And Fin_7
Financial Instruments And Financial Risk Management - Summary of Accounts Receivables (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure Of Ageing Trade Receivable [Line Items] | ||
Total accounts receivable, gross | $ 29,962 | $ 16,726 |
0 to 60 days | ||
Disclosure Of Ageing Trade Receivable [Line Items] | ||
Total accounts receivable, gross | 27,604 | 10,276 |
61 to 120 days | ||
Disclosure Of Ageing Trade Receivable [Line Items] | ||
Total accounts receivable, gross | 1,134 | 5,551 |
120 days + | ||
Disclosure Of Ageing Trade Receivable [Line Items] | ||
Total accounts receivable, gross | $ 1,224 | $ 899 |
Financial Instruments And Fin_8
Financial Instruments And Financial Risk Management - Summary of Contractual Obligations (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | $ 297,209 | $ 145,225 |
Less than one year [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 120,487 | 122,774 |
Later than one year and not later than three years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 176,722 | 22,451 |
Later than three years and not later than five years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Accounts Payable And Other Accrued Expenses [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 86,326 | 62,834 |
Accounts Payable And Other Accrued Expenses [Member] | Less than one year [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 86,326 | 62,834 |
Accounts Payable And Other Accrued Expenses [Member] | Later than one year and not later than three years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Accounts Payable And Other Accrued Expenses [Member] | Later than three years and not later than five years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Deferred Consideration Contingent Consideration And Other Payables [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 19,115 | 59,940 |
Deferred Consideration Contingent Consideration And Other Payables [Member] | Less than one year [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 19,115 | 59,940 |
Deferred Consideration Contingent Consideration And Other Payables [Member] | Later than one year and not later than three years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Deferred Consideration Contingent Consideration And Other Payables [Member] | Later than three years and not later than five years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Deferred Consideration And Contingent Consideration [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 7,247 | 21,901 |
Deferred Consideration And Contingent Consideration [Member] | Less than one year [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Deferred Consideration And Contingent Consideration [Member] | Later than one year and not later than three years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 7,247 | 21,901 |
Deferred Consideration And Contingent Consideration [Member] | Later than three years and not later than five years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 0 | 0 |
Long Term Notes Payable And Loans Payable and Short Term Borrowings [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 184,521 | 550 |
Long Term Notes Payable And Loans Payable and Short Term Borrowings [Member] | Less than one year [Member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 15,046 | 0 |
Long Term Notes Payable And Loans Payable and Short Term Borrowings [Member] | Later than one year and not later than three years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | 169,475 | 550 |
Long Term Notes Payable And Loans Payable and Short Term Borrowings [Member] | Later than three years and not later than five years [member] | ||
Disclosure of detailed information about financial instruments [line items] | ||
Contractual Obligations | $ 0 | $ 0 |
Segment Information - Additiona
Segment Information - Additional Information (Detail) | 12 Months Ended |
Dec. 31, 2020 | |
USA [member] | |
Disclosure of operating segments [line items] | |
Percentage of entity's revenue | 98.00% |
Earnings (Loss) Per Share - Add
Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings per share [abstract] | ||
Dilutive effect of convertible instruments on number of ordinary shares | 146.2 | 152.1 |
Earnings (Loss) Per Share - Sum
Earnings (Loss) Per Share - Summary of Reconciliation for Basic and Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Earnings per share [abstract] | ||
Net loss attributable to Cresco Labs Inc. shareholders | $ (81,925) | $ (43,201) |
Weighted-average number of shares outstanding | 210,466 | 118,318 |
Loss per share – basic and diluted | $ (0.39) | $ (0.37) |
Interest (Expense) Income, Ne_2
Interest (Expense) Income, Net - Summary of Interest Expense, Net (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Disclosure of Interest Expenses [Abstract] | ||
Interest expense – leases | $ (20,375) | $ (7,078) |
Interest expense – notes and loans payable | (14,353) | |
Accretion of debt discount and amortization of deferred financing fees | (6,139) | |
Other interest expense | (40) | (2,380) |
Interest income | 1,414 | 1,583 |
Total Interest expense, net | $ (39,493) | $ (7,875) |
Provision For Income Taxes An_3
Provision For Income Taxes And Deferred Income Taxes - Summary of Provision for Income Taxes (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Statements [Line Items] | ||
Total current | $ 48,167 | $ 13,285 |
Total deferred | (4,447) | 1,176 |
Total | 43,720 | 14,461 |
Federal Tax Expense [Member] | ||
Statements [Line Items] | ||
Total current | 35,784 | 10,455 |
Total deferred | (2,566) | 1,124 |
State Tax Expense [Member] | ||
Statements [Line Items] | ||
Total current | 12,383 | 2,830 |
Total deferred | $ (1,881) | $ 52 |
Provision For Income Taxes An_4
Provision For Income Taxes And Deferred Income Taxes - Summary of Components of Deferred Tax Assests And Liabilities (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | $ 35,483 | $ 16,277 | |
Deferred tax liabilities | (81,182) | (37,728) | |
Net deferred tax liabilities | (45,699) | (21,451) | $ (4,459) |
Share-based compensation | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | 2,080 | 1,177 | |
Net operating losses | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | 12,440 | 1,285 | |
Lease liabilities | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | 20,146 | 13,202 | |
Inventory | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | 188 | ||
Other | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax assets | 817 | 425 | |
Biological assets | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | (7,396) | (4,213) | |
ROU assets | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | (8,699) | (6,488) | |
Inventory | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | (8,026) | ||
Property, plant and equipment | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | (8,407) | (7,923) | |
Intangible assets | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | (48,517) | (18,877) | |
Other | |||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | |||
Deferred tax liabilities | $ (137) | $ (227) |
Provision For Income Taxes An_5
Provision For Income Taxes And Deferred Income Taxes - Summary of Reconciliation Between The Effective Tax Rate (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of accounting profit multiplied by applicable tax rates [abstract] | ||
Expected income tax (recovery) expense at statutory tax rate | $ 4,833 | $ (10,783) |
Tax rate differences | 76 | (5,383) |
Pass through and non-controlling entities | (13,559) | 186 |
State tax expense, net | 11,148 | 1,726 |
Permanently non-deductible items | 29,635 | 16,382 |
Uncertain tax treatment | 7,598 | 4,875 |
Share-based compensation | 3,349 | 3,869 |
Change in tax status | 3,102 | |
Return-to-provision and other prior period adjustments | (4,301) | |
Net changes in deferred tax assets not recognized | 5,586 | 608 |
Other | (645) | (121) |
Income tax expense | $ 43,720 | $ 14,461 |
Effective tax rate | 206.80% | (28.40%) |
Provision For Income Taxes An_6
Provision For Income Taxes And Deferred Income Taxes - Summary of Movement in Net Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Reconciliation of changes in deferred tax liability (asset) [abstract] | ||
Balance at the beginning of the year | $ (21,451) | $ (4,459) |
Recognized in profit/loss | 4,447 | (1,176) |
Recognized in goodwill | (30,199) | (16,108) |
Recognized in equity | 1,504 | 292 |
Balance at the end of the year | $ (45,699) | $ (21,451) |
Provision For Income Taxes An_7
Provision For Income Taxes And Deferred Income Taxes - Summary of Deferred Tax Assets Not Recognized Deductible Temporary Differences (Detail) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | $ 107,739 | $ 4,881 |
Canadian non-capital losses carried forward [member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 55,552 | 1,677 |
Canadian capital losses carried forward [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 0 | 809 |
U.S. non-capital losses carried forward [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 7,637 | 0 |
California non-capital losses carried forward [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 25,864 | 0 |
U.S. and California amortization of intangible assets [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 1,763 | 0 |
Capital raise expenses [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | 10,375 | 2,332 |
Other [Member] | ||
Reconciliation Of Changes In Deferred Tax Liability Asset [Line Items] | ||
Unrecognized deductible temporary differences | $ 6,548 | $ 63 |
Provision For Income Taxes An_8
Provision For Income Taxes And Deferred Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Statements [Line Items] | |||
Unrecognized tax benefits | $ 15,500 | $ 7,500 | |
Unrecognized tax benefits income tax penalties expense | 600 | 500 | |
Unrecognized tax benefits Interest on income taxes expense | 500 | 200 | |
Deferred tax relating to items credited (charged) directly to equity | 1,504 | 292 | |
Increase (decrease) through business combinations, deferred tax liability (asset) | 1,000 | ||
Deferred tax liability (asset) | 45,699 | 21,451 | $ 4,459 |
Adoption IFRS 16 [member] | |||
Statements [Line Items] | |||
Deferred tax relating to items credited (charged) directly to equity | 300 | 400 | |
Deferred tax asset share based compensation [member] | |||
Statements [Line Items] | |||
Deferred tax relating to items credited (charged) directly to equity | 200 | 100 | |
Canadian non-capital losses carried forward [member] | |||
Statements [Line Items] | |||
Operating loss carryforward | 0 | $ 1,700 | |
Deferred tax assets valuation allowance | 55,600 | ||
State and Local Jurisdiction [member] | |||
Statements [Line Items] | |||
Operating loss carryforward | 78,700 | ||
Deferred tax assets valuation allowance | $ 25,900 | ||
State and Local Jurisdiction [member] | Bottom of range [member] | |||
Statements [Line Items] | |||
Operating loss carry forward expiration year | 2038 | 2038 | |
State and Local Jurisdiction [member] | Top of range [member] | |||
Statements [Line Items] | |||
Operating loss carry forward expiration year | 2040 | 2039 | |
U.S. federal country [member] | |||
Statements [Line Items] | |||
Operating loss carryforward | $ 31,000 | $ 12,300 | |
Deferred tax assets valuation allowance | 7,600 | ||
U.S. federal country [member] | Deferred tax asset share based compensation [member] | |||
Statements [Line Items] | |||
Operating loss carryforward | $ 900 | ||
Deferred tax asset payable to shareholders [member] | |||
Statements [Line Items] | |||
Deferred tax liability (asset) | 800 | ||
Deferred tax asset share based compensation reserve [member] | |||
Statements [Line Items] | |||
Deferred tax liability (asset) | $ 100 |
Subsequent Events - Additional
Subsequent Events - Additional Information (Detail) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions | Mar. 18, 2021USD ($) | Mar. 15, 2021USD ($) | Feb. 22, 2021CAD ($) | Feb. 16, 2021USD ($)shares | Jan. 15, 2021USD ($) | Jan. 14, 2021USD ($)$ / shares | Feb. 22, 2021$ / shares | Feb. 16, 2021$ / shares | Jan. 15, 2021$ / shares | Dec. 31, 2019USD ($) |
Statements [Line Items] | ||||||||||
Cash transferred | $ 18,774 | |||||||||
Equity interests of acquirer | $ 48,881 | |||||||||
Non Adjustmenting Events [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Shares issued price per share | $ / shares | $ 16 | |||||||||
Stock issued during period value new issues | $ 9,900 | |||||||||
Proceeds from issuance initial public offering | $ 125,000 | |||||||||
Non Adjustmenting Events [Member] | Bluma Wellness Inc [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Stock purchased during period value | $ 213,000 | |||||||||
Shares issued price per share | $ / shares | $ 1.12 | |||||||||
Stockholders equity note stock split conversion ratio | 0.0859 | |||||||||
Non Adjustmenting Events [Member] | One Plant Florida [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Stock purchased during period value | $ 7,500 | |||||||||
Non Adjustmenting Events [Member] | Verdant Creations LLC [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Shares issued price per share | $ / shares | $ 20 | |||||||||
Stock issued during period value new issues | $ 2,000 | |||||||||
Consideration paid (received) | $ 11,500 | |||||||||
Stock issued during period shares new issues | shares | 127,065 | |||||||||
Non Adjustmenting Events [Member] | Spyder Cannabis Inc [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Par value per share | $ / shares | $ 0.000001 | |||||||||
Debt Instrument held for sale | $ 11.6 | |||||||||
Cash transferred | $ 1 | |||||||||
Non Adjustmenting Events [Member] | Cultivate Licensing LLC And BL Real Estate LLC [Member] | ||||||||||
Statements [Line Items] | ||||||||||
Cash transferred | $ 15,000 | |||||||||
Business combination consideration transferred | 158,000 | |||||||||
Equity interests of acquirer | 75,000 | |||||||||
Business combination, remaining consideration transferred | $ 68,000 | |||||||||
Percentage of earn out payments | 12.50% |